A P P E A R A N C E S

PANEL MEMBERS:
Asa Bradman, M.S., Ph.D., Chairperson
Scott Bartell, M.S., Ph.D.
Marion Kavanaugh-Lynch, M.D., M.P.H.
Thomas McKone, Ph.D.
Penelope (Jenny) Quintana, Ph.D., M.P.H.
Megan Schwarzman, M.D., M.P.H.

OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT:
Dr. Lauren Zeise, Acting Director
Mr. Alan Hirsch, Chief Deputy Director
Ms. Amy Dunn, Research Scientist III, Safer Alternatives Assessment and Biomonitoring Section
Ms. Sara Hoover, Chief, Safer Alternatives Assessment and Biomonitoring Section
Dr. Gail Krowech, Staff Toxicologist, Safer Alternatives Assessment and Biomonitoring Section
Ms. Carol Monahan-Cummings, Chief Counsel
Dr. Laurel Plummer, Staff Toxicologist, Safer Alternatives Assessment and Biomonitoring Section
Dr. Martha Sandy, Chief, Reproductive and Cancer Hazard Assessment Branch

CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY:
Dr. Gina Solomon, Deputy Secretary for Science and Health
DEPARTMENT OF PUBLIC HEALTH:

Dr. Michael J. DiBartolomeis, Chief, Exposure Assessment Section, Environmental Health Investigations Branch, Lead of Biomonitoring California

Ms. Duyen Kauffman, Health Program Specialist, Environmental Health Investigations Branch

Dr. Barbara Materna, Chief, Occupational Health Branch

Dr. Nerissa Wu, Chief, Chemical Exposure Investigations Unit, Environmental Health Investigations Branch

DEPARTMENT OF TOXIC SUBSTANCES CONTROL:

Dr. Erika Houtz, Research Scientist, Environmental Chemistry Laboratory

Dr. June-Soo Park, Chief, Biomonitoring Branch, Environmental Chemistry Laboratory

GUEST SPEAKERS:

Rachel Morello-Frosch, Ph.D., M.P.H., Professor, Department of Environmental Science, Policy and Management and School of Public Health, University of California, Berkeley

Mr. Jason Mihalic, Arizona Department of Health Services

Dr. Amy Mowbray, Associate Director for Policy, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention

Dr. Marc Nascarella, Massachusetts Department of Public Health

Ms. Julie Nassif, New Hampshire Division of Public Health Services

Dr. Bahman Parsa, New Jersey Department of Health
APPEARANCES CONTINUED

GUEST SPEAKERS:

Lovisa Romanoff, M.S., M.P.H., Deputy Director, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention

Mr. Shane Wyatt, Virginia Public Health Laboratory Emergency Response & Radiochemistry Groups

ALSO PRESENT:

Dr. Jamshid Eshraghi, Massachusetts Department of Public Health

Dr. Tina Fan, New Jersey Public Health Laboratories

Mr. Alex Hoepker, University of California, Berkeley

Dr. Veena Singla, Natural Resources Defense Council

Ms. Barbara Toth, New Mexico Department of Health
## INDEX

Welcome  
Lauren Zeise, Ph.D., Acting Director, Office of Environmental Health Hazard Assessment (OEHHA) 1

Overview of the Meeting  
Asa Bradman, Ph.D., Chair, Scientific Guidance Panel (SGP) 8

Highlights from State Biomonitoring Programs – CDC Awardees  
Moderator: Lovisa Romanoff, M.S., M.P.H., Project Officer for State Biomonitoring, Centers for Disease Control and Prevention (CDC) 11  
Presentations: Biomonitoring California and other State Biomonitoring Programs 16  
Panel Questions 53  
Public Comment 60  
Panel and Guest Speaker Discussion 62

Afternoon Session  87

Afternoon Session on Results Return  
Moderator: Sara Hoover, M.S., Chief, Safer Alternatives Assessment and Biomonitoring Section, OEHHA 87

Educating Participants About Exposure to Environmental Chemicals: What Does the Science Say?  
Presentation: Rachel Morello-Frosch, Ph.D., M.P.H., Professor, Department of Environmental Science, Policy and Management and School of Public Health, University of California, Berkeley 88  
Panel Questions 113

Evaluation of Results Return Materials for Biomonitoring Exposures Study (BEST)  
Presentation: Duyen Kauffman, Health Program Specialist and Results Return Coordinator for Biomonitoring California, CDPH 121  
Panel Questions 139
<table>
<thead>
<tr>
<th>Index Continued</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion: Best Practices for Results Return</td>
<td>139</td>
</tr>
<tr>
<td>Panel, Guest Speaker, and Audience Discussion</td>
<td></td>
</tr>
<tr>
<td>Public Comment</td>
<td></td>
</tr>
<tr>
<td>Final Comments from Panel and Wrap up</td>
<td></td>
</tr>
<tr>
<td>Potential Priority Chemicals</td>
<td></td>
</tr>
<tr>
<td>• <em>ortho</em>-Phthalates</td>
<td></td>
</tr>
<tr>
<td>• Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs)</td>
<td></td>
</tr>
<tr>
<td>Presentation: OEHHA</td>
<td>182</td>
</tr>
<tr>
<td>Panel Questions</td>
<td>188</td>
</tr>
<tr>
<td>Public Comment</td>
<td>196</td>
</tr>
<tr>
<td>Panel Discussion and Recommendations</td>
<td>198</td>
</tr>
<tr>
<td>Announcement on 2016 SGP Agenda Planning</td>
<td>206</td>
</tr>
<tr>
<td>Open Public Comment Period</td>
<td>220</td>
</tr>
<tr>
<td>Wrap up and Adjournment</td>
<td>220</td>
</tr>
<tr>
<td>Reporter's Certificate</td>
<td>222</td>
</tr>
</tbody>
</table>
PROCEDINGS

DR. PLUMMER: Hello, everyone. Thank you for coming today. We're going to get going with the meeting. Today our meeting is available via webinar. And I just want to remind you please speak directly into microphone, and introduce yourself every time you speak. And this is for the benefit of the people that are participating via the webinar and also our transcriber.

So the materials for the meeting were provided to SGP members and posted on the Biomonitoring California website. There are some meeting folders including the agenda at the table near the entrance where you came in. Today, we'll take two breaks, one around noon for lunch, and another at around 3:30. And you probably saw the restrooms and emergency exits are just out the back of the auditorium where you came in.

And with that, I'd like to introduce Dr. Lauren Zeise, Acting Director of the Office of Environmental Health Hazard Assessment.

ACTING DIRECTOR ZEISE: Thank you, Laurel.

Good morning, everyone. I'd like to welcome the Panel and the audience to this meeting of the Scientific Guidance Panel for the California Environmental Biomonitoring Program, also known as Biomonitoring California. And thank you all at this early stage for
your participation in this important meeting.

And I'm very pleased to acknowledge and welcome
the representatives from the State biomonitoring programs
and the National Biomonitoring Program who are attending
and presenting at today's meeting, and other invited
guests.

So we're starting this meeting with a tribute to
Dr. Julia Quint, who served this Panel with distinction.
We were very sorry to hear the news that Julia passed away
this weekend. Julia served on the SGP I think since
1980 -- sorry since 2008. And also it was exactly one
year ago today that we received a note from Julia that she
was resigning from this Panel.

Julia was always an engaged and active
participant in the Panel and she provided such thoughtful
advice and guidance to the Program. And she also held a
spotlight on issues for workers. And saw this as an
important group for Biomonitoring California to study.
And she inspired the FOX study of firefighters. And many
of us who knew and had the pleasure of working with
Julia -- actually many of us since the 1980s. Working
with Julia was really a delight. And we all knew her as a
relentless advocate for public health and worker
protection. So we've asked two friends of Julia's who,
again over many years, worked closely with her on public
health and occupational issues to say a few words about her, and her legacy.

So first, I'd like to introduce Dr. Barbara Materna who's Chief of the Occupational Health Branch in the California Department of Public Health.

Barbara.

DR. MATERNA: Thanks, Lauren.

I had the honor and the pleasure of working closely with Julia in the Occupational Health Branch, where she led our Hazard Evaluation System and Information Service, HESIS, until she retired and began her next career outside the confines of State bureaucracy, which I think was a lot more fun.

HESIS -- understanding the science about the health effects of toxic chemicals and sharing practical information to protect workers and the public was a mission that fit Julia to a T. She had the perfect -- oops -- She had the perfect -- what's the best way to aim at this? Okay.

She had the perfect combination of being both an exacting scientist and a passionate advocate. She would not be deterred when industry groups sent in their toxicologists to oppose her arguments for a health protective Cal/OSHA standard for chemicals like 1-bromopropane or n-methylpyrrolidone. She had the
scientific basis to support her positions and the tireless
energy to do whatever it took to move forward on so many
fronts of public health.

As I look around me and what CDPH, Cal/OSHA,
CalEPA, and others are doing now, I can see Julia's
influence everywhere, and realize how much we all learned
from her.

She spearheaded the drive for safer alternatives
to toxic chemicals many years ago with her work on things
like n-hexane and auto repair products. She had the
courage to convince CDPH lawyers that putting the names of
products containing this harmful solvent on our HESIS fact
sheet was the right thing to do. A step that drove these
companies to reformulate their products.

When we got reports of California workers with
severely lung disease from exposure to the butter flavor
chemical diacetyl, she put out the first fact sheet in the
country that clearly identified that hazard associated
with this chemical.

But she was very frustrated that our ability to
get out this information was limited, because we had no
way to know where the chemical was being used in
California. So she had an idea about what needed to be
done next. It took incredible persistence and hard work
and many more years, but one of her most recent successes
was a new California law that effective January, 2016 gives HESIS the authority to ask a chemical company for a list of who they sell a specific product to in California.

Julia's work on pollution prevention and upstream solutions started long before we all heard about green chemistry and safer consumer product regulations. I cannot imagine these efforts would be where they are at now without her influence.

Julia was also a master collaborator, reaching across all kinds of dividing lines, finding people to talk to and work with in environmental agencies, local health departments, trade associations, unions, and community groups. She was amazing, brilliant, kind, a fighter against injustice of any kind and will be sorely missed by all of us who loved and admired her.

I could go on, but Julia would remind us there is so much more work to be done in public health, so let's just get on with it. And I'm going to pass the baton to Gina.

CAL/EP A DEPUTY SECRETARY SOLOMON: So many of us who've worked with Biomonitoring California and, of course, on the Scientific Guidance Panel have had the privilege of working with Julia for many years. Many of us had -- you know, were her close colleagues and friends. And it's a horrible blow to lose her from our midst.
She was always so active and focused and engaged on the Panel. She would ask the best questions, and she also always was so gracious and supportive to the staff. And I think part of it was because she recognized, having worked in government, so many of the challenges that the program faced in terms of resources and other challenges. And so she would recognize those, but would never lower her standards of science for one minute or lower her hopes for what we could accomplish for one minute.

And for Julia, as such a great, brilliant toxicologist, science was for a purpose. It wasn't just for science sake. Science, for her, was really for two main things, one was to protect workers, especially low wage and most exposed workers; second, to protect communities and the public especially the most vulnerable and disadvantaged communities.

And for Julia there was no conceptual gap between occupational health, environmental health, environmental justice. Many of us, you know, have sometimes seen those areas as being fractured and separate. For her, it was all part of the same thing. And I think that that has been really important for me and for many of us to see.

And she showed -- I think one other thing about the biomonitoring -- about Biomonitoring California is that it's not a pure science program, even though it's
very solidly based on science. And it's also not a regulatory program. And in those ways it's very similar to HESIS. And she showed us how, through this sort of three step iterative possess, you can make a huge difference using science in a non-regulatory context by first identifying the problems, the emerging hazards, and then notifying people and sounding the alert about what the concerns and the issues are, and then becoming, you know, alert again to the problem of regrettable substitutes. And she was on top of the issue of regrettable substitutions way before that term became fashionable. She really was the first to focus on that ongoing problem.

So as we continue Julia's work, we need -- I think, you know, from my perspective, we need to remember always remember the workers, always be nimble to evaluate new issues as they emerge, and to call attention to those new issues as they emerge. And then to always remember that we're here to use our science to help others. And there's no time to waste, so let's get going.

Thank you.

ACTING DIRECTOR ZEISE: Thanks, Barbara and Gina. So we've set up a tribute table for Julia in the back of the room. And I invite you to go to the table during lunch and at the break. So now, in the spirit of
Julia, we'll move on to today's important business.

So first of all, just an overview of the last Scientific Guidance Panel meeting. This was held in Oakland, July 16th of this year. And at this meeting, the Panel unanimously recommended that the class of chemicals known as ortho-phthralates be added to the list of designated chemicals for Biomonitoring California. The Panel received an in-depth review from Dr. Antonia Calafat of CDC's work on biomonitoring phthalates and phthalate alternatives, and discussed these important classes of chemicals with her.

And the Panel heard a detailed update on the new Biomonitoring California's program study, MAMAS, Measuring Analytes in Maternal Archived Samples, and heard other program updates, and also discussed with Dr. Karl Palmer, the Chief of the Safer Consumer Products Program within the California Department of Toxic Substances Control, how our Program can inform -- how our programs can inform each other.

So more information on the July meeting is available on our Biomonitoring website at www.biomonitoring.ca.gov.

So now, I'll turn meeting over to our Chair, Dr. Asa Bradman.

CHAIRPERSON BRADMAN: Thank you. Before we
start, I also want to acknowledge Julia's passing and really I guess say one thing. When my father died, a rabbi said to me, no one really dies until everyone whoever knew them also leaves this world. So I think all of us probably can feel that Julia, in many ways, is still present in this room and will be here present for many, many years.

We have a very full agenda today. First, I want to also thank OEHHA for considering me as the Chair of the Panel. And I look forward to continuing to serve the Program in this capacity.

I'm just going to quickly review now our goals for today. And just a reminder, we have a very full agenda today, so we're going to be pretty tight on the time schedule.

But the goals for the meeting today are to hear from representatives of State biomonitoring programs across the United States and discuss issues of common interests, participate in a session on best practices for returning biomonitoring results. And we'll hear from Dr. Rachel Morello-Frosch and Duyen Kauffman from CDPH, and also have a discussion about that content and also engage with the audience. We'll consider the classes of ortho-phthalates and PFOS compounds as potential priority chemicals. And then, as usual for each agenda topic,
we'll have time for both Panel questions and discussion
and public comment.

In terms of just a reminder on how we'll be
handling public comments for those in the room and also
listening on-line, if a member of the public would like to
make a comment, he or she should fill out a comment card
which can be obtained from the table near the entrance of
the auditorium. You can turn the cards into to Amy Dunn.

Amy, identify yourself.

Members of the public who are not at the meeting
can send an email to biomonitoring@oehha.ca.gov. Emailed
comments relevant to the topic under discussion will be
read allowed during the meeting. Public comments will be
subject to time limits and the time allotted will be
divided equally among all the individuals wishing to speak
on that item.

Please keep comments focused on the agenda topics
being presented. There will be an open public comment
period as the last item -- as the last item of the day,
and you're free to comment on anything related to the
Program at that time.

So at this point, I want to introduce Ms. Lovisa
Romanoff from CDC who will be introducing the first agenda
item, which includes a number of highlights from
program -- biomonitoring programs across the country.
MS. ROMANOFF: Good morning. Unfortunately, for obvious reasons, I'm going to be brief. And I'm not going to present today because I have laryngitis. And this is -- we just have concluded yesterday a meeting -- a two-day meeting with state partners and national partners that are involved in biomonitoring all across the country.

And the downside of that is that I lost my voice. So I just wanted to say thank you again for having us out here. And then I'm going to turn it over to my co-worker Dr. Amy Mowbray who is our policy lead and has graciously taken on presenting today to you instead of me, so I can spare you from having to listen to this voice.

So Dr. Amy Mowbray who is our policy lead for the Division of Laboratory Sciences at the National Center for Environmental health.

(Thereupon an overhead presentation was presented as follows.)

DR. MOWBRAY: So let me see if this is -- is this -- can everyone hear me?

Okay. Great. So as Lovisa mentioned. My name is Amy Mowbray. I'm the policy lead for the Division of Laboratory Sciences at the Centers for Disease Control and Prevention. I work very closely with Lovisa who is the Acting Project Officer for the State Biomonitoring Cooperative Agreement.
So I'm going to go ahead and jump in. Our CDC's National Biomonitoring Program is one of six programs within our division at CDC that focuses on analytical chemistry. It's sort of seeded in our capability do that. And what we've done over the years is set up a national program where we conduct ongoing assessment of the U.S. populations exposure to more than 300 environmental chemicals by looking at participants in the ongoing NHANES survey.

We publish our findings in a summary report, which is the National Report on Human Exposure to Environmental Chemicals, and these are meant to provide national reference ranges for folks to use on the priority environmental chemicals that we're looking for.

--o0o--

DR. MOWBRAY: Unfortunately, one of the challenges that we realized early on when conducting our own program is that the NHANES survey and the data then that we get from the NHANES survey are nationally representative, but do not provide exposure information by a specific state or locality.

--o0o--

DR. MOWBRAY: So in 2001, we started the State Biomonitoring Program in an effort to help states use biomonitoring to assess chemical exposures of concerns in
their own communities. And the first part of that strategy was to try to get some funding out to as many states as possible in the form of creating planning grants. So actually creating plans to do biomonitoring in the states, not actually to execute those with a large amount of infrastructure that it requires to do biomonitoring. And we distributed about $10 million to 25 state and regional programs and ended up supporting a total of 33 states to do that.

At that time, we were hoping that funding would materialize, appropriated funding, from Congress to do a full scale National Biomonitoring Program. Unfortunately, that didn't happen during that time period.

--o0o--

DR. MOWBRAY: But we managed to find some intramural funding to support an implementation grant. And we funded eight states, two individual states and the Rocky Mountain Consortium of six states to put those biomonitoring plans into action.

Luckily, at the end of that cooperative agreement, funding didn't materialize for a full-scale state biomonitoring program and we were actually able to put together a five-year cooperative agreement with three states.

--o0o--
DR. MOWBRAY: And we used this dedicated funding to expand state laboratory capacity for biomonitoring, awarding it to California, as you know, and the State of New York and the State of Washington.

At the end of the most recent five-year cooperative agreement here, the 2009 and 2014 agreement, we, at CDC, stepped back and looked at sort of the process that we had been taking to help support states in doing biomonitoring, and what sort of successes we had seen from the full five-year cooperative agreement and to think about --

---00o---

DR. MOWBRAY: -- how we wanted our next round of funding to best benefit and broaden biomonitoring -- the availability to do biomonitoring at the state level. And so the key outcome of our next funding opportunity announcement which was released in 2014 was we wanted to expand the amount of high quality, substantial, and previously unavailable state-specific exposure information. And in doing that, we wanted to be able to get more of the money to more states. So tried to stretch as far as possible.

And one of the ways that we strategized to do that was to really force states to try to leverage existing collaborations and strategic partnerships, which
I think you'll hear a lot about here when the states speak in a few minutes.

We also wanted to build on existing infrastructure. We were aware that a lot of states had instrumentation and expertise that came as a result of the Public Health Emergency Preparedness Grant for the Laboratory Response Network. And we wanted to try to get a little bit away from providing laboratory infrastructure and to really support actual biomonitoring studies.

And so as a part of the funding process, we had 20 applicants that actually represented a total of 27 states that provided applications for this funding, and they were evaluated by a review panel.

--o0o--

DR. MOWBRAY: We were grateful to select six awardees to receive funding for five years at a total of $5 million, and you can see those states here. And we are very excited. We've been working with the states for over a year now on their projects, and I am going to turn it over to them to talk more specifically about what their goals are for their individual projects.

So to kick that off, I'd like to introduce Dr. Michael DiBartolomeis. I'm sure you all know who he is. He is the Chief of the Exposure Assessment Section at the California Department of Public Health and the lead of
Biomonitoring California.

DR. DiBARTOLOMEIS: Thank you, Amy. And good morning, Panel, and everybody in the room. It's been a tough year. First, we lose George Alexeeff and now Julia Quint. I hope you all memorize that photograph of Julia that was so nicely done by Mary Deems in the Occupational Health Branch, because it's the smile that is so Julia.

It didn't matter whether we were at a birthday party, or she was fighting industry for something, or our own administrative people up through the Department of Public Health, she always had that smile. And I've known her for 27 years, and I never remember her ever not having that smile. So as others have said this morning, I think the best way to honor her memory is to keep fighting on, and so we shall do that.

(Thereupon an overhead presentation was presented as follows.)

DR. DiBARTOLOMEIS: I also wanted to -- we had a great meeting the past two days. And I just want to say, that was -- it was fantastic and thank you for those who participated. I failed to mention one person who helped put this together, Dennis Tavares, our IT person. All these microphones and everything, it's because of him. So thank you.

--o0o--
DR. DiBARTOLOMEIS: So this is going to be really quick in terms of the usual stuff we do I just have a quick personnel announcement, just some highlights of some ongoing studies, and then I'm going to introduce a new study that we haven't really talked much about over the past few meetings.

---o0o---

DR. DiBARTOLOMEIS: So basically, I just want to welcome two new staff. They're actually in the Environmental Health Laboratory as visiting scholars. Su Zhang from Shanghai who is working on non-targeted screening, and Heng Wang who is working on environmental phenol analyses.

---o0o---

DR. DiBARTOLOMEIS: And I'm not going through this slide in any detail. There's going to be more information about this in the next meeting about our regular study updates.

I just do want to highlight a couple of things. With regard to Pilot BEST, we have an analysis of the results return evaluation. And Duyen Kauffman will be presenting that this afternoon. So I wanted to call that to your attention. With respect to the Expanded BEST, we had a couple of major milestones. We returned many, many packets with the second round of chemicals in August. It
was a big process. And again, Duyen deserves a lot of credit, as well as the other folks in OEHHA and EHIB and the labs.

And also, we are following up with participants in the Expanded BEST with regard to those who had elevated arsenic levels. And we're going to be asking if they're interested in a retest as a clinical follow-up. So more on that some time in the future.

--o0o--

DR. DiBARTOLOMEIS: I have brought this up before in various different ways, but we have, as you know, over the past -- starting with the end of -- actually, it was about a year ago, we presented some initiatives that the Program -- after it evaluated itself, some initiatives that we wanted to push forward in the next five years. You know, again, here they are in a nutshell. We've talked about statewide monitoring surveillance. We talked about targeted community and targeted populations, including workers. And we're -- of course, the principle of environmental justice, we want to incorporate into our work, not just in name but in principle and in action.

The one I want to concentrate on for the next -- for the rest of the talk is this consumer product chemical exposure concept. We've talked about this before. We've talked about policy over the past two days and how -- what
pushes policy and how biomonitoring can affect policy. It's my personal belief that working with consumer products and use -- doing shorter term exposure analyses and informing policymakers about chemicals in consumer products is one of the better ways we can push public health policy.

--o0o--

DR. DiBARTOLOMEIS: So with that highlighted, I want to introduce a new study, which we are calling FREES or Foam Replacement and Environmental Exposure Study. And this is a collaboration -- let me catch up to my notes here.

This is a collaboration with UC Davis, with the Green Science Policy Institute, the Environmental Working Group and Silent Spring with money from UC Davis being the EPA STAR grant, which I think many of you are aware of. And with Biomonitoring California, it is the CDC funds, as well as the State donate -- you know, State funding.

And we're asking the question, is there a benefit to replacing foam furniture? And I think by benefit, we mean is there a reduction in exposure to certain chemicals, and ultimately, the implication is a reduction or an improvement in health outcome over long-term exposures.

And we are concentrating on flame retardants.
There are, of course, other chemicals in furniture, but these are the chemicals we're biomonitoring.

--o0o--

DR. DiBARTOLOMEIS: So the study goals are displayed there. And I want to emphasize this is a pilot study. This is not meant to be the kind of beginning and end of all furniture replacement studies. We want to see if this is something that biomonitoring can participate in in terms of informing consumer product safety of regulations and those sort of things.

So ultimately, we're looking to assess, as a cooperative collaboration, changes in levels of flame retardants when furniture is removed -- or the foam is replaced, and that includes dust, as well as biomonitoring, you know, levels of chemicals in the blood and urine of people.

So it's -- we ultimately are after looking -- evaluating whether this type of methodology of replacement, coupled with biomonitoring and environmental assessment, is an effective way to assess exposure and also to, I guess, inform reduction strategies.

--o0o--

DR. DiBARTOLOMEIS: Our analysis plan is actually also fairly simple in terms of just, you know, breaking it down. The UC Davis portion of this would be to model and
measures -- changes in the dust levels of flame retardants over time both, you know, at the time -- at the baseline and then over time as the foam has been replaced.

And the Biomonitoring California part of this is, of course, to biomonitor for PBDEs in serum, for organophosphate-containing flame retardants metabolites in urine. And I want to stop for just a second to say this study, along with -- we're moving ahead with reanalyzing some of the FOX urine samples for OPFRs. These are the first times we're implementing these new -- this methodology. So this is a big break-through for the Biomonitoring Program, and for biomonitoring in general. So just keep that in mind, you know, as you're thinking for your own state or at the federal level. This is groundbreaking in many different ways.

And we're also going to be looking at PBDEs and OPFRs in hand wipe samples from actual people's contact with the foam and the dust.

--o0o--

DR. DiBARTOLOMEIS: So the timeline on this study is about a year and a half, and we're into it now. So we're -- time zero has already started clicking. And so zero is the baseline. We're looking for dust levels of PBDEs, and I presume OPFRs -- actually, I'm pretty sure of that. And serum, urine levels in people, so we're going
to get the baselines, the hand wipes, and then we'll have a baseline questionnaire to administer. And I think we're at various stages. I have -- let's see. Hold on. That's the next slide.

And then in six months, we will be doing a follow up with the dust in urine and exposure questionnaire. That is after the foams have been -- the foam has been replaced. And then after a year, we do the whole spectrum again. And then finally after a year and a half, we finish off with the three again.

So this is again a pilot, but the study design looks like it's -- it could be something that could be extended to a much larger kind of study design.

--o0o--

DR. DiBARTOLOMEIS: So where are we with this? We're calling phase one the actual dust and biomonitoring part of the pilot for the initial population that we want to study. It's a convenience sample of residents in San Francisco and the East Bay that are knowledgeable about chemical pollutants. So it's a fairly not random -- could be any sample, because these are very knowledgeable people. It's about two-thirds complete, the actual baseline biomonitoring, the collection of specimens, et cetera. The next collection for these would be due in June of 2016, if you looked at our schedule.
Phase two, I didn't mention yet, but phase two is where we want to bring the EJ concept in. We've learned that there is a proposed partnership with First Community Housing in San Jose for finding households that are of lower income and more vulnerable, you know, in terms of where they're -- in terms of other socioeconomic, you know, factors. And the recruitment for that study would begin in January 2016.

Overall, we're hoping to have 20 to 30 households with about -- you know, up to 50 participants.

--o0o--

DR. DiBARTOLOMEIS: And with that, I'm just going to show you, you know, our ever-changing acknowledgments slide. I'm never on there. I don't know when I -- I guess when I'm on there, that means I'm not here anymore.

(Laughter.)

DR. DiBARTOLOMEIS: So thank you very much.

(Applause.)

CHAIRPERSON BRADMAN: I just want to comment that we're going to hold questions and Panel discussion until after the States presentations are complete.

DR. MOWBRAY: Okay. Just as a heads-up, the order of the states that -- it will be Massachusetts, followed by New Jersey, then the Four Corner State Biomonitoring Consortium, Virginia and New Hampshire.
So our next speaker is Dr. Marc Nascarella. He's the Chief Toxicologist at the Massachusetts Department of Public Health, and the Director of the MDPH Environmental Toxicology Program.

So here's Marc.

(Thereupon an overhead presentation was presented as follows.)

DR. NASCARELLA: Good morning, and thanks for hosting Massachusetts here. I'd like to take a minute to say that the State based biomonitoring program in Massachusetts are the efforts of two bureaus within the Department of Public Health, the Bureau of Laboratory Sciences, and the Bureau of Environmental Health.

So this presentation represents work by myself and my team, as well as the team that's led by Dr. Jamshid Eshraghi in the Division of Analytical Chemistry in the Bureau of Laboratory Sciences.

--o0o--

DR. NASCARELLA: So the goals of our cooperative agreement with CDC are to enhance the capability, capacity, and readiness of the State Public Health Laboratory and the Bureau of Environmental Health to evaluate vulnerable populations in targeted high-risk communities - and in those communities, we're looking at metals - and to conduct a statewide surveillance and
collect samples from a representative portion of the population to determine baseline levels of both metals and PCBs and to also document our emergency response capability by providing biomonitoring for acute chemical exposures and that will be provided for the suite of metals that we're looking at, as well as acute exposure to PCBs.

--o0o--

DR. NASCARELLA: So a little more texture to those three goals. Within the vulnerable population, we'll be looking at children between the ages of five and 12. And why five?

Well, that's where the Childhood Lead Poisoning Prevention Program leaves off, and that's where we're hoping to pick up. We'll be looking at blood and urine analyses for lead, mercury, cadmium, and manganese. From the statewide population, we'll be looking at adult residents, looking at both serum and blood analyses for PCBs and manganese, as well as a suite of metals for urine analyses.

And as part of acute and episodic events in Massachusetts, we'll be responding with our Hazmat and other State partners to conduct biomonitoring as part of accidental or intentional chemical releases. And we're also using it to augment existing, kind of risk assessment
approaches. Those of you familiar with the APPLETREE style health assessments through ATSDR, we'll be providing biomonitoring as a service to individuals that are concerned about exposures at National Priority List sites.

--o0o--

DR. NASCARELLA: So some highlights and accomplishments of what we've been able to do in this first approximately year and a half of funding. We've purchased and installed new instrumentation, a new ICP-MS in our laboratories, bringing that on-line through a completion of method development plans and experiments. Our metals will be analyzed via ICP-MS, and our PCBs via GC mass spec, mass spec. And we have an existing capability with PCBs. And we've been doing that for some time.

We've been able to hire five new staff. And I'm glad we put that up there in contrast to Michael's slide, where we see all of the Biomonitoring California staff. Hopefully, we're able to show you what we're able to do with these five FTEs. We have two staff that we've hired as junior toxicologists and two laboratorians and kind of a pivot person in the middle who has a background in both environmental health and laboratory sciences that serves as our coordinator.

We've established and convened an advisory panel.
And we've also partnered with our health survey team to implement a statewide sampling program that takes advantage of the behavioral risk factor surveillance survey, that's a CDC instrument in each state.

We've also developed outreach material for participants and collaborators, I'll go through that a little bit at the end. And we've developed technical resources for health based interpreting of biomonitoring results. And mainly, we've done that through responding to some episodic and acute chemical exposures in Massachusetts.

--o0o--

DR. NASCARELLA: Some of the challenges we face, and I think this is universal across all biomonitoring programs, is the recruitment and enrollment of participants. I think we know how to do it, but with five FTEs that are dedicated to biomonitoring and the programmatic responsibility to health department staff to do everything else, it becomes a real burden, the enrollment of participants. It's an iterative process, and it takes a lot of time to build these relationships with community organizations as well as contact the individual participants.

There are challenges with establishing health-based thresholds for these analytes of interest.
As part of the National Exposure Report, those of you that have become familiar with it, you'll see it's stated there implicitly many times that these are exposure levels and these are not health-based thresholds.

Unfortunately, that doesn't address the concerns of the individuals at the Massachusetts Department of Public Health that want information on is this a level of health concern, or participants that approach us and say should we be concerned, or interactions we have with clinicians that are looking for guidance from us on the health impacts of exposure to this level. So that continues to occupy a great deal of our time as well.

Developing results communication to participants is also a challenge. Absent of good health-based thresholds, it's difficult to interpret that and explain it in a manner that's coherent to someone that is not involved in the background of why these levels don't exist.

PCB congener analysis is a technical challenge for our laboratorians. Finding a serum matrix that's free of PCBs continues to be a challenge. And complete removal of PCBs during the clean-up is a challenge.

--o0o--

DR. NASCARELLA: With respect to participant recruitment and enrollment and how we're accomplishing
that through our vulnerable populations sampling, where we're really hoping to leverage our community health networks and go into some of these communities with trusted partners and leverage those relationships to collect samples and address community needs.

As I mentioned previously, we're also leveraging existing health survey resources within Massachusetts, using random digit dial surveys, where we ask an individual question. Are you interested in having a call-back from a member of our biomonitoring team? And then we'll seek to enroll them.

And we're also leveraging our relationships with local health departments, as well as the hazardous materials response teams. We're leveraging relationships with our Massachusetts Emergency Management Agency, as well as the federally funded State Emergency Response Commission. And we're also leveraging our relationships through the Human Health Risk Assessment Network that's in our state, working with both ATSDR and EPA Region 1, as well as our local risk assessors.

--o0o--

DR. NASCARELLA: So a quick example of year one activity is we've been be able to respond to a number of mercury exposure events. Through this, we've been able to really streamline our coordination with local board of
health and state agencies. We've kind of greased the
skids for our urine collection sample, collection analysis
and interpretation, and our interaction between the Bureau
of Environmental Health and the Bureau of Laboratory
Sciences.

We've used it as an opportunity to develop
outreach material and get feedback on that, and respond to
some drinking water concerns, both respect -- with respect
to developing reference levels for measurement of
manganese and serum, as well as look at dermal exposures
to arsenic.

--o0o--

DR. NASCARELLA: And with that, I'll wrap-up by
saying a true thank you to CDC. This is a true
cooperative agreement where CDC is able to provide us to
the funding, but almost more importantly, we have almost
unfettered access to expertise at CDC. And that has been
invaluable in implementing this program, and kind of
establishing best practices in the state that are
consistent with some of the federal approaches.

(Applause.)

DR. MOWBRAY: Our next speaker is from New Jersey
is Dr. Bahman Parsa. He is the director of the
Environmental and Chemical Laboratory Services at the New
Jersey Department of Health, and he is also the PI for the
New Jersey Biomonitoring Program.

(Thereupon an overhead presentation was presented as follows.)

DR. PARSA: Thank you very much.

--o0o--

DR. PARSA: Good morning.

Here at New Jersey our experience with the clinical sampling is limited just working as LRN-C laboratory. But once we got the grant, we established ourself with six goals.

The goal number one, which is the first and the most important goal in this program, is to have the laboratory capability and capacity in place, and specifically for analysis of PFC, PCB, metals and metals speciation. In that respect, we have developed three projects, which will encompass the goal two, three and four.

The goal number two is the PFC exposure in communities with contaminated drinking water. Goal three and four, the projects -- is the biomonitoring study using blood banks and clinical laboratory samples to determine the baseline levels for a number of analytes in blood and serum. And the third project is the expectant mother biomonitoring study.

The goal five is the increased collaboration and
communication within the Department, outside the Department agencies, as well as the scientific communities.

And goal six is the permanence and sustainability, once the -- this grant has been terminated.

---o0o---

DR. PARSA: The project one is the environmental contaminant levels in blood and urine specimens from New Jersey clinical laboratories and blood banks. The objective is to determine metals, PFCs, PCBs in blood and urine among the New Jersey residents 20 to 74 years old, using remnant clinical laboratory and blood bank specimens.

Establishing the biomonitoring data for target analytes based on the gender, age, geographic location, and race to screen for disparities across the study population in New Jersey.

And then third is demonstrate laboratory capability to capacity to conduct biomonitoring in New Jersey for environmental pollutants and to develop infrastructure to respond to actual exposure incidents.

---o0o---

DR. PARSA: Project two is assessing PFNA body burdens following drinking water intervention. The
objective is to determine if individual residents residing in communities with PFNA-contaminated drinking water have higher PFNA serum levels than the general population based on our baseline study in project one; evaluate the effectiveness of the interventions implemented to reduce exposure to PFNA in drinking water by monitoring serum concentrations of PFNA over time; estimate the half-life of PFNA in the body; estimate serum -- serum to drinking water ratios for PFNA and assess how they may inform the risk assessment of PFNA in drinking water; and, finally the PFOA -- we do analysis of other PFC compounds, PFOA, PFOS and the other things.

--00o--

DR. PARSA: The project, three which is under development, we haven't done much about it, is the -- to do the analysis for the expectant mothers and target analytes, or metals and PCBs; and sample collection is recruitment from hospitals, OB/GYN offices, and insurance providers.

--00o--

DR. PARSA: The progress that we have done for goal one, laboratory capability and capacity building in the PFC side, we have been fortunate to be able to get staff on board and also purchase an LC-MS/MS equipment. Method validation is under development. And also the
training of the individual at the CDC has been completed. For PCB, we have completed the purchase of the high resolution GC-MS/MS equipment. Unfortunately, not been able to recruit the person that we have, due to the procedure of problems that we have at New Jersey for getting new hires. Metals speciation, we are going to be purchasing the equipment and also the same issue of hiring person.

And the goal 2, investigational support, we have done the IRB application. Approval pending. Outreach for subject recruitment, sample collection is in progress, and the questionnaire we have also developed.

--o0o--

DR. PARSA: The project one study plan has been completed. Partnership with clinical labs and banks have been developed. Planning for sample collection is underway. IRB application has been approved.

Project three, assessment environmental exposure of pregnant women to toxic metals is under development.

--o0o--

DR. PARSA: The goal five we have already formed the state biomonitoring program, established a New Jersey State Biomonitering Commission, and outreach and partnership with a different organization in New Jersey has been established.
Goal six, the permanence and sustainability is the -- first of all, the capabilities in goal one we have been in progress; foundation built, which is in goal five; and pursuing additional state funding as early as 2017.

DR. PARSA: The challenges that we have is -- currently is the hiring the staff, as I mentioned, obtaining IRB approvals for the remaining projects, managing large number of samples in the LIMS and the storage of the samples, and reporting the data are the issues that was discussed yesterday as well.

Under general challenges for us is building a coherent biomonitoring program, harmonizing the efforts of our laboratory with the priorities, which is of the other department, environmental or epidemiological sector; and also the transition from grant funding to state funding, which is going to be a challenge for us.

Thank you very much.

(Applause.)

DR. MOWBRAY: Our next speaker is representing the Four Corner States Biomonitoring Consortium, which consists of Utah, Arizona, Colorado, and -- did I say Arizona already? -- New Mexico. Okay. Sorry.

(Laughter.)

DR. MOWBRAY: Jason Mihalic is the Chemistry
Office Chief at the Arizona Department of Health Services and he is representing the four corner states.

So welcome.

(Thereupon an overhead presentation was Presented as follows.)

MR. MIHALIC: Thank you.

Hello. My name is Jason Mihalic again. And I'd like to also acknowledge that here are -- represent Arizona, but there's also -- oh, thanks -- New Mexico -- representation from New Mexico, Colorado, and Utah in the room.

--o0o--

MR. MIHALIC: Our group has a history of biomonitoring, in that, as Amy mentioned, we are one of the grantees at the Rocky Mountain Biomonitoring Consortium, back in 2001 to 2010 -- or actually more 2005.

And so in addition, many of our states are Environmental Public Health Tracking Network grantees. Collectively our four states encompass an area of roughly two and a half times that of California, but with only 40 percent of the population. In practical terms, that means that we're a land of notable population centers, such as Denver, Albuquerque, Salt Lake City, and Phoenix, but we're also combined with a lot of small communities, whose base economic structures are based on farming, ranching,
and mining.

--o0o--

MR. MIHALIC: Because of a similar geography, we share many of the same public health concerns, and these became the backbone of our work, and include metals exposure through private drinking water wells, phthalates from common household products, 2,4-D herbicides, para-dichlorobenzene again from common household products, and pyrethroids, which are used for mosquito and tick abatement efforts within our community.

On the laboratory end, the chemical and/or their metabolite shows we've adopted CDC methods to analyze all of these analytes of interest, and we've begun with metals and pyrethroid -- actually metals and phthalates.

--o0o--

MR. MIHALIC: We've incorporated these concerns into five projects to complete within the five-year grant period. And while this does come out to one project per year, we don't really look at it that way. Some of the projects are ongoing, such as the well water study, while other of the projects will be encompassed over a one-year period. And we really take in regional interest, geology, population risks, mining and agricultural exposures into account.

--o0o--
MR. MIHALIC: In terms of participant recruitment, there's really no one-size-fits-all approach when you have four states involved. So what we have instead is a tailored approach unique to each state. Colorado, for example, has a leg up on all of us, because they have merged this project into an ongoing assessment in the San Luis Valley, which is a predominantly low income agricultural area and already has a participant base to work with. And the rest of us have started from scratch.

In that end, we've used various techniques, including direct mailing, using well water registry databases for the well water study, working with school boards to get the word out, local health departments, health fairs, community liaisons, sign-up sheets in government buildings, health clinics, and doctors' offices. So it varies state to state, but so far they've been fairly successful.

--o0o--

MR. MIHALIC: One year in and we have experienced some successes. Each state has had their IRB approved. Assessment tools have been developed for the first two projects metas and phthalates. Sample collection protocols, which be uniform throughout the consortium, have been established, and communication, which is no
small feat when you're dealing with four states over a large area, we've tackled by having monthly phone calls for lab and epi, periodic phone calls for both, and then two face-to-face meetings during the year.

In addition on the laboratory side, method development for the metals in urine, creatinine, which, of course, in urine as well, and then the phthalate metabolite, which is also in urine are complete. And we currently have completed or are undergoing our validations.

--o0o--

MR. MIHALIC: Both New Mexico and Utah have developed -- have already begun their sample collection. Colorado and Arizona are -- will be collecting soon, hopefully by the end of this year. Of course, there's only one month left in this year.

One of the advantages collaboration is that we're able to use each state's experiences for the benefit of the consortium. For example, New Mexico took the lead on an exposure assessment, Colorado in providing results back to participants, Utah in analyzing data, and Arizona with the method development.

--o0o--

MR. MIHALIC: Lessons learned in terms of contracting complexities. You know, it's one thing to
have a CDC grant and it's another thing to work with State lawyers.

(Laughter.)

MR. MIHALIC: So while it just didn't go as smoothly as we had assumed it would - and it's just the nature of contracts. Issues such as a venue of dispute, indemnity, insurance all came to the fore, which are really boilerplate, and had to be dealt with. Using student interns it seemed like a great idea at first. But the reality is we train them and they leave. So that begs the question of whether or not that's worth it.

And in addition, also with student interns, some states have issues with non-state employees riding in state vehicles, which is another tactical issue.

--o0o--

MR. MIHALIC: The big takeaway I'm hoping to be able to impart is that the collaboration is achievable, as we've shown over the last year. As resources dwindle, affordable biomonitoring, that perhaps collaboration is inevitable, especially if regionalization becomes an economically viable alternative to single-state funding.

--o0o--

MR. MIHALIC: And lastly, I'd like to thank the Consortium and then also the CDC.

(Applause.)
DR. MOWBRAY: Okay. The next speaker is Shane Wyatt from Virginia. He is the lead scientist for the Virginia Public Health Lab Emergency Response and Radiochemistry groups, and is the co-project lead for the biomonitoring program.

(Thereupon an overhead presentation was presented as follows.)

MR. WYATT: Thank you. Good morning. Can everybody hear me?

Hi. I'm Shane Wyatt. I'm one of the co-lead investigators for this grant in Virginia. My partner, the co-lead, Chris Retarides, was unable to make it this week, so hopefully we'll move forward, and then you're the timekeeper.

Okay.

--o0o--

MR. WYATT: I think before I get started real quick, it's important for me to point out that the Virginia Public Health Laboratory is structured a little bit differently from most other public health labs. We are part of a cabinet level department that is not associated with the Department of Forensics or the Public Health Department. So we are completely separate from the Virginia Public Health group.

And as part of that, for us to operate with them...
and perform biomonitoring studies with them, we actually have to have a memorandum of understanding or an agreement -- operations agreement between us and them, so that we know who's responsible for what and how we move forward.

I'm not going to give a real in-depth overview of the program initially, due to time constraints. I'm hoping that that will come out as we go through and talk about some of the successes and challenges.

One of the biggest successes we've had so far has been with the other State agencies that we have targeted to work with. And probably they're not listed first, but probably the most important one out of that group is the Department of Health.

As I said, we're not part of that laboratory, so we do have to meet with them on a regular basis. They are providing access to -- for us to the local health departments. They are also helping us with access to toxicologists, as well as activities on the biomonitoring advisory committee that we have proposed. The Department of Environmental Quality, the Agricultural and Consumer Services and the Department of Fire Protections have also extended their willingness to help us with these different projects that we've proposed, and they're all involved in one way or another.
And they will all be involved in the advisory committee at least partially, depending on the projects that are going on. We had an opportunity earlier this year to present the biomonitoring grant.

And biomonitoring in Virginia is really a brand new project. It's a brand new activity for us. We did partake in the planning committee -- the planning grant initially. However, we never -- no real actual biomonitoring studies were conducted or have been conducted for -- essentially on an ongoing basis.

And so last fall, we were given the opportunity to present to the local health departments this grant that we've been awarded and discuss what we're -- you know, the projects that we have ongoing and some of the initial -- and some of the future plans. We propose three propose three projects initially that -- our intent is not to maintain those projects or those would be the only projects that we approach through the advisory committee and/or through the health districts. We plan that other projects will come up as they're brought to our attention.

And they -- we received a lot of very positive responses from the local health districts. They're very, very excited about having this resource and being able to come forward and use it.

--o0o--
MR. WYATT: Like I said, we propose three projects, two of them have been combined down into one project, so we had two IRB applications. We did the IRB application through our health department. It went fairly smoothly for us for toxic combustion to firefighters, which was one of the projects we proposed.

The other one we had initially proposed a detection of uranium in urine and perchlorates in urine, and the general population within Virginia. We expanded that out to toxic metals. And the toxic metals and the perchlorate were two separate proposals and we combined them down to one IRB application, because we're both -- we're going to be analyzing urine for both of them and we just wanted to do one collection.

I'm not sure what happened. We had a delay on getting this one approved, mostly because the IRB board couldn't find the application, after we had submitted it. So we resubmitted it, and it went through relatively quickly.

--o0o--

MR. WYATT: And I think -- since this is a brand new program for us, and I think some of the other states have run into this as well, our biggest challenge for our opinion has been establishing the infrastructure. We are the public health laboratory. We are very good at the
analytical methods. We're very good at analytical method
development. We're very good at handling samples and
reporting out results.

What we're not good at is going out and getting
them. Samples just -- generally come to us. If people
want to give us samples, they're beating down our door
saying we have stuff for you. Very few people are aware
of the biomonitoring program since it's a new one. And us
going out is a new function as a laboratory. Us going out
and collecting samples and doing recruitment and informing
the public of the ability and the things that we can do.

So establishing this infrastructure has been one
of the bigger challenges we have. But to try to make that
a little bit easier, one of the things we focused on were
analytes we had experience with, and analytes we had
methods for.

So we are leveraging some of our LRN-C
capabilities. We are a Level 1 LRN-C laboratory, and we
are using the cyanide method as well as the toxic elements
green method from that program to do the analysis for the
firefighters.

The perchlorate method is one that we developed
in-house at the request of the LRN-C, so we had one ready
to go for that as well.

--o0o--
MR. WYATT: We're working with the fire protection services to collect samples at this time. The big issue is that we're having issues scheduling times to go out and collect the samples. The fire protection programs is they do controlled burns to train firefighters on a regular basis throughout the year. It's a facility that's relatively close to our laboratory, but we're having some discussions on how to best get the samples, who to do the draws, because it's going to include a blood draw, and whether or not they can do that themselves or we have to provide somebody to do that.

--o0o--

MR. WYATT: This one I wanted to spend just a second. I want to hit this real quick.

The toxic metals and perchlorates study is intended to be a statewide general population study. However, we wanted to narrow the focus of our recruitment activities to something that would seem to be a little bit more manageable initially. And so what we decided to focus on were community colleges.

There are a lot of community colleges in Virginia. And because -- they're part of the Virginia university system. All of the credits that you take at one college are completely transferable to another. So a lot of people take advantage of that, and a lot --
especially local community individuals. So we have a broad range of ages. We have a broad range of communities that participate in the community colleges, and we have several staff at DCLS that are adjunct professors at the different community colleges.

We have access to these campuses. We have ways to contact the administrations and ways to work with them. We can get in contact with them. We are fairly well along with one of the local community colleges, and we're in the final approval stages to be able to go in and start collecting samples. And this will strictly be a urine collection. And we'll be doing the toxic metal and the perchlorate study.

--o0o--

MR. WYATT: And perfect timing. As I said, Chris Retarides is the other principal investigator for this.

Thank you.

(Applause.)

DR. MOWBRAY: Okay. Our final speaker is Julie Nassif. She is the Chemistry Program Manager in the Division of Public Health Services, Public Health Laboratories for the State of New Hampshire.

MS. NASSIF: Thank you. I appreciate being here and giving you an overview of what we're doing in New Hampshire.
(Thereupon an overhead presentation was presented as follows.)

MS. NASSIF: We have -- when we put together our proposal, we really thought it would be an opportunity to build on our existing biomonitoring capabilities, as well as an opportunity to leverage our emergency response capabilities through the LRN-C.

--o0o--

MS. NASSIF: So this is New Hampshire. And what we've proposed as part of our efforts are really two studies. The first is a targeted effort that -- I don't have a pointer, but is located in the southern part of New Hampshire. It's our population center. And the geology in that area is such that there's a lot of granite. And the opportunity for leaching of toxic -- of elements to leach into the groundwater there.

So our first project is to look at total arsenic, uranium, and speciated arsenic in elevated individuals in the southern part of the state, and then in 2017, to launch a statewide surveillance study that would look at a much broader range of chemicals.

And in preparation for our proposal, we reached out to a lot of partners within the State, both our public health partners in the asthma control program, climate change, environmental public health tracking, our local
health officer -- some of the major cities have health
departments. We spoke with them. We spoke with some
community advocates, and we put together what we think is
an interesting list of analytes that are relevant to our
jurisdiction.

--o0o--

MS. NASSIF: So a little background on the
arsenic and uranium study. A very high proportion of the
population of New Hampshire is reliant on private bedrock
wells for their drinking water. It's actually gone up,
since about 50 percent of the population is reliant. The
geologic formations coupled with past land-use practices
related to apple farming provides a lot of opportunity for
arsenic exposure and contamination of the groundwater.

Our previous data have shown that there is
definitely groundwater contamination. And our data also
show that there is a significant correlation between those
that drink that water and having elevated arsenic.

I viewed this, and many others do, as the most
significant environmental health problem in New Hampshire.
We have the second highest rate of bladder cancer in the
country, second only to our neighbor to the east in Maine.

--o0o--

MS. NASSIF: So recruitment from this high-risk
area will be broad. We'll try to reach all age
populations with a special emphasis on reaching underserved and sensitive populations. There is a major city right in that area that's -- that has public water, and we hope to recruit participants from there as a control population.

We'll be collecting a significant amount of data from people regarding their recreational, residential, and occupational histories. Because of the association between organic arsenic, we'll be asking them to refrain from eating seafood, and we'll ask them to do a food diary. As an incentive for them to participate, we'll ask them -- we'll offer them free well water testing as well.

--o0o--

MS. NASSIF: The surveillance project is broader and potentially significantly more challenging to implement. We'll be looking at establishing some baseline ranges for New Hampshire. Much like our partners in Massachusetts, we'll be looking at BRFSS data to try and get a representative population. If that doesn't provide sufficient numbers, we will look towards this opportunistic recruitment. And these are some of the places that we'll be looking to that. Recruitment at blood donation centers, college campuses to reach a demographic that we might not otherwise be able to tap.

A state employee complex. Our laboratory is
located with a number of other state agencies. And we may be able to recruit some participants there. We've had discussions with some local hospitals and clinical partners that are interested in perhaps having us recruit participants from their offices and practices.

And we're working with both -- we hope to leverage the NP students at the University of New Hampshire to helps us -- they'll be doing their capstone project, and we hope to work with them, perhaps in some discrete projects around survey development and other projects like that.

And we're in discussion with Dartmouth College, where they house an NIEHS superfund toxic metals core and about some specimen exchange with them.

--o0o--

MS. NASSIF: These are the analytes that we'll be looking at in our surveillance project, a whole suite of metals. Our city health officials were particularly concerned in pesticide application and misuse in indoor environments. So we'll be looking at metabolites of organophosphate and pesticide -- organophosphate and pyrethroid pesticides, cotinine, the marker for environmental tobacco smoke, perfluorinated chemicals, which I know you're going to be talking more about this afternoon. And we're hoping to get some good statewide
numbers for the perfluorinated chemicals as we have known sources of contamination in the state. And there's some interest in nutritional biomarkers, specifically iron and folate as well.

--o0o--

MS. NASSIF: Now, we have had successes. I didn't put the successes up. We've been able to hire one individual. My colleague, Amanda Cosser, is here today. And she's serving as our project manager. And we have purchased analytical equipment. We have an ICP-MS/MS which is the same instrument that Massachusetts has.

We have had a number of administrative challenges related to acceptance of the funding. Some policies that are apparently unique to New Hampshire and lack of a state budget that forced us into a continuing resolution for several months, which really exacerbated our ability to hire staff. So we are really at the inception of the program now. We're in the process of hiring. We have -- we have three analytical chemists that we'll be hiring, as well as a project specialist.

Some challenges that are not unique to us, participant recruitment and developing an advisory committee that has a balance between technical expertise and community engagement. And I'd be happy to talk more about community engagement and what we've done initially,
which is reaching out through our Health Officers
Association as well as our Healthy Homes group.

And thank you very much. That's what we're going
to be doing in New Hampshire.

(Applause.)

MS. HOOVER: Thank you so much. That was a lot
of information an a short time, so great job. And what
I'd like to do is ask all of the people who just spoke to
come and sit in the front row, and be available for
questions, and then we'll pass mics around.

I also wanted to let Panel members know that a
lot of that information that was just presented is
available on the program profile forms. You have those in
your packet and they're alphabetical. So if you have
questions about some aspects of the program, take a look
at those program profile forms. So we'll start with --
Asa will be facilitating from now on.

CHAIRPERSON BRADMAN: Yeah. Okay. Thank you.

So just to clarify the next period of time, we
have about 10 minutes for Panel discussion and questions,
and then we'll have some time for public comment and then
more opportunity for discussion.

So I guess to start right now is to ask are there
any clarifying questions from the Panel to any of the
speakers or related topics?
Tom.

PANEL MEMBER McKONE: Tom McKone, University of California.

I guess it's probably a point for discussion later. But first of all, these are all really great programs. I mean, a lot is going on. It's fascinating to see it.

The one thing that didn't come through is how much integration and communication and sharing and whether there's ways to link the different state studies together. I know that goes on. Again, each talk was about what's going on in the state. And I think the next step is to figure out -- I'm assuming this goes on, but it would be nice to make sure we learn a little bit more about analytical methods.

CHAIRPERSON BRADMAN: Tom, a little closer to the mic.

PANEL MEMBER McKONE: I've got remember to be on the mic.

Just more information about coordination and even some meta-studies maybe taking different data sets for the same agents and then combining them across states.

DR. MOWBRAY: So I'm going to take a starting stab. This is Amy Mowbray from CDC.

Part of CDC's role as a -- for the cooperative
agreement is substantial programmatic, you know, involvement in what the programs are doing. And one of our goals is to help keep communication between the funded states open. So what we've done historically, and are continuing to do, is provide opportunities for state conference calls, and then at least one in-person meeting of all the funded states each year, where we talk about analytical issues, programmatic issues, and we allow information sharing.

We are also -- and I would say this is a collaboration between CDC and the Association of Public Health Laboratories, as well as our state programs, we are working on the development of a National Biomonitoring Network that will really help us allow the laboratories to set -- to sort of harmonize approaches for lab and for sample design an sample collection and help us to really integrate across the state programs.

And if anyone else at the states wants to say more about that?

MS. HOOVER: This is Sara Hoover of OEHHA. I'll just add too that, you know, we also had two days of discussions with programs. And we actually made a lot of good connections and mentioning the network. So that's definitely a big thing we were working on over the last couple of days.
CHAIRPERSON BRADMAN: Are there any other questions from Panel members about this recent presentation?

Go ahead. Jenny.

PANEL MEMBER QUINTANA: Is this on?

Okay. Hi. I'm Jenny Quintana from San Diego State University. I had a question to do with how your consent forms ask the participants for their permission because I noticed that sometimes your list of chemicals is maybe shorter than you'd like to expand to in the future. And I'm wondering if there is a general approach of asking for permission to do further analyses than you're currently planning to do or even beyond environmental contaminants looking at other factors such as genetics or other markers and how you approached that by the different states?

MS. NASSIF: Our approach to the informed consent has been to consent individuals to this testing, but to have an optional consent for further environmental testing. Genetic testing would probably not be well received in New Hampshire.

MR. MIHALIC: From the Four Corners point of view, we initially thought that we would have one approach for all four states, but the IRB process pretty much eliminated that, because in some states it's more thorough
than others, some states -- for example, from Arizona, we were only able to be -- to involve people in one project that we were working on right now, whereas other states are able to sign up participants for all five projects. So it just varies state to state in our case.

MR. WYATT: Virginia has taken an approach very similar to New Hampshire. We are looking for permission to participate in the study that they're being recruited for, and then they have the option of allowing us to test their samples at a future date for environmental chemicals. We -- as she said, genetic testing probably would not go over very well, but we do intend to store our samples for future testing.

DR. DIBARTOLOMEIS: And I think, you know, that that's similar to what we do in California. I think the only thing that I haven't heard, when we do go in for -- to do additional testing, I do believe we still have to go back to the IRB for -- we don't for an amendment?

I'm getting a shake of the head back there from my IRB.

MS. WU: We do tend to write our consent forms and the IRB protocol to be fairly expansive to include the option of coming back and doing other relevant environmental chemicals. We use language where we can expand on other panels. We do have the requirement of
returning results, which brings in an added complication if we are years down the road, and we want to -- we want to alert people that they might be getting that information long after their participation seems like it has ended.

CHAIRPERSON BRADMAN: Okay. I just wanted to mention this particular time period was budgeted for clarifying questions, and then we'll have the public comment period, and they'll have time for more discussion. It's kind of hard to distinguish between those sometimes, but -- okay. Well, I have a clarifying question, and then a few discussion things I'll cover in a moment.

But in terms of the -- I think this is for New Jersey. There was talk about use of the remnant samples and from clinical labs and blood banks. And I'd be interested to hear more about that and, you know, what are the mechanics and how the material was collected. And I assume those are -- that's done anonymously, but I'd be interested in hearing more about that.

DR. PARSA: Yes, the subjects are de-identified, so we really do not have any idea what the names and so on. We just know the age. We know their, you know, gender, and so on. So what we have done is contacted the blood banks and to ask them to give us what is left from
their analysis.

Now, in the blood banks they have consent from the individuals to provide their samples for research and so on, so there is that part is covered. But for the clinical labs, we really do not have that consent and -- but since it is the identified, we are not obliged to give anybody any results. We may -- we are considering -- actually, it's not approved in our biomonitoring commission, to give the results to these participating labs just as a recognition of their collaboration with us.

CHAIRPERSON BRADMAN: Right. Okay.

MS. HOOVER: Another collaborator from New Jersey wants to add something.

DR. FAN: Tina Fan from New Jersey Public Health Laboratory. I'm the CT and the biomonitoring program manager.

I want to just answer -- add some information regarding your question. Yes, these are the remaining samples, but we are really talking very closely with the providers as was the clinical laboratory or the blood banks regarding the sample collection. And, for example, exact know what the tubes we want. And also many of them actually they have enough samples, we should be able to even know about when the sample collected. So we're going to document all those information regarding the sample
conditions. So we tried to try our best to get what integrity of the samples.

CHAIRPERSON BRADMAN: Thank you. I think given.
PANEL MEMBER BARTELL: Asa one more question.
CHAIRPERSON BRADMAN: I'm sorry one more comment.
PANEL MEMBER BARTELL: I don't think we have time.

MS. HOOVER: Actually, we're going to pause and just call for public comment now. Then we'll go to the full Panel discussion, so there will be plenty of time for questions and comment.

CHAIRPERSON BRADMAN: Okay. So just to reiterate, we do have time for public comment right now. I don't know if there are any questions that have been submitted, either on line or by email?

MS. DUNN: This is Amy Dunn. I just want to remind people before I read the public comment that we are not only broadcasting this, but also recording it, so I'd very much appreciate it if people can try to make sure to speak into the microphones, so that we can capture what you say.

We have a comment that came in from Courtney Carignan. And this is a question for the speaker from New Hampshire. "Why not measure arsenobetaine in urine rather than ask to avoid seafood"?
MS. NASSIF: This is Julie Nassif from the New Hampshire Public Health Laboratory. Thank you for that question, Courtney. We will be measuring arsenobetaine in the speciated arsenic method.

MS. HOOVER: And were there any public comments or questions from the audience now?

DR. PARK: June-Soo Park, Toxic Substances Control, CalEPA. My question for Shane from Virginia -- I believe Virginia biomonitoring group. I was just curious why perchlorate was chosen for monitoring? I wonder if there was any -- there has been any concern on exposure from drinking water or groundwater?

MR. WYATT: The perchlorate method was one we were actually asked to develop by the LRN-C program, so we had it. And we had done some initial screening of some basically the lab workers. And we found that everybody had some in their system. Virginia itself is very heavily involved in the aerospace industry, and there's a lot of rocket launches. It's also a very heavily agricultural state, and perchlorates are a natural part of certain fertilizers that are used.

And there was no concern, there has been no concern expressed about it in the environment or being in -- you know people being exposed to it. However, it was something that we'd some discussions with the CDC.
about. And we decided to pursue this one just to see if we could establish a background or a baseline for what was in the population.

MS. HOOVER: Other questions from the audience, or comments?

Okay. Take it away.

CHAIRPERSON BRADMAN: All right. Thank you.

So now we can move into a more standard period for questions and also more discussion. And I'll have you take the lead. Thank you. Sorry for the interruption earlier.

PANEL MEMBER BARTELL: Thank you. Oh, that's all right. Scott Bartell, University of California.

I think it's very interesting what's going on in a variety of states. And you see I think though a tension sometimes between the designs in terms of where you're getting sample, either targeting high-risk populations or, you know, trying to work towards -- I don't think anybody is quite there yet, but trying to work towards a statewide representative sample.

And I guess one thing we've talked about a little bit in this Panel earlier this year is, you know, given the great expense and difficulty, although it's a laudable goal to do the statewide sampling in a representative sample, it's, I think, a lot more logistically complicated
and expensive than, you know, trying to actually go after high-risk populations.

And I think one can ask, you know, to what extent you actually gain information if you end up, you know, with contaminate levels that are similar to NHANES, which, you know, is a possibility once -- but you wouldn't learn that, of course, until you implement the statewide sampling.

So I guess the question I kind of have for CDC and/or the states is to what extent your cooperative agreements lock you into this goal of working towards statewide sampling? And if indeed you decide that your resources are better spent perhaps going after high risk populations, would you be able to shift those resources under the current cooperative agreements?

DR. MOWBRAY: This is Amy Mowbray from CDC again.

We have built in a pretty good amount of flexibility within the cooperative agreement through the funding opportunity announcement to let states decide what are their priorities when doing biomonitoring. So we -- I think early on in the first five-year cooperative agreement, we put a heavier focus on a statewide surveillance study. In this new cooperative agreement, we've really left it a little bit more open for states to determine what are the exposures they're most concerned
about. And in the presentation I sort of hit on this. We really want to just get more high quality data that is not available that can help states make decisions in their own communities.

MR. MIHALIC: Well, we've talked about this a lot with the four corners, and we're using the well water study for our statewide outreach, because mostly in the rural communities are where you find people whose primary source of drinking water is well water. However, in terms of the phthalate, we can do that in our larger cities, as well as the pesticides. We may end up going to agricultural centers for some of the pesticides, but you're absolutely correct it is very expensive.

So of the five projects, we're really looking at the one for statewide and then the others, if we can.

PANEL MEMBER BARTELL: Thank you.

CHAIRPERSON BRADMAN: Dr. Schwarzman, I think you had a comment earlier that you were --

PANEL MEMBER SCHWARZMAN: I did. It mostly got answered.

CHAIRPERSON BRADMAN: Okay. Did you want to ask anything else?

PANEL MEMBER SCHWARZMAN: Maybe I will spend just another moment on this, because this partially addressed my question. I was just mulling a little bit this notion
of establishing a baseline. A couple states mentioned this work to establish baseline levels for the State. And mine was sort of less a thought about resources, although very -- that's very relevant, and more about what we're doing with that information.

How much you might expect that it would differ from national levels obtained by the CDC, and also what -- how we're interpreting that kind of baseline information, because I think there's this human tendency to treat baseline as acceptable, and then to be looking for variations from that. And yet, if your entire population is actually exposed to a significant level of something, we wouldn't want to interpret, you know, that baseline measurement of time zero as equal to, like, well, this is just background levels or something like that.

So that's what I was mulling on, and I guess I would just be interested if any of you had reflections on why you're seeking that information or how you would like to use it?

MR. WYATT: This is Shane Wyatt from Virginia. Originally, the reason why we proposed the uranium study was Virginia has some very large uranium deposits. Most of the central and southwestern portion of the state is basically one big uranium mine. And a lot of the groundwater out there is contaminated with uranium. And
so what we specifically wanted to do was to move into those areas and target those populations, so that we could try and evaluate, like we said, a baseline.

However, our expectation is, is that we're probably going to see areas that are above the NHANES level. And we have intentions or our plans are to areas that we feel are elevated or of areas of concern to continue to do monitoring and/or do more focused monitoring in those areas. If we find areas that we're not seeing elevated levels, we may move on and go to another section of the state.

We have had this show up in the past with other communities, and we've been able to work with the health department to implement -- help the communities implement water filtration processes to help remove it from their drinking water systems. And then we've come back a year or so later and remonitored the community, and found that the levels have all decreased. So that's kind of where we're going with this, but we -- like I said, it's a very resource intensive sort of project to collect that many samples that recruit people.

DR. DiBARTOLOMEIS. I have a philosophical response as well as a more applied response.

Philosophically, you're right on target. There should be no chemicals that have no benefit or no
physiological purpose in your bodies if they're coming from a contaminated environment. I mean, you just basically have pollution in your body, and they don't belong there.

So if you can detect it, you probably want to get it even lower or completely eliminate it. So that's the philosophical sort of precautionary approach. It's certainly not a risk based approach, and we still have that tension between risk and precaution.

From an applied point of view, having a baseline established for the population will allow you to look at trends over time. So obviously, if we are doing the right things in terms of environmental protection and, you know, all the other types of regulations, we should see that baseline drop. If we see it go up, we're not doing the right thing. So there still is a reason to collect that baseline. We just have to frame it in probably a different way, in my opinion.

DR. NASCARELLA: Marc Nascarella, from the Massachusetts Department of Public Health. I think another aspect to look at is the high-risk communities that we're sampling are kind of a priori identified as these communities are ones that we'd like to sample, because we suspect that their levels are higher than other levels in the state, but I think there's also the
obligation of the health department to look at the entire community across the state, to the extent that you're not entirely sure what the vulnerabilities in that community may be. And they may not entirely fall into pre-established criterion, namely an environmental justice criteria or be inside of an inner-city area where most metrics would identify them at high risk.

To some extent, we don't know all the risks and -- of exposure to some of these analytes. And I think for that reason, it's important to establish a baseline level of exposure. And to some extent, if your levels do differ from national levels, then perhaps your entire state has had some level of increased risk. And that's an important piece of information to inform policy in your state.

MS. NASSIF: This is Julie Nassif from New Hampshire. The only thing I would add -- I was going to say much of what Marc said, but the only thing I would add to that is it's a very useful point of comparison when you're looking at a community with a known contamination issue to have a point of comparison to the state and not just the national averages, because at this point, we don't know if our individual states look very different than the national averages.

PANEL MEMBER SCHWARZMAN: Thank you all for that
reflection. That's exactly the kind of thinking I was hoping was going on. And I'll be curious to see the results of -- and whether there are these differences from the national data.

DR. PARSA: As far as New Jersey is concerned, we considered that this study that we are starting is going to be a pilot study. Definitely, we're not going to be covering all the state with this. Our sampling is limited, but we try to be as extensive as we can.

But really because New Jersey is well known for its Superfund -- it's the highest in the country, and maybe to fix the problem as well, we would like to get a catch on that and find out if there is indeed reality to a one to one ratio. And if it is, then this would beg to have a much more extensive study throughout. And then we will have to really control what samples we're getting and all that.

DR. FAN: I want to just add a little bit of comments about the New Jersey -- we talk baseline study. Using PFC as an example, you know, it's -- in New Jersey, there's a source of PFC. So from that -- you know, that's why we're doing both from the, you know, blood banks and the clinical laboratory. Give us some general ideas about the, I wouldn't say truly general population, but still can give us some ideas about the levels are, and then are
doing the targeted communities, you know, the PFC.

On the other hand, I think it's about PFC has the source, not just only from the water, it's in some other as well. So actually that would tell us, you know, if you really do an intervention in our targeted community, if that really -- if the PFC is going to reduce when you compare it to the -- like our project one, which we call general population exposure. So we think that's another thoughts we have there.

CHAIRPERSON BRADMAN: I have a question, a kind of derivative of the last discussion. I think of all the presentations, it was Massachusetts that talked about establishing health-based thresholds for analytes of interest. And I'm curious to hear more about that process, especially for things that don't have an established, you know, reference dose.

And then perhaps a larger discussion of how the states are dealing with issues of risk assessment and risk interpretation of the measurements. And if that's programmatic or -- programmatic within the biomonitoring programs or if that's handled in a different arena?

DR. NASCARELLA: Marc Nascarella from the Department of Public Health in Massachusetts again. Thanks for the question. That is a -- I think that's a problem that every state faces, and to some extent it also
exists with the -- at the federal level, certainly with interpreting the National Exposure Report data.

I think for some analytes, there's established levels at both clinical levels of concern, as well as levels of concern that indicate elevations in the general population. Much of our effort is mining the literature and mining different resources and pulling them together to understand where those levels -- what those levels might be and what the most appropriate level is for the given scenario, whether it be an acute exposure or a chronic exposure. So that's one approach.

The other approach is to begin to kind of -- I know years past, there was a discussion at this forum on BEI levels. And the approach we're taking is somewhat a hybrid of the two, where if we have an analyte, and there is no established clinical reference level, but there is an environmental exposure level that has been developed based on a critical effect in an organ system, whether it be in an epidemiological or an animal study, begin to really mine those toxicological data and understand what the critical effects are.

And then couple that qualitative or semi-quantitative information with the information that's quantitatively based on the biological monitoring to establish the level of exposure, and then begin to ask the
participants about once these levels are above an exposure level of concern, do they have health concerns, comorbidities that are consistent with the toxicological literature to prioritize? If you are above a median level, a 90th percentile, 95th percentile - and these are details we're working through now - what level of concern is a concern that's perhaps not a concern for the general population, but given your comorbidities, it might be a concern for you?

And these kind of considerations are really important at the participant level and become very important in the acute response. And when conducting statewide surveillance, perhaps less necessary, if it's from a normal healthy population, but information learned through the statewide sampling also informs that kind of approach.

Generally, that's kind of what we're working through. We're about a year and a half into our funding, so --

CHAIRPERSON BRADMAN: And it sounds like that investment of toxicological analysis and communication with the individual is really within the program. And I'm curious is that -- within Biomonitoring California, our Panel has generally suggested that the Program stay away from tox interpretation just because of the potential, you
know, gnashing of teeth between different stakeholders on
how to interpret it. And incorporating that
potentially -- those potentially fraught issues within the
Program, you know, can create challenges that should be
handled more in regulatory arena. And so I'm curious,
does that come up in Massachusetts or in other settings?

DR. NASCARELLA: Well, I think, you know, one of
the benefits of a Biomonitoring Program in the health
department in Massachusetts was we are not the
environmental regulator, and it's not a regulatory action.
We are really focused on providing information to the
participant that either informs a public health
intervention or provides them with meaningful information
to seek treatment, if necessary.

So it doesn't have to be a regulatorily -- a
regulatory enforcement level. It doesn't have to go
through that level of scrutiny. It simply has to provide
meaningful information to the individual on this is
information that we recommend you talk to your physician,
or usually we recommend you take this information to your
physician and call this number. And we'll refer them to
the PEHSU or we'll refer them to a medical toxicologist,
but it's really providing them with information.

And in the background, we use the research I
mentioned to really underscore how hard we sell that
message. In other words, we recognize that you have impaired biliary excretion. You've been exposed to a chemical that this is a concern for you. We strongly recommend you speak with your physician about this, if you have any of these health effects that you see on this participant outreach information.

So we're not establishing levels that have to be technically right. We're establishing levels that are informed by the toxicological information to enable the participant to have a conversation with their physician.

CHAIRPERSON BRADMAN: Thank you. That's great.

DR. NASCARELLA: You're welcome.

CHAIRPERSON BRADMAN: I'm curious, do any other states or any comments from the Panel on this issue?

MR. MIHALIC: Just real quick. In our -- this is Jason Mihalic with the Four Corners. Our states take a very different look. Utah, for example, will use the information for policy purposes. Whereas, Arizona will use the information for recommendation -- public health recommendations. So it really depends on the politics of the state as to how this information will be used.

CHAIRPERSON BRADMAN: Dr. Schwarzman, was there another comment down here too or -- okay well, I guess you're up first.

PANEL MEMBER SCHWARZMAN: Thank you. I had
follow-on question to Dr. Bradman's line of inquiry, and hearing what Massachusetts is doing with the health effects level. It sounds like you're doing an amazing amount with very -- what can be very spotty data, and difficult to sort of draw conclusions from. And I wonder how you deal with exposures to pregnant women?

DR. NASCARELLA: So thank you for the question. Marc Nascarella, Department of Public Health in Massachusetts.

The exposures pregnant women we handle them, I guess, much in the same way. Many of these -- many of these chemicals, if they have toxicological information that indicates that they are a developmental toxicant, we convey this information to them as well. We provide them with information on our participant outreach material that indicates the risk to both the mother and the developing fetus, if the data from the toxic -- the review of the toxicological database indicates that it's warranted.

And, you know, for many of these chemicals, you're right, the critical effect is -- has been developed based on an understanding of an in utero exposure.

CHAIRPERSON BRADMAN: Dr. Quintana.

PANEL MEMBER QUINTANA: Hi. This is Jenny Quintana from San Diego State University. I was -- on a different topic, I was very pleased to see New
Hampshire -- representative from New Hampshire talk about measuring cotinine in the biological fluids, because of course exposure to secondhand smoke is truly a source of metals and PAHs, and some of the many contaminants that you mentioned measuring.

   So I guess I'm curious as to people who are not measuring measures of tobacco smoke, how you approach this issue? And for New Hampshire, given the rising popularity of e-cigarettes, and the fact that cotinine may also reflect exposure to nicotine in e-cigarettes have you thought about moving to NNAL or other markers as well?

   MS. NASSIF: That's -- that is the question, isn't it? So, at this point, we have not thought about moving to those others simply because of a capacity issue. I think we'll start with cotinine, and as we move forward, if it appears, and the data coming out of CDC, and other states that are looking at e-cigarette information, if it appears that we should move in that direction, then maybe in subsequent years we will.

   PANEL MEMBER QUINTANA: So for other states, are you considering -- how do you handle exposure to secondhand smoke, which is truly a big population source of, and can help interpret, levels of these markers in biological fluids. For metals and PAHs how do you handle that exposure?
DR. NASCARELLA: In Massachusetts, we do administer an exposure questionnaire where individuals will identify if they are a cigarette smoker above a certain level. We quantify that level.

And I agree with you that cigarette smoke is a contributor to many of the analytes we're measuring. And that's essentially how we ascertain if they are a smoker or not a smoker.

MR. MIHALIC: From the Four Corners, we did consider cotinine in our application process, but opted for the actually six analytes of interest that we felt had a bit more bearing on the Four Corner states. Not to say that secondhand smoke is unimportant. It's just that we're really looking more from the sample collection and methods utilizing urine, rather than sputum. So when we sent in our application, we opted not to include cotinine.

MR. WYATT: Shane Wyatt with Virginia. We're taking the approach, as like Massachusetts, we're discriminating between smokers and non-smokers in the exposure questionnaire.

PANEL MEMBER QUINTANA: This is just an issue where I feel that it's helpful to measure secondhand smoke exposure, as well as firsthand smoke exposure - and I'm also speaking to the State of California here - not so much to measure that exposure per se, but to help
interpret variability in the results to the participants.

MS. TOTH: Barbara Toth, New Mexico Department of Health.

I would like to add to what Jason said about our attempt to measure cotinine, but what we are doing in -- at the Four Corners Consortium states, we -- similar to Massachusetts, we are using exposure survey, which has several questions about past and current smoking exposure, and smoking habits as well as -- if the participant does not smoke or has never smoked before, if there is any other member of the family who smokes? So it would capture also second-hand smoke exposure.

CHAIRPERSON BRADMAN: Any other comments from the Panel?

Dr. Bartell.

PANEL MEMBER BARTELL: Just a brief comment. And I think you all are probably aware of this. But, you know, one concern about relying solely on the questionnaire data is particularly if you're going after high-risk populations like pregnant women, they're sort of notorious for underreporting smoking, and other things during pregnancy.

PANEL MEMBER McKONE: I have another topic.

CHAIRPERSON BRADMAN: Sure.

PANEL MEMBER McKONE: Have we finished
confounding or smoking?

CHAIRPERSON BRADMAN: I think we have. So, please.

PANEL MEMBER McKONE: Okay. So I'd like to raise another issue, which is I sort of raise this wearing a hat of like a research -- what researchers can expect, particularly researchers working on research that supports regulation the decision-making on exposures.

And, you know, the NHANES data has, over the years, been remarkable for doing a lot. But the one thing that you can't do with it -- you can do a lot of population variability, but you can't do geographical variability. And there's a very good reason for that. It's not like CDC is being unfair. I mean, CDC had a choice, and you can't include the kind of representation and probabilistic sample needed. By trying to capture that other element, it would destroy the value of the data. So I understand why it's not done. I think we all do up here.

But the question is, as we move forward and the states start doing more of their own biomonitoring, there may be an opportunity -- and again, I'm looking at this for the future of our research -- to see more geographical variability and how that might play out.

I mean, it's a bit of a dream in some ways, but
maybe it's coming closer to something we can have, because there's been a lot of regulatory decision-making at places like EPA, but even CalEPA that require and understanding of hot spots or hot regions and you can't -- you can't use NHANES. It's a national sample. You really need something much more specific. So my question is like is that under consideration. And if so, what are the opportunities and maybe some of the timelines for bringing about the opportunity for geographical variability?

DR. MOWBRAY: So this is Amy Mowbray from CDC. I can't give you a timeline. I would say that, you know, over the course of the last several years, we've been very focused on building infrastructure for biomonitoring and the states to just establish capability.

And I mentioned earlier that we're working with the Association of Public Health Laboratories on a National Biomonitoring Network. And we had a meeting in June of stakeholders from various, you know, obviously the states, but EPA and our sister divisions within the National Center for Environmental Health that are involved in the Public Health Tracking Network as well.

And I think a lot of the discussion is focused on starting small and starting to look at harmonization at a very sort of small level, where we're talking about the laboratory functions. I think, you know, everyone sort of
felt that the comparability of laboratory data across states was going to be a very big bite for us, but we are trying to engage other partners. And I mentioned the Public Health Tracking Network about how we might be able to look at data comparability across studies that would eventually get us to that point.

So again, this is sort of a very non-committal answer, but I think we are exploring those relationships and exploring how we might be able to house some data in the future and get data that would be comparable across states, but it's very early for us in that regard.

CHAIRPERSON BRADMAN: Okay. Dr. Quintana. And when you're done, I have a question too on a new topic.

PANEL MEMBER QUINTANA: Oh, go ahead.

CHAIRPERSON BRADMAN: No, go ahead.

PANEL MEMBER QUINTANA: Actually this question is for the Four Corners representative. In your paper, you mention tribal involvement, but I don't remember you talking about that today. And, of course, when I think of the Four Corners, I think of a very large tribal population with interesting exposures to uranium and other things.

MR. MIHALIC: Absolutely. And pardon me for not mentioning that in the talk. It was rather time limited, and I beg your pardon. Tribal, it's -- we are very
interested in working with the tribes, not just the Navajo Nation, which is -- goes into three of the four states, but in Arizona there are 28 tribes. So we've actually begun outreach to that end. It's a bit more complicated, just because each tribe will have their own IRB process. And this may be a process that lasts beyond the five-year grant, quite frankly.

But one of the -- the pyrethroid project actually came about from a tribal exposure question. Indian Health Services was using -- or actually it might BIA, pardon me, is using a pyrethroid pesticide for tick abatement. And there have been complaints to our health department in Arizona with regards to the safety of that particular pesticide.

And so it's projects like that that originate in a community that we've then wrapped up into the grant, that will then allow us to go back into that community and work. And in addition, the well water study is also of huge interest with our tribes. And in addition, one of the advantages really of being a consortium in this case is to work with the Navajo Nation.

Since they do cross state borders, they tend to -- obviously, they see themselves as a whole, but the three states see the entities within their state, but we are approaching the Navajo Nation as a whole, because we
are all part of the same. And it's little factors like
that that really allow us to at least gain entry. And so
that's very much on our radar, absolutely.

CHAIRPERSON BRADMAN: I have a last question - we
have a few more minutes - about children and sampling from
children. I've noticed that both in Utah and in Colorado,
there was talk about sampling down to kids as young as age
three. I had a question for Michael of the FREES study.
Is there any plan to look at exposures in young kids, in
any of these, I think, households? It wasn't clear to me.

And then I'm curious across the board, have --
has there been attention paid to getting samples from very
young children and just curious about the success or
challenges with that?

DR. DiBARTOLOMEIS: So this is Michael
DiBartolomeis. Let me just get the specific question out
of the way. The pilot study does not involve children.
If this works we may, you know, in the future expand.
We're actually going to talk about that a little this
afternoon about what's on the 2016 kind of agenda items.
And I think children is going to come up. So with that,
I'll pass it on to whoever else wants to respond.

DR. NASCARELLA: I'll say that our study design
does include obtaining samples from children. We have
this year responded to several acute exposure events where
we've collected samples from children.

We do have IRB approval for surveillance of public health surveillance. So our work is not research, so we kind of have IRB authorization to do this, clearly focused on a public health intervention or to inform our programmatic responsibilities to the state. When collecting the samples from the children, we have both a consent and an ascent procedure for children that are of a certain age. We have them go through an ascent booklet, which describes the process and what's going to happen, so they understand in an appropriate manner. It's a coloring book style what's about to happen. And we get their ascent as well as the parent's consent.

MS. NASSIF: In New Hampshire, we will collect urine specimens from children. We've decided not to collect blood specimens from children, unless it's a medically indicated test.

DR. PARSA: Currently, New Jersey don't have any plan for children's studies.

CHAIRPERSON BRADMAN: It's about 12:00 o'clock. We have two minutes. If there's any -- anyone dying to ask one more question?

Otherwise, we have statement now on the Bagley-Keene and the upcoming break.

MS. HOOVER: Yeah. Let me just -- I'm going to
hand you this little note. Two things before you do that. One is so I mentioned these program profiles, which some in the audience might not have. Those will all be posted on our website, so those will be available. And it's really fascinating to learn about what's going on across the states.

Asa is going to make a quick announcement about lunches, and then Carol will give the Bagley-Keene reminder before we break for one hour.

CHAIRPERSON BRADMAN: Thanks. So for those of you who purchased lunch boxes ahead of time, those will and be available shortly, and they're set up in Room C160. And for those of you who did not purchase lunch ahead of time, which is probably most of us, there's a cafeteria you probably saw right around the corner, and there's food available there.

We're going to take a break at 12:05. We're going to have a statement about the Bagley-Keene rules in terms of discussions while we're not in session. And importantly, we're going to start promptly at 1:05, at the end of the lunch hour. And we ask that people return here by 1:00 PM, so we can get settled in and really get started at 1:05.

CHIEF COUNSEL MONAHAHAN-CUMMINGS: Hi. This is Carol Monahan-Cummings. I'm sitting behind you. I'm the
Chief Counsel for the Office of Environmental Health Hazard Assessment. And I'm just here to remind you that the Panel does have some discussion items this afternoon, where you're going to be taking a vote. And so please don't discuss those with members of the public or among yourselves, unless you come back and explain what you talked about here on the record. So probably best to talk about something else. Sounds like there's plenty this morning to talk about.

So anyway. Thank you.

(Off record: 12:00 PM)

(Thereupon a lunch break was taken.)
AFTERNOON SESSION

(On record: 1:05 PM)

CHAIRPERSON BRADMAN: We're going to get started now. I want to -- are we missing -- just one, okay.

I want to welcome everyone back from lunch and officially call the meeting back to order. And I want to introduce Sara Hoover, who is the Chief of the Safer Alternatives Assessment and Biomonitoring Section and the OEHHA lead for Biomonitoring California.

And she'll be introducing the afternoon session and the speakers, so take the floor.

MS. HOOVER: Thank you, Asa. Yeah, welcome everyone back to our afternoon session. We're really pleased to have two speakers today. Dr. Rachel Morello-Frosch and Duyen Kauffman at CDPH. And Rachel is going to talk to us about the topic you see on the screen, educating biomonitoring participants about their exposure to environmental chemicals, what does the science say?

And we've had a long-time collaboration with Rachel in these topics. We've worked for years together on this, so we're thrilled to have her come to talk to us about it.

Rachel is a professor in the Department of Environmental Science, Policy Management, and the School of Public health at UC Berkeley. Her research examines
race and class determinants of environmental health among
diverse communities, with a focus on social inequity,
psychosocial stress, and how these factors interact with
environmental chemical exposures, and she's looked at
these kinds of questions in a variety of contexts,
including, for example, her work on prenatal exposures to
environmental chemicals.

She's also looking at applications of
non-targeted approaches for biomonitoring, and she's also
analyzing the bioethical challenges of exposure assessment
and chemical biomonitoring in marginalized communities and
how to communicate results in ways that inform study
participants about exposure sources and potential health
implications. Rachel.

(Thereupon an overhead presentation was
presented as follows.)

DR. MORELLO-FROSCH: Hi, everyone. It's a
pleasure to be here today. As Sara said, it's been great
working with the California Biomonitoring Program both on
a project, which I'm going to talk about today, the MIEEP
project, and then also figuring out the ethics of results
communication in studies, and the best way to sort of test
our materials, which I want to talk about today as well.

--o0o--

DR. MORELLO-FROSCH: Okay. So today I want to
give you just a quick and dirty overview of some of the things that this Panel has talked about before in terms of scientific challenges and ethical frameworks for results communication, and then touch a little bit on some research that we've done in terms of lessons that we can learn from other fields, such as genetics research and brain neuroimaging research, and then segue into some work we have done where we have interviewed study participants in a variety of studies. I'm not going to talk about all the results here today, but just give you highlights of how participants reflect on getting their results back, and then what are some of the implications for ethical decision-making and results communication.

--o0o--

DR. MORELLO-FROSCH: So, you know, we're very lucky, in that technologies for biomonitoring just keep getting better and better. We can analyze more chemicals at lower and lower levels, and -- which is great, but our technology is definitely outpacing what we know about the implications of the exposures that we find for the communities that participate in our studies.

And so this is particularly true for emerging pollutants, novel chemicals that we discover. And sometimes we often can't say anything about what it means for health. And sometimes, we can't say very much even
about how people are getting exposed. And so as one of our study participants who we interviewed who participated in a biomonitoring study has eloquently said, you know, none of these chemicals that you've told me about, you know come with a return address. In other words, that sometimes it's difficult to figure out where this stuff is coming from and what I can do about it.

--o0o--

DR. MORELLO-FROSCH: But we have ethical issues in terms of reporting back. And for some chemicals it's a no-brainer for something like lead. We have guidelines and levels of concern that trigger reporting requirements. Most health departments have protocols for how to do that. And we do it because we want people to be able to take action to reduce their exposures, and so lead is a good example of that.

--o0o--

DR. MORELLO-FROSCH: But a harder example are some of the emerging contaminants for which we don't have benchmarks or levels of concern, or for compounds that have been banned, okay, and yet are still very persistent in the environment and which still show up in our bodies, and/or compounds where maybe at an individual level you can do something in terms of consumption behaviors, eating organic. But other participants, for example, farmworkers
who are exposed to pesticides, you tell them about their exposures, but their ability to control conditions in their workplace to reduce those exposures is quite limited.

So the tension between right to know, your information in terms of what you're exposed to and the realities of your ability to act upon that information.

--o0o--

DR. MORELLO-FROSCH: The other issue I think that emerges is scientific uncertainty when you encounter incidental findings, which often happens in biomonitoring studies. And sometimes tensions that we have in terms of individual versus community right to know, individual participation in studies which can have implications for entire communities.

--o0o--

DR. MORELLO-FROSCH: So probably the poster child for that kind of individual community tension was the first study that was done on the Inuit in the circumpolar north in Canada. And the idea was to test breast milk for certain industrial compounds. And originally people thought that this community would be an ideal quote unquote control community, and that levels would be -- expected to be quite low, because they were not living in places near industrial production.
When those results came back, the levels in breast milk for things like PCBs were unbelievably high. And so initially what happened was when it came out that, you know, these surprising results, the impact on the community was problematic, because the initial community that was tested faced a fair amount of stigma. Because they were known as the PCB people, other Inuit communities didn't want to trade with them.

Eventually, it was revealed that this is -- was a ubiquitous problem within communities across the circumpolar north. But this is sort of a -- sort of cautionary tale in terms of really understanding those tensions and the broader community impacts when we're doing results communication.

--o0o--

DR. MORELLO-FROSCH: So given some of the scientific challenges, as well as some of the ethical issues, our perennial challenge is what do we tell study participants about chemical exposures, both in terms of personal exposures in their homes, if we're not just biomonitoring. I know the focus here is on biomonitoring, but this can also be about personal exposure assessment, air and dust sampling in homes, for example, as well as biomonitoring.

--o0o--
DR. MORELLO-FROSCH: So until recently, most people followed what we like to call a clinical ethics model, where individual level report back to participants was based on whether or not we had a clear sort of benchmark, and clear implications for health were -- could be conveyed. So this is very kind of biomedically focused, very expert driven, health professionals and scientists decide when and how to report back.

And so -- that means that for a lot of chemicals for which we don't know the health implications, there wouldn't be any report back. And now I think more people are realizing that there are some drawbacks to this kind of clinical ethical framework for results communication.

One is that it somewhat contradicts the current trend in medicine where patients are increasingly being encouraged to be empowered and proactive in directing their health care, patients are getting the results of lots of tests in health care settings. Sometimes the implications are not always clear. The other thing is it -- by not reporting back, we're limiting participant's ability to learn from their participation in studies and also maybe depriving them of opportunities to reduce or prevent exposures.

And we also know that benchmarks change, and that
there are -- now we know that there are potential health
effects below action levels. In the case of lead and
mercury, we know that's definitely the case. Here's just
sort of the evolving --

--o0o--

DR. MORELLO-FROSCH: -- benchmarks over time.
Okay. So if we sort of use that as our strict threshold
opportunities for prevention are far gone, which is
ethically problematic.

--o0o--

DR. MORELLO-FROSCH: The other sort of project
that we have written about in our work is -- and this
aligns with this current trend in medicine to provide more
information to patients is known as the Open Notes
Project.

And this was developed by Delbanco and colleagues
to really see whether or not patients could get access to
doctor's notes during regular appointments and see them
and what is their reaction to getting that kind of
information, does it improve their understanding of those
meetings, indicators of their health status, does it
enhance decision-making -- shared decision-making, and
empower them in terms of understanding what's going on?

There was some concern that maybe patients would
be worried at seeing that kind of -- those notes. And, in
fact, the results have been that in terms of testing, that
patients who had access to their doctor's notes were more
likely to adhere to medical regimens. They reported
feeling more informed, in control of their health care,
and they didn't have a lot of privacy concerns or worry or
confusion in terms of access to the notes.

--o0o--

DR. MORELLO-FROSCH: Other fields are the fields
of genetic research. Genetics is kind of -- is someways
similar in terms of trends, technological innovations,
that's going on in chemical biomonitoring. We have a lot
of technological change in genomics. It's catalyzed a lot
of large scale projects, and increasingly people are
wanting access to their genetic information when they
enter these studies.

Similarly, neuroimaging research has expanded and
has crossed a lot of fields. It's not just neuroscience
anymore. It's economics, psychology. There's even a
field called neurolaw. So a lot of these neuroimaging
studies come across incidental findings. And again, this
field has struggled with the extent to which they should
be reporting back this type of information to study
participants when the clinical significance may not be
clear.

--o0o--
DR. MORELLO-FROSCH: So there's been some work done in the field of genetics research in particular, but also neuroimaging research, where they have interviewed patients who are participating in genomic studies. And there is lot of support among participants for wanting to get this information back, even if there is a pretty high level of uncertainty about the health implications.

In fact, learning their results in participating in these genetic studies is a huge motivator for them to participate in these studies in the first place and to keep them in. They want this information. It's something that keeps them connected.

The other thing is that the reporting of genetic results, contrary to what people initially thought, does not necessarily cause undue worry. So there's -- in one particular study they did a randomized psychological assessment on disclosure of a genetic allele associated with increased risks of Alzheimer's disease, and it did not increase reporting of -- that result to participants did not increase in terms -- did not lead to more anxiety and depression and worry among participants who got that information.

--o0o--

DR. MORELLO-FROSCH: So there has been a consensus workshop among genetics researchers as well as
neuroimaging researchers to kind of address this question. And how do we think about this a priori before we -- when we're developing our study protocols about when and how we're going to report incidental findings or genetic information whose clinical implications are not particularly clear.

And this schematic seeks to kind of put this in sort of -- create a visual. So here we look at sort of the potential health risk of the information from low to high. Is there a clinical utility of the information, so that a condition can't be treated, or what it means is really not known to very high -- has high clinical utility.

And then looking at sort of the net benefit to the participant from low to high. And so they tried to come to some kind of consensus about when they might report in terms of participant preference at when they are enrolled in studies.

So they have decided that when all of these things are low little clinical utility net benefit and health risks are low, they would not disclose. But as you go up this chain, you would disclose even in situations where you have participants when the health risk and net benefit and clinical utility are high, even where a participant has indicated at the beginning of the study
that they are not -- they want to support science, but they don't necessarily want this information that you might actually break that.

So this effort of them to kind of struggle with this question I think is interesting for those of us who are in the field of biomonitoring. I also -- I don't have time to talk about this today, but I also -- this is also becoming, I think, increasingly relevant, because genetics is also becoming more privatized. There's a lot of direct consumer marketing for genetics. Biomonitoring less so, but there could be a situation where there is more sort of privatization and direct marketing to people who are interested in being biomonitored and getting that information.

--o0o--

DR. MORELLO-FROSCH: So in terms of our work, we have been interested in whether or not, you know, people who get their results experience undue worry and harm. And in our studies, and in studies that we have looked at that were not carried out by us, in general, people overwhelmingly want their biomonitoring results, if given an opportunity to get them.

And the other thing is knowledge of chemical exposures does not necessarily lead to counterproductive behavior. So a good example of that is breast milk
studies, does telling people that there are chemicals in their breast milk change breast feeding behavior?

So I think a lot of people have assumed that it very well could. There has been one study that has looked at this, and that found that, in fact, it did not appear to change the duration of breast feeding in that population. So I think that, right now, it doesn't appear to change these kinds of behaviors that we care about.

--o0o--

DR. MORELLO-FROSCH: So we are definitely in new a kind of era where before we had sort of been constrained by clinical ethics framework, and now I think a lot of biomonitoring programs and even academic studies that entail biomonitoring have moved towards right to know. California -- Biomonitoring California is clearly one of them as this is codified in the law itself.

--o0o--

DR. MORELLO-FROSCH: And so now our challenge is we have to tell participants what we find, and what do they want to know?

Our experience is these are sort of the basic questions that they are interested in having us answer. Very straightforward, and as we know not necessarily always the easiest to answer. What did you find, how much, is it high, is it safe, where does it come from, and
what the heck should I do about it?

--o0o--

DR. MORELLO-FROSCH: So we embarked on a study called the Personal Exposure Report-Back Ethics Study. We have been interviewing study participants from a variety of biomonitoring studies across the country. So these include more traditional academic studies, as well as, quote unquote, advocacy biomonitoring studies led by NGOs, where participants are more public about their participation in these studies.

We've also been interviewing, in addition to study participants, IRB members, and as well as researchers themselves to get their opinions on these. We've held workshops. We've done a lot of user testing of biomonitoring reports, and we're also in the process of developing a digital report-back interface known as DERBI.

And collaborators on this include Silent Spring Institute, Berkeley, Northeastern, Harvard, Commonweal, and we've gotten NIH funding to support this.

--o0o--

DR. MORELLO-FROSCH: So our interviews with study participants are about an hour to an hour and a half. We analyze them for different kinds of themes in an iterative process. And we're basically just trying to get a sense of what kind of meaning they find in their results and
what is their experience.

DR. MORELLO-FROSCH: So one of the studies where we have followed up is a collaborative biomonitoring project known as Maternal and Infant Environmental Exposure Project, which we undertook with the Biomonitoring Program as well as UCSF. It was also known as Chemicals in Our Bodies. It's a little more clearer for the study participants. We sort of changed the name when we were consenting them in the study.

So this was a project where we recruited around 90 pregnant women who were getting prenatal care at San Francisco General. We measured chemicals in the mothers and their babies at delivery. And most of them are predominantly Spanish speaking. They were also English speaking.

DR. MORELLO-FROSCH: And we analyzed them for chemicals in maternal and cord blood. And we also -- we -- they -- the participants got their results back. And I'll tell you the process by which we did that, but I want to give you a sense of sort of what they -- what their reactions were to getting the results.

We went back after participants got their results, and interviewed them. And these are the kinds of
things that people learned, and both in Chemicals in Our Bodies but also in the other studies in which we interviewed study participants.

People learned that there are a lot of chemicals in their bodies. And many of them -- actually, people, for example, who are very self-aware sometimes go into these studies assuming that you're not going to find much, and they're kind of shocked when you do, so people who eat organically, these kinds of things.

The other thing that's surprising to them is that we find chemicals that have been banned for decades that are still in their bodies. That the stuff comes from a variety of sources, and they're very -- they want to know where they stand. They want some kind of point of reference, like where did I come out compared to other study participants, where am I compared to the average, and even better, if there were a health guideline, but usually there isn't.

And the other thing that's a huge eye-opener for many participants is for them chemicals are something that you are exposed to from out there, a large facility, a roadway. And many of them realize that a lot of their exposures come from household products, things that they use every day, which is a huge eye-opener for them.

--o0o--
DR. MORELLO-FROSCH: Participants go into these studies, in part because they are motivated to help the science, to advance scientific knowledge. That is a huge, huge motivator for them to get involved in these kinds of things in the first place, what we call research altruism. The other thing is upon getting these results, you know, pollution becomes personal. It makes them think, how am I getting exposed, how does this affect my health, how might this affect my family, what are the health implications?

And the other thing is how come there isn't more regulation and health information on these chemicals? That sparks that kind of conversation, and a sense of what we start to call toxic trespass. Despite some of their best efforts, you know, they're still exposed.

--o0o--

DR. MORELLO-FROSCH: So some of the reflections are frustration at information gaps, really trying to understand how they might reduce exposures. So here's a quote from a study participant. This is not in Chemicals in our Bodies, but in terms of what they want. And so what -- what I would want from this study is give me something I can do about it. Don't just give me information that tells me I have problems, because that's frustrating.

But I'm proactive enough to say, okay, I have
this information, and now it's up to me to do something. So a lot of motivation to try and reduce exposures.

--00o--

DR. MORELLO-FROSCH: Different reactions to receiving results. Some people are really surprised, okay? So people say I don't have any strong chemicals in my home, I don't have anything out of the ordinary that some other person wouldn't have. So what did I do to get such harmful things in my body, and more than anything what can I do to eliminate them?

But then you have other participants, this one -- these are from Chemicals in Our Bodies, who say, "I know the world we live in". In other words, they're not surprised. They fully expected us to find something.

And then others who expected it because of the nature of the work that they do, and they assume that they're probably going to have high levels or levels of something.

--00o--

DR. MORELLO-FROSCH: The other issue is definitely trying to understand and distinguish between individual and community action, and sort of realizing that maybe government isn't doing as much for them as they could. So one participant says, "I'd like to see an increase in a factor of about 100 in the governance
interference in the manufacturing process. We are at an absolute low point in governmental regulation. We are so far from what the government should be doing".

"Well, it was useful that it doesn't matter how cautious you are, because you are always exposed to all kinds of chemicals, also, one is more aware of what one can do and the precautions one should take".

--o0o--

DR. MORELLO-FROSCH: So we interviewed researchers as well. And researchers are finding that this report-back process is useful to them. It's an opportunity to just -- for discovery. When you talk to participants about what you find, you start having conversations about potential sources. Some participants even say that you can actually learn a lot from an N of 1, when you have, for example, anomalous results. And you go back and you talk to that participant about what's going on, you might discover new sources of chemical exposure.

The other thing is there's always a temptation among researchers to reassure participants, you know, when you're reporting that you find chemicals in their bodies. So a lot of statements of, "...there's no evidence that...", outdated EPA guidelines. Sometimes they realize that when they say, "...there's no evidence that...", it doesn't mean that studies found negative results. It's
just that there isn't any data.

So -- and still some people struggle. It's like
is reporting this information really helpful? Are we
causing people undue worry? On the other hand, people
have a right to know. That sort of tension, I think,
researchers still struggle with that.

And then just help them rethink this -- the ideas
about health literacy and giving participants agency, and
sort of democratizing and helping them understand the
scientific process and all of its challenges.

So one researcher participant said to us, "When
science is uncertain, the goal is not a public health
message to tell people what to do, but stimulate a
conversation having. Heaven knows, we need to find a way
to talk about health policy above the first grade level".

So sort of getting beyond sort of traditional
public health messages and really just helping people
understand the nature of environmental health and
chemicals and what are some of the broader implications of
these exposures.

--o0o--

DR. MORELLO-FROSCH: So in terms of
recommendations, in materials just really thinking about
the cultural context in which you're doing report back,
and really understanding the difference between cultural
competency versus literacy. We really promote engaging
different learning styles and visual styles. Some people
are text people, some people are graph people. And some
of the challenges are just, you know, we don't have
benchmarks, so how do we do our best job in terms of
contextualizing these results. And then the challenge of,
you know, the time gap between when we take samples and
when we return results to participants is -- still can be
really long. So when you come back to participants,
they've almost forgotten about you --

--o0o--

DR. MORELLO-FROSCH: -- or sometimes they
wondered where the heck you'd been for all that time.

And I think the other strong issue I want to
emphasize is that we want to address opportunities for
individual versus collective action. I think often we
focus on individual action. And I think we want to lift
up opportunities for participants to engage in collective
action.

So, you know, participants says, "At first, I was
thinking, 'God, I wish I didn't know all this', but the
more I think about it, the more I understand it, the more
I feel like it helps me to do whatever I can...if you know
the information then you can't not participate in trying
to make change".
DR. MORELLO-FROSCH: So really thinking about when we're reporting back helping participants distinguish between exposures which might be more conducive to individual action, like eating organic, or changing your purchasing behaviors. And then there's just some exposures that individuals can't -- don't have any control over. And I think it's important for us to be transparent about that. And that requires more fundamental policy change.

DR. MORELLO-FROSCH: So here's an example. You know, pesticides -- you know, individual action can really go a long way. Organic, you know, the research really is pretty compelling on that, at least in terms on the consumer exposure side.

Flame retardants, less so, okay. People's ability to control their exposures to those things are much more limited.

So the last thing I want to cover here is that participants can really help us think about results communication protocols and how we can develop these in ways that are helpful to them. And so where -- you know, it was great when we did the MIEEP study with Biomonitoring California, because we had the opportunity...
to actually trial run materials before we actually did report back, which was just phenomenal.

--o0o--

DR. MORELLO-FROSCH: So we did what's called usability testing in our Chemicals in Our Bodies participants, where we showed them prototype materials and before -- you know, before report back happened and asked them, you know, what do you think? We want you to pretend that these materials are your data go through this and tell us what you think, and what's good about it, and what's terrible, and how can we make it better?

--o0o--

DR. MORELLO-FROSCH: So just to give you an example of how participants can really help you make things better, this is the prototype that we started out with in terms of summary materials. And this is what we showed participants. So lots of texts going in all kinds of directions. And after usability testing, several iterations of usability testing, this is what the text ended up looking like, okay?

So it became -- it was initially crammed on -- all on one page, and then we ended up with a lot more space and spread out over two pages.

--o0o--

DR. MORELLO-FROSCH: They also gave us feedback
on our graphs, and graphs are an interesting issue. Some people love them, some people don't. And here, it worked pretty well with this population, but they gave us some nice feedback on changing the legend. This blank, they didn't quite know what it mean. So other sort of tweaks to make that more understandable, helped us improve the legend, and make clear when levels were below the detection limit.

--o0o--

DR. MORELLO-FROSCH: So again, I think usability testing when you engage study participants before you report back, you can really sort of have a great opportunity to make sure your protocols are resonating with them. These are some of their reactions when we -- when they were reviewing the prototypes, which I think was really helpful and made us feel like, okay, this -- we're doing the right thing here in terms of which messages are resonating. And then also getting feedback on which ones maybe not so much.

--o0o--

DR. MORELLO-FROSCH: So I just wanted to leave you with some materials. We -- as a result of a lot of our work, we have created a report-back handbook called, "When Pollution is Personal". It's available for free on Silent Spring Institute's website. We've also published a
lot on this topic.

--o0o--

DR. MORELLO-FROSCH: And we are developing a
digital exposure report-back interface, which hopefully
will make report back less cumbersome and more nimble
depending on the study population that you're working
with. The beauty of this is that it's geared towards
people who are more digitally inclined, but you can also
still continue to give people paper for those participants
who are not, you know, computer savvy.

And this is now being used in several different
studies currently. We're currently in the process of
doing focus groups and testing it for a study that we're
doing on -- with firefighters in the City of San
Francisco.

And it has also a lot of really nice features for
researchers themselves in terms of understanding what the
data says in different kinds of groupings. And the other
beauty of this is that you can collect analytics when
people are opening up their results. You can get -- you
can see what the mouse clicks are, where people -- which
pages people are hanging out on, all kinds of things. So
it can give you information that you might not otherwise
be getting by just using paper.

--o0o--
DR. MORELLO-FROSCH: So I just want to conclude here by saying that -- make a real plug for, you know, these biomonitoring projects and engaging study participants in results communication itself in the development of protocols. I think it's a huge opportunity to promote the program, to enhance environmental health literacy and to make sure that results communication and report back is useful to participants and to help them distinguish between the things that they have control over as individuals and the things that they may not.

And when you can engage them in that process, you can take into account what their expectations are from studies before you, you know, report back to them.

And I think the other thing that I have learned in my work doing biomonitoring studies is that results communication protocols are always in beta mode. You're just always making them better. You're always tweaking them. And you're always going to be changing them, depending on the community or the types of participants that you are collaborating with or engaging and enrolling in your studies.

--o0o--

DR. MORELLO-FROSCH: So I just want to thank colleagues both here at Biomonitoring California that has enabled a lot of this work, as well as my other colleagues
and our funders.

--o0o--

DR. MORELLO-FROSCH: And we have a lot of papers. I'm happy to make them available to you electronically. And thanks so much.

(Applause.)

CHAIRPERSON BRADMAN: Thank you. We have about -- a few minutes scheduled right -- yeah, 10 minutes scheduled right now for just clarifying questions and then we'll go into our next topic. I want to emphasize that we have after the next talk, we have a lot of time scheduled to discuss this issue in depth. So let's just limit questions right now to clarifying questions, but we'll have a lot more time for discussion.

Any questions -- and that includes the audience, not just the Panel?

It looks like we have one question. Dr. Quintana.

PANEL MEMBER QUINTANA: Hi. Jenny Quintana, San Diego State University. One of your slides you had divided environmental exposures into things that were under their personal control and things that weren't, such as flame retardants versus consumer products, but I was curious how you -- if you had thought about including diet more explicitly, not just organic versus non-organic, but
a lot of persistent pollutants are coming through the diet via magnification. And I'm just curious if you had thought about that as another category and how you felt about it?

DR. MORELLO-FROSCH: Oh, yeah. So again, I think, for example, for the persistent pollutants when we're reporting back, you know, in this sort of what you can do about it, we do lift up when there's opportunities for dietary changes. Those are individual actions. So I'm not saying there's like, you know, only one or the other for each chemical.

Oftentimes, it's a little bit of both, but I think the tendency, particularly those of us in public health, is we feel like we're not doing our job if we don't give things that individual people can do. And I think if we need -- in addition to giving people individual things they can do like dietary changes or changes in the products that you use and bring into your home. There is also -- I think we could do a better job at acknowledging that you can do all of that and you still will not eliminate all of your exposures. That there are kind of fundamental policy issues and regulatory issues that are -- need to change to really completely eliminate or really, really decrease. And for certain categories of chemicals, those are really -- there's just some that are
very hard to control your exposures as an individual.

DR. FAN: It's a very interesting talk.

Tina Fan from New Jersey Public Health Laboratory. I just have a question. It's very interesting. I just wonder whether you have done analysis, like you got a different response. You know, when you give the results to the participants, so you got different response from them. So have you tried to analyze that -- you know, the response based on what is their education level or different type of background what type of response you get?

DR. MORELLO-FROSCH: Yeah. So we are in the process of doing that. So we're fortunate in that the studies that we have looked at vary a lot in terms of the demographics and educational attainment level, race and ethnicities, and geography. And even within some studies, there's some variability in terms of educational attainment level and things like that. So we are trying to look at that more systematically, mostly within studies, because some of these studies, for example, have been motivated by very localized kind of concerns about certain types of pollution sources, while others are kind of more general like, you know, Chemicals in Our Bodies, which is -- could be from anything.

So it's interesting, I think the educational
differences -- it's not that they're not important, but
they don't necessarily manifest themselves in ways that
you would expect. Yeah, so some -- some people become
very -- people, for example, with low levels of
educational attainment who hadn't thought about
environmental health before, they get their results back,
and all of a sudden this becomes a really important issue
to them, and they're very interested, because of the
learning that goes on.

Others are like really happy to contribute to
science. You give them their results, but there's a lot
of other issues going on in their life, and this is not a
big one for them, so...

CHAIRPERSON BRADMAN: Michael.

DR. DiBARTOLOMEIS: So thanks, Rachel. I thought
I knew a lot about this subject, but now I've learned that
I don't, so --

(Laughter.)

DR. DiBARTOLOMEIS: -- you had a slide where it
was kind of hidden, and it said the community or people
trust -- or distrust industry and government, I guess, in
terms of giving information. So I was wondering in your
research -- and if this is a discussion topic, then we
defer, but in your research or in your surveys, who do
people trust and, you know, if -- and then maybe in the
discussion piece, what do we do about incorporating the people that do -- that people do trust into our messaging and our return results?

DR. MORELLO-FROSCH: Yeah, I think the trust issue varies also by study. So I think the issue of trust emerges when people -- you're showing them that they have a lot of exposures, that these chemicals are of potential concern, that they come from products that they use all the time, and all of a sudden they realize that things that they thought were just assumed to be regulated by the government are not. So it's sort of like, well, so what is the government doing?

So, you know, I think that's -- but that opens up a conversation about why that -- why that happens. Other trust issues are very specific to their experiences. So some of these biomonitoring studies, as I've said, emerge because of community concern about a very specific source, and the community feels like the government has not done enough to protect them from particular -- from the industries that are responsible for those exposures.

So that sort of distrust of government comes from a very different place than, for example, someone who learns that consumer products aren't as regulated as they should be.

CHAIRPERSON BRADMAN: Why don't we just have one
last question and then we'll move on to the next presentation and more discussion.

DR. ESHRAGHI: This is Jamshid Eshraghi from Massachusetts Department of Public Health.

I was just curious when you did this study, did you notice any difference in responses based on their educational background?

DR. MORELLO-FROSCH: Yeah, so in answer to the previous question, you do notice some differences, but not necessarily as systematic as you might otherwise expect. I think some of the differences that you see is, you know, some people just have not thought about environmental chemicals before, so they were very happy to kind of participate in a study, and contribute to scientific knowledge, but they hadn't thought about chemicals before. You give them this information and all of a sudden this becomes a topic of interest to them, and they had never experienced it.

Other people you give them these results, they are of a lower socioeconomic status, it's interesting to them, but it's not -- compared to all the other issues they're dealing in their life, this issue of environmental chemicals is kind of low in the pecking order in terms of the things that they're concerned about in their life.

So you give them the results. You ask them if
they have questions, and then, you know, that's kind of it.

DR. ESHRAGHI: So the undue worry wouldn't make any difference on them -- people who are educated are less or more worried about this information?

DR. MORELLO-FROSCH: I would say that people -- it's -- the -- some of the worry is more from like -- the people I think who are most surprised and potentially worried are people who actually know a lot of chemicals -- know a lot about chemicals, and people who have done a lot in their life to try and avoid them, like who are knowledgeable and do all the quote unquote right things.

And then you come back and you say we still found stuff. And they're like, gosh, you know, I've done all the right things and I still have chemicals, what more can I do? Those -- I wouldn't say it's worry. It's just kind of more like frustration.

MS. HOOVER: Actually -- so, Sara Hoover, OEHHA. Rachel, I just had a couple questions, and sorry if I missed this. Have you actually used the electronic report back or you're still developing it?

DR. MORELLO-FROSCH: It has -- it has been used. Yeah, and it's also been used in paper format.

MS. HOOVER: And the next question is on the firefighters study in San Francisco --
DR. MORELLO-FROSCH: Yeah.

MS. HOOVER: -- are you doing any particular adjustments to the results return materials? Have you talked to that population up front or --

DR. MORELLO-FROSCH: Yes. So we're doing a series of focus studies. We just did one actually -- we biomonitored ourselves, the study team, and went through the experience of actually using that interface and getting our results, and then sort of did a debrief amongst ourselves. That has led to the first iteration of tweaks to the prototype that we will then test in focus groups with a subset of our participants.

Again, they will get kind of fake results, but they will be asked to log on and pretend that it's theirs and go through that process. And they'll have a focus group and get their reactions to what they thought about the interface, things we should be thinking about. And then after the series of focus groups, we will do one -- you know, the final round of tweaks before we actually roll-out the actual results when all the analysis is done.

So basically, two sets of focus groups, one on ourselves and then one on both our -- we have firefighter participants and office worker participants, so we'll do it on those groups.
CHAIRPERSON BRADMAN: So again, we'll have time for more discussion on this subject following the next talk. And, Rachel, were you going to introduce -- you were going to introduce Duyen.

MS. HOOVER: I am. Sara.

CHAIRPERSON BRADMAN: Sara.

(Laughter.)

MS. HOOVER: Yeah. I am really happy to introduce Duyen Kauffman. She's a Health Program Specialist at the California Department of Public Health. And she has been our results return coordinator since 2011. And she has overseen the return of individual biomonitoring results to more than 600 English and Spanish speaking participants in three of our major studies. And that count, I'll point out, is the number of people, not the number of packets. So she has done an enormous amount of work in producing really high quality packets for our studies.

Before she joined the Department of Public Health, she worked as a trilingual case manager for low income Latino and Vietnamese immigrants at the Public Health Clinics in Marin County. She has nearly 20 years of experience working in public health in the U.S. and abroad, including over three years as Vietnam country director for World ORT, which is the Organization for
Educational Resources and Technological Training.

Duyen.

(Thereupon an overhead presentation was presented as follows.)

MS. KAUFFMAN: Sorry.

Hi. Thank you, Sara, for that introduction, and I think I've just skipped ahead.

--o0o--

MS. KAUFFMAN: Okay. And how is that?

Okay. Good afternoon. Okay. So today, I'd like to start with an overview of my presentation. I'm going to give a little background on the Pilot Biomonitoring Exposure Study, or BEST. I will briefly show you the Pilot BEST round 2 results return packets, so you will have an idea of what it is that we were asking participants to evaluate. And then I'll present some results of our participant evaluation.

--o0o--

MS. KAUFFMAN: So Pilot BEST was a collaboration with the Division of Research, Kaiser Permanente Northern California. This was a stratified random sample of English speaking adult Kaiser members from the Central Valley. We recruited 112 participants who were evenly distributed across race/ethnicity. And the median age was in their fifties.
And for our study design, participants were enrolled by mail, and we were able to send staff to participant's homes to collect exposure questionnaire and blood and urine samples. And that took place between May 2011 and July 2012.

--o0o--

MS. KAUFFMAN: So for Pilot BEST, we returned results in two rounds, the first in December 2012, and then the second and final in July 2014.

The evaluation was mailed to 92 participants in January 2015. And we only sent out 92 surveys instead of the full 112, because the first 14 participants enrolled hadn't -- they had signed an earlier form of the consent form, which didn't allow for contact for evaluation, so we had to exclude them, as well as the six remaining people who either didn't want their results or didn't have any results to report.

So even though this was -- we weren't sure what to expect with a mail-in survey, but we did have a higher response than we did with a previous survey we'd done electronically, and 36 participants responded. So that's about 39 percent. And of those, 22 agreed to a 20-minute follow-up interview. And I was ultimately able to reach 19 of those participants for the phone interview, and that was through April of this year.
MS. KAUFFMAN: So today I'll be presenting the results of both the survey and then the follow-up interviews. And those sought to answer the following questions -- research questions:

Did participants read their packets?
How useful was the information?
Did participants seek additional information or assistance to interpret their results, and if so, where or from whom?
Was there other information that they would have liked to receive in the packets?
Did they take any actions to reduce their chemical exposures?
And how did participation and/or their results impact them?

And then I also had the participants' individual results in front of me in case they wanted to review any specific information or the results while we were on the phone, and some of them actually did.

MS. KAUFFMAN: So I wanted to talk a little bit there, but I wanted to show you what the packet actually looked like. This is a bound packet. This is the round 2 -- this is the actual packet that people received. It's
got eight sections. So they're marked by colored tabs. So this was a 46 page packet, and it included metals, pesticides, PBDEs, PCBs, PAHs, phenols, phthalates, and perchlorates, so a lot of information.

One impression, people thought it looked very professional and well presented. So I think that -- it made a good initial impression on people. And if you wanted to have a closer look at our sample packets, you can do so on our website there.

--o0o--

MS. KAUFFMAN: So inside the packet we've got -- we always include a cover letter with our packets. And that would include logos, so of our -- any collaborators in here. We put Kaiser first, since they were more likely to be recognized than Biomonitoring California. We also provide basic study information, so the name, year, and purpose of the study, basic information about the results included in the packet, so the year of the study, and how many study -- chemicals were measured in the study and which matrices, a table of contents to help orient the participant, explanation of the comparison information that we include, a reminder of the usefulness of their participation in the studies and thanking them for participating, and then we always include names and contact information for both -- for all PIs, because we
feel it's important to have a named study -- a named --
sorry, oh, boy -- a named project staff, so people know
there's a person with a phone number that they can
contact, if they have any questions. And I'll try not to
do that again.

--o0o--

MS. KAUFFMAN: Sorry. You don't want to hear
this twice. Okay. So the next element that we include in
our packet was what we call the project description, or
the FAQs about the study.

So this provides a brief description of the kinds
of information that participants can and cannot learn from
this study. It also has an explanation of the comparison
information that we present in the packet and discusses
briefly the limitations of those comparisons. We also
talk about whether chemical levels can -- in the body can
change and briefly describe some factors affecting
chemical levels in the body, including the level and
extent of exposure that a person has had to that chemical.

--o0o--

MS. KAUFFMAN: And I don't touch anything.
Okay. Let's see. There we go.
Thanks. Okay. I'll try not to touch that
anymore. Grab the pointer.
Okay. So let's see, where was I?
Oh, and in the side bar we also have some information about the study, so criteria for selecting the chemicals for the study, study design, and then geographic location.

--o0o--

MS. KAUFFMAN: Okay. This is an example of a chemical results page. We have one page like this for every chemical or chemical group that we present, and we have the participants' results in a table, along with some comparison information, so the study range, the detection frequency, the median, and the 95th from NHANES and then the level of concern, if we have one. And then all of this information is repeated in text below.

--o0o--

MS. KAUFFMAN: This is an example of a chemical fact sheet. We also have one of these for each chemical or chemical group that's being returned. It follows directly after the results page, so people can see immediately what it is that was measured in their bodies. And this is divided into three parts, where is the chemical found, what are possible health concerns, and then what are possible ways to reduce exposure?

--o0o--

MS. KAUFFMAN: So given that this is a 46-page packet, the first thing we want to know is did
participants read their packets?

So the 36 respondents to the survey, 22, or 61 percent, read the entire packet, five read some sections thoroughly, eight skimmed the packet, and then one preferred not to answer.

And reasons given for not reading the entire packet were time constraints, so work, or family obligations, including deaths in the family. One person said he focused only on his individual results, but not the rest of the packet. And then someone found the level of information a little too technical.

--o0o--

MS. KAUFFMAN: So then how useful was the information in the packet?

For the cover letter that I just showed you, many people, 89 percent, remarked this was a useful reminder of the study, so the when, and the where, and the what, since it had been two to three years since they had enrolled and donated their samples. So 89 percent found this at least somewhat useful. And the other choices were not very useful, not useful at all, or prefer not to answer.

So this is a typical comment, you know, "It explained exactly what the packet was and what it was about".

The FAQs, that project description, fewer people
MS. KAUFFMAN: And then moving on to the chemical results pages, that's a total of 94 percent found this somewhat use — at least somewhat useful. And so seven of the 19 people I interviewed also said that they really appreciated the comparison information that was in this packet. So this a — typical of a response. "It gave me a threshold, how do I compare to others in the study and across the board".

Another person remarked, "These were my results, which is more interesting than a general report, and that's why I participated".

MS. KAUFFMAN: So moving on to the chemical fact sheets. We asked participants to evaluate each section. So 85 percent of the respondents found this -- where the chemical is found section, at least somewhat useful. Eighty-five percent found the health -- possible health effects section useful, and then possible ways to reduce exposure are also -- that was 88 and then 85 for the reducing exposure.

And I particularly like this quote, because it's essentially stating the purpose of our fact sheets. "If you know where chemicals are found, you might want to
avoid or cut back on consumption of that, depending on what the chemical was and how harmful it is”. And then there's this sort of interesting harm reduction stance, "If it's something bad, then try to avoid it or just cut back if you really like it".

(Laughter.)

--o0o--

MS. KAUFFMAN: Okay. So they found it very useful, but then did they seek additional information or assistance to interpret their results? So eight participants did say that they sought additional information from various sources, including the Internet four people. And two of them -- two of these participants had elevated levels of chemicals in personal care products, and they said that they did more research on the products that they use specifically. Three people consulted their personal doctor at Kaiser, and then one person consulted a family, friend, neighbor, or co-worker. And then three participants also just unprompted brought up their intention to keep the packet as a reference, as a buying guide, or one person said in the case of future health problems.

--o0o--

MS. KAUFFMAN: So was there other information that participants would have liked to receive in the
packets? And the overall response was that the packet was thorough and well designed, but it may be that having an even longer packet wasn't an appealing thought, so --

(Laughter.)

MS. KAUFFMAN: But, yeah -- so one person said, "I think you guys covered it all". And then someone else pointed out some of the -- you know, the tabs and how that made it easy to navigate. A second language learner pointed out how we presented results on the chemical results pages, both in the table and in words, and that was helpful.

--o0o--

MS. KAUFFMAN: Then we wanted to quantify some behavior changes. And this -- the full question was, "As a result of your participation in BEST, did you try to take any actions -- did you take any actions to reduce your exposure to chemicals?" And please mark all that apply.

So 66 percent said, yes, they did. And for specific actions that they could mark, it was multiple -- it was choices offered. They -- forty-nine percent, this is the top answer, said they clean their fruits and vegetables more carefully before eating them, 46 percent wash their hands more frequently.

--o0o--
MS. KAUFFMAN: And then there was a tie, 26 percent said they choose different types of personal care or household products. And when doing home improvement projects, they take more precautions to protect themselves or their families. And then the last two choices, 23 percent said they cleaned more frequently using a wet mop or damp cloth, or that they eat different kinds of food.

--o0o--

MS. KAUFFMAN: Some people also offered specific actions that they took to reduce their exposure. So we had one person who replaced a disintegrating foam mattress, citing elevated PBDE levels from the study as their motivation. Another person said he use protective clothing and more ventilation and washes work clothes regularly to reduce lead exposure specifically. Someone mentioned wearing gloves and several people mentioned organic gardening.

--o0o--

MS. KAUFFMAN: So then we wanted to know how they felt about participating in this study. So overwhelmingly, that's 97 percent for both of those two questions, at least agreed that they were glad that they participated in the study, and were satisfied with the information they've received about their results.

--o0o--
MS. KAUFFMAN: And then they were asked to -- about this -- whether they agreed with this statement, "I was well informed about this study and what my involvement would be when I agreed to participate". And several people commented on what a positive experience it was having someone come to their home and collect the questionnaires and their samples. So this person said, "I was more comfortable asking questions in my own home with the person there rather than being in a lab or somewhere else".

--o0o--

MS. KAUFFMAN: Then we wanted to know, 46 pages, was the results packet too long? And about 29 percent agreed. So I can't really blame them for that, but 61 percent disagreed with that statement. We wanted to know if it was confusing, and 23 percent of the respondents did find something in the packet confusing, but then 65 percent disagree with that statement. So that's one end of the spectrum. "Great questions. Why aren't there regulations"?

And then someone else said, "It was down to earth language. I didn't have to put my thinking cap on".

--o0o--

MS. KAUFFMAN: So do people agree with the statement, "I'm more interested in learning about
chemicals that I might be exposed to based on my participation in this study"? So that's 84 percent agreed, and nine percent disagreed to some extent with that statement.

Several people did wonder about connections between chemical exposures and health issues that they or family members had experienced, so things ranging from allergy, to diabetes, MS, Parkinson's. And as the interviewer, I had to be careful to resist the natural urge to reassure participants about their levels or imply anything about the health implications of their results, since we just don't know.

So other participants speculated about diseases like cancer and Alzheimer's in general and wondered whether there might be a connection to environmental chemicals that we're all exposed to in modern life.

So the next question was whether or not people had talked to others about how to reduce exposures to chemicals in the environment?

And 60 percent agreed with this statement, so a little less. Several people mentioned concerns about their children and grandchildren or even their future grandchildren, and what their exposures might be with one participant stating specifically she would talk to her daughter about lead paint in her house, since she had a
younger child.

And then I love this quote here, "I'd like to see more information out to public. You raise awareness, and then people can make their own choices. Some people could eat rice seven times a week and have no problems, but other people might have problems". So that just -- it shows a very sophisticated understanding of individual variability and sensitive subpopulations, so that was great.

--o0o--

MS. KAUFFMAN: So we wanted to know how else their participation or results impacted them. Surprise was a pretty common reaction. And these are typical surprised responses. "Surprise I'm so exposed. Also, surprised you can find out so much from one little sample". So that's appreciation for the lab analyses that we do. Surprise. "I had no idea there were so many chemicals in everybody products...is this really hazardous or something that everybody lives with"?

--o0o--

MS. KAUFFMAN: And then other reactions. We had some overwhelmed. So I thought -- you know, first, "I thought, 'Oh, my gosh, I want to read all of this'. And then I started looking at the elevations in the graphs and then I got overwhelmed". So overwhelmed by the sheer
volume of information or the technical level. And then there were some neutral or indifferent. "I didn't have a big reaction".

--o0o--

MS. KAUFFMAN: So this is the research altruism that Rachel was -- had mentioned earlier. There was a -- there were quite a few reactions or feeling of contributing to science and the greater good. So people were aware that, you know, even if they didn't get any personal benefit from knowing these results, they understood that they were making a contribution to others. And this may be a reflection of this older population, but there was also sort of, "It's too late for me", kind of attitude, but, you know, maybe it will help someone else. (Laughter.)

MS. KAUFFMAN: So, "I hope you guys gain some knowledge from this study and apply it to future generations to help the planet".

--o0o--

MS. KAUFFMAN: So what did we learn?

Participants had positive reactions overall. And I should acknowledge that the response rate to the survey was 40 percent. So it's possible that people with neutral or negative responses to their packets just didn't want to talk to us or didn't want to respond to the survey.
But that said, the 36 respondents to the survey and the 19 people I interviewed generally did find the information interesting and useful. They felt empowered by their results. They took some actions to reduce chemical exposures. They were motivated to learn and to stay informed, and they enjoyed making a contribution to research. Some people said, "Will you put me on the top of the list for the next study?" That's sort of a typical quote of someone with that attitude who just wants to do more.

--o0o--

MS. KAUFFMAN: And then, you know, what are we going to do next then?

Rachel had mentioned too, we do also feel that it's important to continue to evaluate our materials on an ongoing basis starting during recruitment preferably to ensure that our materials are meeting our participants' needs. We'd like to explore options for producing graphics, if there's a demand, and we have the resources. And the Silent Spring's DERBI on-line interface might be an exciting possibility for us in the future.

We'd like to develop new elements and approaches for upcoming studies. And that could include community meetings for input on materials and presentation of study results. Several participants in the interview -- in the
survey and the interview did specifically ask about this. And it is something that we are considering in the next round of smaller studies that our program is planning. So for these smaller studies we'll be in the field beginning at study initiation, at community meetings and other events. We'd like to cultivate closer relationships and gather information and then we can elicit feedback for tailoring our materials to different study populations, which will include materials and languages in other than English and Spanish, which is our current capacity.

These smaller studies will also make it easier for us to offer one-on-one meetings with participants, so they can have their questions and answers -- questions and concerns addressed by our study staff or maybe trained community members. And this did come up during the interviews with people expressing appreciation for the survey and the chance to have a dialogue with somebody, and to go over their results with a person.

And in the near future we'll continue to produce our printed packets, but we'd like to complement those hard copies with electronic results, possibly through a secure log-in on our website. And we've had some requests in the past for electronic copies or for reprints. And so if people misplace their packets, this would be a way for
them to access them afterwards.

And then we're also hoping to borrow from or to be able to use the digital -- the DERBI program that Rachel had mentioned earlier as a good option.

--o0o--

MS. KAUFFMAN: So I'd like to end by acknowledging my colleagues at Biomonitoring California, Kaiser Permanente Division of Research, Pilot BEST participants and our funders.

And I'd like to leave you with one more quote.

--o0o--

MS. KAUFFMAN: And I'm happy to answer any questions, or I can answer clarifying questions or -- is that okay?

CHAIRPERSON BRADMAN: Right now. We have 10 minutes of clarifying questions, but then that actually morphs into a more general discussion with both the Panel and the audience. So I think you can really engage on anything right now.

MS. KAUFFMAN: Great.

(Applause.)

DR. ESHRAGHI: Again, this is Jamshid Eshraghi, from Massachusetts Department of Health.

Two -- one comment and -- actually two comments I want to make here. One is that I think your response was
very good 30 percent or so getting response. And it seems
like if people read the whole packet, then they
participate. It's a matter of getting them to read. So
maybe if you put something like a free T-shirt somewhere
as a question somewhere --

(Laughter.)

DR. ESHRAGHI: -- you get more response, and it's
very effective, or a doughnut or something like that.

(Laughter.)

DR. ESHRAGHI: But the other thing I want to say, I noticed all day today and yesterday, I think being a
chemist, the word, "chemicals", it has a negative
connotation. I feel people -- general population when
they say chemicals, oh, I have all these chemicals. Well
matter is chemicals. I think we should also be careful
telling people, you know, that -- define what chemicals.
Not every chemical -- what is chemical? If you're
drinking Coke, Pepsi, it is all chemicals in your body.

So what is it that say I have so many chemicals.
You see, I think it's misinterpreted. People get these
things and you can scare them by just saying there are
chemicals in their bodies. So I just want to make that
comment.

MS. KAUFFMAN: And some people get it, they say I
know I'm a big bag of chemicals. I mean, that's what
we're all made of. But, no, you make a good point. And we are working on sort of fine-tuning our messages through a messaging platform. And this is something we've talked about how to distinguish all chemicals from the chemicals that we're concerned about here.

MS. HOOVER: Yeah, this is Sara Hoover. Actually, we had many conversations about this. And in some of our materials, I mean, we do try to make that distinction in some of our educational materials. We talked a little bit about that. So we're totally aware of it. But in the end, sometimes you just have to go with the simpler knowledge, because that's actually how people understand the word, you know, in the general population, so -- but acknowledged, yeah.

CHAIRPERSON BRADMAN: Any comments from the Panel?

Questions?

Anyone -- if I wait long enough, somebody will raise their hand.

(Laughter.)

CHAIRPERSON BRADMAN: So let's think about this. I had a question actually though about returning results. I mean, this maybe more general, because it hasn't been for Biomonitoring California, but Rachel or -- I'm sorry. I'm not good with pronouncing your name Duyen?
MS. KAUFFMAN: If you think of the D as a Z, then you've got it. Duyen.

CHAIRPERSON BRADMAN: Okay. About returning results to children or -- have you had any experience doing that? I know right now it's not true for Biomonitoring California, but we can anticipate in the future there will be. And I don't know, Rachel, if you've had returning results where there were actually measurements from a child, but you were engaging with the parent or maybe the parent and the child. I know in our experience, we've only dealt with the parents at this point.

DR. MORELLO-FROSCH: Yeah, we have -- we have dealt with one study where the results are shared with the parent, and then the parent decides if they want to have the scientists talk to the child.

CHAIRPERSON BRADMAN: And did -- did involving the children change the -- kind of the process or the implications of returning results to the parent? I mean, just the fact that you were taking measurement from a child, did that change how you interacted with the parent?

And then did it also have any impacts on worry or concern, that sort of thing?

DR. MORELLO-FROSCH: Well, so this was a study where the results return had already happened, so we
weren't involved in that process. We were just more interviewing people about how they -- how they navigated that process after the fact. So there were some studies where we were able to do pre-interviews before they got their results back and then interview them after, other studies that we were actually conducting and did the report back ourselves and then studies where the report back happened and we recruited them later.

So I don't -- I can't answer your question as well as I'd like, because that particular study, the report back had happened, and then we asked them if we could talk to the participants to get a sense of their experience.

CHAIRPERSON BRADMAN: Okay. And that wasn't our study.

DR. MORELLO-FROSCH: No.

CHAIRPERSON BRADMAN: I should say -- we're just evaluating how we'll we've done in some of our studies. Well, I shouldn't say how well we've done, but rather, you know, how it's gone in returning results in some of our studies.

MS. KAUFFMAN: And, Rachel, I'm curious how old the kids were in that study?

DR. MORELLO-FROSCH: So they were adolescents.

CHAIRPERSON BRADMAN: Okay. Questions back
there, comment.

DR. DiBARTOLOMEIS: Michael DiBartolomeis. I'm now assuming you -- because that was sort of a discussion kind of question, we're sort of moving into that, so --

CHAIRPERSON BRADMAN: Exactly.

DR. DiBARTOLOMEIS: So this is not clarification.

This is more of a question -- discussion. Neither Rachel nor Duyen mentioned anything about actually evaluating whether people were upset by delays in getting their results back. I know that we've had issues in California about having immediate response back in terms of getting results back.

So I don't know if there's research out there already, or if you have information about that, but I'm nervous about that aspect about biomonitoring, is it does take a while especially for labs that are, you know, somewhat overwhelmed to get the results back. So apparently there's some answers for me.

Thank you.

MS. KAUFFMAN: Unfortunately, I don't have the numbers here, but we did ask that, whether or not people thought that the results were timely. And a lot of people said yes to our surprise. So we thought, well, we don't think it was timely, so I didn't present that today.

DR. MORELLO-FROSCH: Yeah, so it's been mixed. I
mean, we interviewed people in studies who, for example, had lost funding in between, so there were significant delays before they got their results. And so, yeah, some people are annoyed at how long it takes.

And, you know, I think the best prescription for that is to try and really set expectations and really tell people we really appreciate you're going to be here and it's going to take a year or two before we get back to you.

Other PIs have really tried to kind of communicate in the interim with participants to kind of let them know so we're doing this category of chemicals. And remember, we're going to get back to you in six months or a year, but just to let them know like things are progressing, analysis is happening, we haven't forgotten about you.

MS. KAUFFMAN: Yeah, I also have read a bunch of the -- you know, with chemicals -- with studies that have many chemicals, we've also considered returning results as they're produced by the lab, and just -- it will make shorter packets, and just sort of keep people hopefully more engaged, because yeah, some people did say who are you guys again? Which study is this? So yeah, just sort of keep the lines of communication open.

DR. MORELLO-FROSCH: Just to make a plug for
digital interface, that's why -- like that gives you the
flexibility to kind of upload results as they come in.
And then, you know, each time the person gets a
notification, they can log on and look.

DR. DiBARTOLOMEIS: So that was good. Thank you
for that response. Now, I want to just kind of go to the
next step. If results aren't being returned for let's say
two years, doesn't that then mean our -- we have to
consider that their levels could have changed dramatically
in the past two years and do our results return material
need to address that in some way.

DR. MORELLO-FROSCH: Yes.

(Laughter.)

DR. MORELLO-FROSCH: Yeah, absolutely. I mean, I
think you have to be really clear that -- you know, I
mean, a lot of studies show actually how dramatically
results can change and trends in population can change.
Particularly when you have a big policy shift or something
is getting phased out, you can start to see immediate
decreases. So I think it's important when you have that
information to convey that to study participants.

MS. KAUFFMAN: And people realize this and some
people say, so you're calling me back, are you going to
re-measure me now? Let's see, you know, how I've done in
the last couple of years. So it is something that we're
considering as a program, you know, intervention studies, and giving people multiple results over time.

MS. HOOVER: Hi, this is Sara.

CHAIRPERSON BRADMAN: Sara, we had question back here too.

MS. HOOVER: I'm sorry. Let me just address this though.

CHAIRPERSON BRADMAN: Sure.

MS. HOOVER: We actually have a paragraph about can my chemical levels change over time? So we explain some of the factors involved in changing chemical levels.

MR. HOEPKER: Alex Hoepker from UC Berkeley.

I had a question about collective action, what kinds of possibilities exist for a State program like Biomonitoring California OEHHA to recommendations -- so to go beyond individual action, which in many cases is obviously not enough, what can be done?

MS. HOOVER: Well, I mean, Rachel brought up collective action, so I thought you could comment on collective action. I'm not passing the mic off, so I won't say anything.

DR. MORELLO-FROSCH: Yeah. So we've had an interesting conversation about that, because, you know, I think agencies have to -- have to proceed with more caution for obvious reasons. But I do think that there
are opportunities, I think, to at least help again participants distinguish when maybe individual level action is insufficient to reduce exposures or there needs to be more than.

Also, you -- I think there's now opportunities to point to different kinds, for example, of medical societies that have taken positions on certain kinds of environmental policies and chemical regulation that can give participants more information about sort of what's going on and the positions that different kinds of professional societies are taking that have been published and peer-reviewed.

So I think we could think creatively about opportunities that agencies could take to point to more opportunities for collective action while still, you know, being understanding of the restrictions that government agencies tend to operate under.

MS. HOOVER: Yeah, we just had a conversation about this. And a couple of things, one is we actually do -- we're aware of the distinction that Rachel was alluding to about some places you have more ability to change your levels and others it's really very difficult. And on some of our fact sheets, we've acknowledged that. We actually note that it's difficult to reduce your exposure to wide-spread ubiquitous contaminants like flame
retardants.

So we will note things like that. We also will point to external links. So we point to external links to others like in a pediatric association giving advice. So yeah, I mean, we're definitely open to pointing to that when we can. The other thing I want to emphasize though is that it's -- you know, there's our role. And OEHHA in particular, we have a really strong commitment to producing good science. So our job, as we often talked about, is we produce really high quality biomonitoring results, scientifically accurate and understandable descriptions of those results, but we also have community partners.

You know, we have people who are interested in the biomonitoring results who can then take them and do more with them. So that's kind of the construct we're working under, and we certainly have really excellent community partners involved in the program as well.

DR. SINGLA: Hi. Veena Singla, staff scientist with the Natural Resources Defense Council. Thank you both for very excellent and informative presentations.

And I had a comment and a question. My comment is just that I'm so happy to see these presentations and this discussion happening today, and I'm channeling my colleague Nancy Buermeyer of the Breast Cancer Fund who
wasn't able to be here today to say that the results return we do feel is a very critical and important part of the biomonitoring process. And I think from both the presentations we can see how much it empowers people to understand their own exposures, and to potentially take collective action as well.

And my question was about if you could maybe speak a little bit more to the kind of challenge or tension of communicating to people about kind of their individual results and connections, or lack thereof, to their health versus what we know about environmental exposures and population health on a larger scale to say that. You know, one of the quotes that stood out to me was, you know, why are we looking at these particular chemicals? Is this a bad thing?

And there's a reason we're looking at those particular chemicals, because we're concerned about them. Research is showing there's associations with adverse health effects, but we know we can't say your exposure caused your health effect. So is there a way to be able to communicate that nuance to say that, you know, yes, these chemicals and environmental exposures are connected to people's health, but without that certainty that it's causing your particular health effect, I know it's a challenge, but I think it's an important nuance for
participants to be able to understand the connection to health.

DR. MORELLO-FROSCH: So I can talk about the studies that we've done. So we spent a lot of time in the consent process talking -- you know, when we're enrolling participants in biomonitoring studies, so these are not health studies, making clear kind of the distinction that you describe, which I think is a really important one, that we're studying these chemicals because evidence suggests that they are problematic for health. These are the kinds of health outcomes that are associated with the chemicals that we're looking at.

We also tell people that a lot of the evidence is actually not in humans, but a lot of it can be in animals. And so we're -- one part of trying to understand what the impacts are in humans is to even get a sense of what exposures are, and which is why we're doing an exposure study and not a health study.

And we make clear that this is not a health study. We also make clear that we're going to tell you what the levels of chemicals are, if you want that information, but we can't tell you if any of the exposures that you had are associated with any kinds of illnesses or health issues that you're currently dealing with.

That said, you know, people -- it's a natural
thing to have -- reflect on that one. I mean, you know, we biomonitored ourselves in the firefighter study. And, you know, I mean, I'm a Ph.D. in environmental health science, and, you know, you get your results back, it does get you thinking. You know, you can't help yourself. So I think it's important to kind of acknowledge that and allow people to have those conversations. And, you know -- but yeah, it's a fine line. And I think the time to really start having that conversation is actually right when people are enrolling in the study, and then you keep having it throughout.

MS. KAUFFMAN: I agree with that approach. And also any contact that I have with participants, so for these interviews or any community meetings or anything, after people get their results, I also -- you know, people say they're frustrated, what's going to be done, when are we going to know? I say, well, you are a part of how we will find out. This is why we do these studies. I mean, you -- the information we learn from this study could help contribute to that body of knowledge.

So, you know, it's kind of a "stay tuned" sort of thing. But I think just to emphasize the importance of, you know, people in biomonitoring, we need them to participate to learn more.

MS. HOOVER: And I'll just add one last thing.
We actually spent a lot of time crafting language in our packet to try to explain exactly that. So we put a big effort on what do we say on the results pages, what do we say on the study page, and what do we say on the fact sheet page. And we really developed our template with the idea of conveying that kind of information. So I think -- I mean, from the reactions we got of the people we talked to, I think we actually did a pretty good job. They got the idea that there was this uncertainty, and that we were doing the best we could in terms of conveying the information. In general, is that a fair -- yeah, fair statement?

DR. PLUMMER: Hi. This is Laurel Plummer from OEHHA. I just wanted to ask you, Rachel, if you could comment on, you know, the one-on-one participant discussions or the community meetings kind of to larger groups of participants and what kind of questions, you know, they ask in those types of environments, and if they kind of go beyond things that people respond to in surveys or just maybe you could comment on your experience in that, like, kind of a different environment, which is -- our Program recently participated in a collaboration where we had an experience like that, and it was my personal first time in that environment. And I -- it was different than I expected.
Good, but, you know, there were different things, you know, thinking about how to phrase your answer on the spot or things like that. So I just thought -- wondered if you could comment on that.

DR. MORELLO-FROSCH: Yeah. So the studies that we have done are -- you know, tend to be community-engaged participatory exposure studies, either, you know, household exposure studies where you're monitoring air and dust in people's homes or biomonitoring studies. So, you know, that's a big caveat.

And so it sort of goes without saying that part of the report-back process is individual level report back, like along the lines of what we've been talking about, but then also providing opportunities for participants to -- and actually not just participants, but representatives of the communities that are being studied, so people who didn't participate in the study, but who are, you know, from that particular community of interest, whether it's geographically defined, occupationally defined, to look at aggregate results.

And one, I think, it's best to make sure that you have given everyone their individual level results before you have those group meetings, because people have a chance to digest the information, and ask their questions, and there's no surprises when everyone gets together.
Plus, if the media happens to show up when everyone gets together, you know, and it gets covered, a participant doesn't find out that the study has results without having gotten their individual level results.

And I do think that providing opportunities for participants and participant communities to collaboratively process and understand and interpret the information can highlight certain interesting things that you might not see on -- with one-on-one conversations. And then it also highlights opportunities for how they want to disseminate and share their results who they want to talk to, and also potential opportunities for collective action for reducing exposures.

Again, whether that's occupational or whether it's getting involved in policy campaigns or influencing land-use decision-making, all kinds of things. So I think those are opportunities to have meetings with participants in participant communities can help elucidate sort of more collective paths of action, too.

PANEL MEMBER QUINTANA: I have -- sorry, two of the Panel.

MR. HOEPKER: Please, go ahead.

PANEL MEMBER QUINTANA: I just had a question about results return, given you showed that binder with all those different classes of chemicals. And within each
tab, there's multiple different chemicals within that class. And I was just thinking for me, I would like to have -- I want to know what I'm high at first, and then I would want to know what I was low. And I was curious if you ever thought about ordering a results return, which you could do electronically from high to low, or if you're higher than the median, print it on pink paper. And if it's lower, it's not pink or something, where people could easily find the ones -- because that's what I would like to know, first, if I was looking at the packet. And I was just curious if you discussed this?

MS. KAUFFMAN: So for the metal -- for the chemicals that do have levels of concern, we do have language crafted around that. And we have a specific protocol that we follow. We call people --

PANEL MEMBER QUINTANA: Yeah, I didn't mean of concern. I just meant you're higher than the median, let's say, and we have no idea what that means.

MS. KAUFFMAN: Right, right. So, no, we have not fine-tuned our materials to that extent, but it's a good suggestion.

MS. HOOVER: I think programming would be potentially challenging in putting things together. And I would just say too that we had a pilot study in -- with just a convenience sample of like lab staff and Program
staff. And the results came back and there was some color
coding. And we had a big discussion about color coding,
you know, like if you're above.

And one concern we had is that we kind of didn't
want to imply that there is an interpretation necessarily,
if you're above the median, because we don't know what
that mean -- you know, is -- maybe everybody -- maybe it's
bad for everybody, like regardless of what your level is,
or maybe it's like, no, the concern is a much higher
level.

So we were concerned about making that
implication just based on statistically, you know, where
it was. Now, that being said, we also -- like, I really
have always appreciated -- I think this was a study that
Rachel was involved in, the idea that, you know, if one
person is high, you can go and find out -- like the PCB
example, where you find a new source of exposure.

So we always have that in mind, too, that, you
know, just one high level. I'm always interested in
looking at are there outliers? Who are those people? Is
there some specific thing we should be aware of?

And we have done -- I want to do more of that
going forward, but we have done some of that. So we
are -- even if there isn't a level of concern, we are
conscious of, you know, people with high levels. But no,
we have not redesigned our packet with that in mind.
   
   Yeah, we've kept it more as an index, and also
just going forward for people to be able to easily find
the different categories of chemicals and stuff. So,
yeah, lots of different options.

   CHAIRPERSON BRADMAN: Yeah, question?

   PANEL MEMBER KAVANAUGH-LYNCH: Yes, probably to
Rachel. I was curious how IRB panels have responded to
even requests to do studies on returning results and
especially since so many IRBs are so focused on the
clinical model, which, as you pointed out, is kind of --
it does not ascribe to this theory of giving people
information, even if we don't know what to do with it.
Can you talk a little bit about how you -- how you've
handled IRBs?

   DR. MORELLO-FROSCH: Yeah. So the short answer
is that the IRB situation is evolving. So when we first
started doing this and when the -- in one of our studies
where we decided to report back results to participants in
air and dust monitoring, the IRB was very -- was not very
excited about that idea, because, you know, for them we
were -- what we were suggesting seemed ludicrous. We were
going to tell people that we found chemicals in their
homes, and we didn't know what it meant for their health.
And so they just thought it would stress everybody out.
So, you know, we had to have a lot of back and forth. We had some meetings. They were kind enough to actually to allow us to do kind of an in-service education to kind of make the case for why, from an ethical point of view, this is actually a really good thing to do, and allow -- sort of give them some parallels about, you know, that there is some precedent, maybe not in chemical biomonitoring, to provide this information.

And I think a lot of IRBs are getting a lot more educated on this issue. I think it's changed a lot. It's gotten much better. It's not quite so controversial. And now, the more studies that do this -- you know, the fact that the California Biomonitoring Program has it codified that you have to provide those results, it's like -- it's not unusual anymore.

So we're fortunate -- and I think that even IRBs who have not confronted this, if you can point to precedent now, and there's now much more of it, it becomes easier to educate them. But in the early days, you know, it's been hard, and there's been a lot of back and forth. I have colleagues who have had trouble and had to do a lot of education and back and forth and convince the IRB to allow them to do this. But I think it's getting much easier.

MR. HOEPKER: I was actually wanting to pick up
on the question by Veena earlier about the connection between health and biomonitoring. I'm taking it back a little bit simply because it's almost implicit in the name of OEHHA, you know, assessing health. And I'm wondering what the road blocks are of not communicating health impacts as many of us might want to or what are those road blocks, and how could we make inroads and communicating about health impacts?

MS. HOOVER: Yeah.

MR. HOEPKER: I'm sorry. Alex Hoepker, UC Berkeley.

MS. HOOVER: Actually, hang on to the mic, because I have a follow-up -- I have question about -- maybe -- so what do you mean by road blocks for communicating health impacts?

MR. HOEPKER: Well, it seemed to be, the way it came across to me is that we can't communicate health impacts. So say somebody has two percent mercury in their blood or PBDE, we can't really speak to longer term health impacts that that chemical might have, right? Is that communicated in the package or --

MS. HOOVER: No, I -- yeah. So actually, we can send you the link of the packets and our fact sheets are on our website. We definitely flag a whole section of each fact sheet as possible as health concerns, including
long-term health impacts. And then specifically, the example you raised of mercury. I mean, we have done extensive, you know, follow up in like one case in the MIEEP study, there was someone who has highly elevated in mercury. And actually, there was a big effort to track down why were they highly elevated, to talk to them about it, them and their baby. That turned out to be the whitening cream incident.

So I -- maybe I'm not understanding your question. Yeah, he needs the mic back.

MR. HOEPKER: I think that the case of mercury is very clear, right? The health implications are very obvious, but there's so many emerging chemicals that we're monitoring currently. I mean, tons of endocrine disruptors that -- where health impacts are maybe not as clear, but there's a lot of evidence. Are those communicated in a package like that?

MS. HOOVER: Yes, they are. In fact, that's one thing that we're really fortunate, in Biomonitoring California, we're not a regulatory program. We're an exposure assessment program, so we actually make a very big effort to focus on researching relevant health effects at low doses.

So we specifically look into what could happen at environmentally relevant levels of exposure, and we do
communicate that. We talk about possible effects on the body's hormones. We talk about, you know, any -- you know, immuno effects. We actually have spent a lot of time -- we do all the scientific research and then we spend a lot of time, how do we translate this into an understandable message for individuals? And we actually tend to focus much more on those kind of facts rather than any high dose maybe more commonly understood effects of some chemicals.

MR. HOEPKER: Thanks.

DR. SANDY: Martha Sandy from OEHHA. Just to add to that. We aren't telling people their individual risks though. We're discussing population risk, what we know. We can't make any statements about an individual and their level, unless it's --

MS. HOOVER: Yeah, I mean, that's -- I understood the question to mean the general health impacts of those chemicals, as opposed to -- yeah, we weren't -- I mean, we actually were advised by our Panel on the number of occasions, as Dr. Bradman alluded to, that there was -- actually, earlier in the Program, I -- we had developed a proposal for hiring somebody to develop specific biomonitoring reference levels based on health effects in order to do more of that individual level interpretation of results. And we had many consultations to this on our
website. And I can point you. They're all on our
website.

And the Panel -- you know, in the end, it was
thought that really our -- the mandate of the Program is
exposure assessment, and our job is to generate high
quality biomonitoring data. And the whole idea of
developing risk-based levels is fraught with a lot of
issues. And so we were directed to, you know, just focus
on exposure and focus on, you know, interpreting and
explaining the results to the extent possible with
information. And we use already established levels of --
by State and federal agencies for known hazards. And like
I said, we do the additional thing of looking at very
highly elevated individuals as well and see if there's
something we can say about that.

DR. SANDY: So I had a question for Rachel. I
believe I heard you -- in discussing the question posed by
Laurel about community meetings and giving results back, I
believe I heard you say you should return the individual
results before you have the meeting -- community meeting
to discuss that.

DR. MORELLO-FROSCH: (Nods head.)

DR. SANDY: And I wondered if you wanted to
expand on that. I'm thinking about discussions -- a
presentation we heard yesterday from New Hampshire where,
in giving some results back, they gave individual results and that got people very upset or nervous before the community meetings. So I wanted to see if I could get a dialogue going on that.

DR. MORELLO-FROSCH: Well, so I think if people -- if you have a community meeting and people have an opportunity to get their results at that community meeting, it works great, because then actually people have the opportunity to get the results, or if after the community meeting, they're like ignorance is bliss, I don't really want my results, they have that option.

And then also, you tend to have researchers right there on the spot, so they can look at their stuff. And if they have questions, they can literally sit down and talk to you. And that's been done quite successfully. I've seen that happen.

I just think what I -- what doesn't work very well and what -- at least the communities I've worked with who have had bad experiences with other researchers in the past is there's a meeting to discuss aggregate results. It gets covered in the press. Those people don't attend the meeting. They were participants in the study, and they're like, you said you were going to return your individual results to me, and now I'm hearing reading in the newspaper that you found, you know, what happened.
You know, so that's the kind of thing you want to -- I'm saying it's probably good to avoid, if you can.

DR. DiBARTOLOMEIS: I think better when I stand up. Michael DiBartolomeis.

So I want to go back to what Dr. Schwarzman and I kind of went back and forth on a little bit this morning. And then, Dr. Quintana, when you mentioned circling results or having them highlighted or whatever as higher than, I guess, the background of the general population, it triggered this back -- it triggered that conversation we had just briefly this morning. We -- I think we have to be really careful again not to say that, well, you're okay, because all your levels are basically what we have in NHANES across the country.

I mean, because those levels shouldn't be there anyway for most of these. We don't know if they're going to lead to cancer down the road or whatever, but we have a pretty good idea that there are -- it's a significant contribution from chemicals in the environment to the outcome later in life, or even early.

So I -- this results return problem is still -- in my mind, I can't resolve this. You know, how do we get away from -- we talked about individual risk. We talked about, you know, kind of thinking about sort of a population health outcome whatever, but we still haven't
really addressed what background means. And I don't know how to do that in a way that will make sense. I mean, I think we all probably, in this room, can come up with our own way if we were asked that question by our, you know, Aunt Betty or something like that.

But the truth is, is that how do you communicate that your -- even though your results -- okay -- you know, your results are not circled, your -- and you're closer to what everybody else has, that doesn't necessarily give you a clean bill of health either. And it doesn't necessarily mean you should go off and jump off a cliff, but, you know -- so I just -- I throw this out for furthering this discussion.

DR. MORELLO-FROSCH: Yeah. So we struggle with this, because, you know, in reality, when you're trying to contextualize results, you don't have an absolute benchmark really to say whether it's high in terms of like concern for health. In most cases, we don't have that, and so we're stuck with these relative measures like where are you in the distribution with other participants or how do you compare with a representative sample of the U.S. population from NHANES.

And you want to make sure that people aren't interpreting that in absolute terms, like because I'm below the median it's safe, or below the 95th percentile.
And so we have asked people some specific -- in usability testing, we have asked people questions to see if they can distinguish between an absolute value and a relative one, and to make that distinction.

And some people -- and surprisingly actually, people can, but you have to really kind of provide the context and the information to make sure that people understand that. That just because you're low compared to everybody else in the study doesn't necessarily mean that you're low in absolute terms.

MS. HOOVER: Yeah, I think -- this is Sara again. I agree it's an issue, and I think it's a natural tendency if you say, oh, I'm below the median. That's pretty good. I got some results and that's -- that's what you look at, you know, am I relatively low? So I think you're right about that. And I think that is kind of a typical reaction of participants as well.

And I do know that in usability testing with the firefighters, they actually did have an understanding of we tried -- I think it was with manganese, we tried to not give them a reference level, and say there is no reference level. And they said, there must be a reference level. I'm going to look on the internet. There has to be a reference level. So we actually worked really hard to come up with a reference level for manganese. We started
with Canada. They're like, no, I don't want Canada. I want the U.S.

So we found a reference level that ATSDR I think indicated was considered to be a normal -- you know, a normal range for manganese. So there was an understanding. That just understanding where they were in the study population wasn't enough. They actually wanted a reference value. So that's the preference, I would say.

PANEL MEMBER SCHWARZMAN: Can I chime in on this point also? This is Meg Schwarzman.

Just because I pulled up the sample results from the BEST study that are on the Biomonitoring website. And I'm looking at the lead one, particularly because this issue was raised earlier about -- I think it was in Rachel's talk about the -- how acceptable levels change dramatically over time. And I noticed that the level of concern provided for lead is 10 and above. And it specifically has an asterisk that says it's for men age 18 and older and women age 50 and older. And, of course, those -- except for occupational exposures, which tend to be much higher, you know, the population we're concerned about lead exposure in is much younger than that and a much lower level than that.

So I only raise it not to criticize these materials, which are obviously excellent, but just because
there is so much complexity to it and it's a hard thing to
do well.

    MS. HOOVER: Yeah. Okay. You want to address
that?

    MS. KAUFFMAN: Sure. Yeah, that's -- right,
that's a sample of a page that a man would get. There's a
different level of concern for a woman of reproductive
age. And, you know, we have -- the State has a whole lead
program. And any levels above levels that they've set, it
triggers a whole other notification process through the
lead program.

    PANEL MEMBER SCHWARZMAN: So but that -- so this
level of concern is for the particular participant. It's
not just --

    MS. KAUFFMAN: Right.

    PANEL MEMBER SCHWARZMAN: -- the information
that's provided by the asterisk?

    MS. HOOVER: Yeah. No, we target it, you know,
to the particular individual. And we -- I think we've
even -- in some packets, we note, yes, this is the level,
you know, for a man. But, by the way, you know, for women
of child-bearing age, it's lower, because we're aware that
these packets might be shared. So we include, even if
we're -- even though we do some tailoring of packets like
to firefighters or you're an adult male, so maybe we
change the order of health effects, but we leave in the
information specific to children and women, because we
know -- we don't want to mislead. You know, even if we're
communicating with one male participant, he has a family,
so we try to include all that information.

PANEL MEMBER SCHWARZMAN: Presumably share some
of the exposures.

DR. PLUMMER: Hi. This is Laurel Plummer again
from OEHHA. I was just wondering if you had thought --
have put any thought into including language about how
some of the chemicals obviously have similar health
outcomes and how maybe like the cumulative, you know,
exposure that people receive -- you know, is that a
concept that has been considered and results returned,
because, you know, I could give several examples. You
know, phthalates is, you know, the entire class or PFCs is
the entire class, or any -- you know, any number of groups
that have similar potential effects.

DR. MORELLO-FROSCH: Yeah. We have put that in
kind of general information, that, you know, one of the
reasons why we're analyzing so many chemicals at a time,
you know, because the -- you know, as the BEST study
showed it's quite voluminous. And so people often say why
are you looking at all these chemicals? And we say we're
interested in also understanding the level of multiple
exposures people have, because we know that these can have, you know, cumulative and potentially synergistic effects. And they can have similar outcomes, even though the mechanisms might be different.

MS. HOOVER: This is Sara again. And I would say, well, as you know, we do fact sheets by groups of chemicals. So we do allude to that. Also, we had a conversation in MIEEP with Rachel about thinking about possibly giving them totals -- you know, actually reporting totals of PBDEs and talking about that more specifically. In the end, we decided given our mandate to return every result, we didn't end up doing that, but we've definitely thought about those issues.

MS. DUNN: This is Amy Dunn from OEHHA. I was wondering since we're having this conversation about tailoring -- a little bit of tailoring of results, and the idea of the possibility of posting on-line results, I guess I would be interested to hear if members of the Panel have thoughts about -- or concerns or considerations? I mean, I'm not really sure the timeline where that might become available to us, but it would be, I think, useful for us to hear from you if you have thoughts about pros and cons.

MS. HOOVER: Pros and cons of electronic return, is that --
MS. DUNN: Of electronic return.

CHAIRPERSON BRADMAN: Anyone want to respond? Well, I have some comments on that, and then perhaps some more comments.

But specifically, you're talking about the digital interface?

MS. DUNN: (Nods head.)

CHAIRPERSON BRADMAN: I mean, when I heard that -- about that earlier, I was kind of intrigued by that. You know, in the context of the work that I've done, you know, I don't see how that would be feasible at all, just because we've, you know, mostly interacted with a relatively low literacy population. And I think that would be a challenge with this interface.

When we talk about though with larger studies, I mean, the thoughts that were going through my mind was, huh, you know, there's a big touch factor with returning results. And would this be a way to expedite contact in returning results in a way that is useful for participants, and also potentially have a method or venue to more personal contact, if needed.

I'm not sure I have an opinion about it, rather more I'm intrigued by the idea, and I'll be curious to see how, you know, it plays out in terms of evaluation.

And I'm curious, did anyone else on the Panel
have thoughts on that?

Dr. Quintana.

PANEL MEMBER QUINTANA: I remember in the National Children's Study that they had a lot of video consent as part of the consent process. And I'm just curious if your electronic record would allow personalized videos to the participants or some kind of video return as well as reading it on the screen?

DR. MORELLO-FROSCH: Right now we don't have that, but conceivably that could be something -- a feature that could be added to an electronic interface. The other advantage of the electronic interface it sort of connects with your earlier question of can you -- it would enable you to lift up some of the take-home messages. So, for example, if participants want the immediate list of the compounds where they are above the 50th percentile of the study group, a digital interface like DERBI allows -- makes it very easy to provide that information and that format for people, if they sort of want to get the take-home messages. It gives them a lot of opportunities to sort of decide what they want to focus on without going through a lot of paper.

And then the other thing is in terms of the work that -- the ways in which Silent Spring has deployed DERBI, they've always reserved the ability to have a paper
option to address Asa's concern that just some people are
not going to access that information through a computer or
digital interface.

CHAIRPERSON BRADMAN: Obviously, too, there would
be some security issues. Given the level of breach we've
seen in this country, I'd be, you know, concerned
obviously that is be secure.

When I think of studies like NHANES, which does
not return results, you know, I see a digital interface as
something that would be able to work on a larger scale
that would be impossible to achieve otherwise. And, you
know, given the long-term goal of California's Program, at
least to have a representative sample, I mean, there is
kind of an underlying, you know, goal to have a much
larger information base, to me, it's really interesting.

I don't know if we, at this point, even, you
know, need like a recommendation from the Panel. It seems
like we're not -- you know, nothing like that here.

Are there any other comments?

MS. HOOVER: I just have a question, because I
didn't see -- I haven't seen much about DERBI, and I know
you said it has been used. And I'm just wondering what --
have you heard, you know, the reaction so far, and the
success with participants, and that kind of thing with
using the electronic interface?
DR. MORELLO-FROSCH: I think in terms of its deployment in studies, I think you want to talk to Julia, who spear-headed -- who has spear-headed that process. I can talk about how it's worked so far in firefighters, which is -- the reception has been quite good. I think just -- you know, people's ability -- it just made it kind of easy for them to -- you know, they get an email. There's a secure link with a password. They can poke around and focus on what they want. And they -- you know, people, I thought -- you know, we still -- there's many ways to make it better, and so -- but people who used digital -- who are kind of digitally-oriented already, I think really -- it really resonates for them.

I think another interesting frontier, which we haven't tackled yet is to maybe -- more people use smartphones for these kinds of things than computers. So if we can get the kind of computer thing going and we could actually make it so that people who might not interact with something like this on a computer might be more open to doing it on the smartphone. But that's a sort of new frontier. We still need to work out the kinks in this one.

MS. HOOVER: Yeah, I wanted to allude to something you said in your talk about medical results, because I have now had the experience with Sutter where
they provide, you know, your test results virtually instantly electronically. And it was awesome. I mean, took care of my mom for a few years. And let me tell you, being able to just log on and look at the results and act on it, it's huge.

So I think people actually -- they're going to get more and more used to that idea. And I think it's definitely a really good direction.

DR. SINGLA: Hi. Veena Singla with NRDC. And I wanted to speak to Laurel's earlier comment about the -- thinking about cumulative exposures. I thought those are a really great point. And I wondered if there was -- in thinking about not necessarily the results return to an individual participant, but how results are reported out to the larger community and public at large, whether there was any thought of bringing in some of that information to the way those results are reported out? Right now, typically, the results are reported just by specific chemical or chemical class. And I think it would be -- as people are starting to think about cumulative exposures and common co-exposures to report out some of that aggregate information from the various study populations as well.

DR. MORELLO-FROSCH: I'm trying to make sure I just understand your question. But, yeah, I mean, as Sara
mentioned, we do -- we've had -- in some of our studies, we've had some flexibility to report out results by accumulating certain chemical classes. And then I think there's some interesting options. You know, I don't think an exposure assessment program that's strictly focused on exposure, but, you know, if you're doing a scientific study, you could also, for example, do some forms of toxicity weighting when you're looking at certain chemical compounds, for example.

And I think there's some interesting recommendations in some of the National Academy reports around cumulative risk, cumulative exposure where you could sort of do more to report in an aggregate way compounds that make sense to aggregate together, particularly in similar classes.

MS. HOOVER: I just have two more small thoughts on that. One is one thing we have done, and this is, you know, not a really great way to convey that. But one thing we did in writing fact sheets we tried to use very consistent language when we were describing a particular health effect.

So as people read, they see, oh, this chemical, this chemical, this chemical all affect the body's natural hormones. So we started adjusting our language and making sure that we didn't describe it in multiple different
ways.

So, yeah, then you have to read your packet, you know, to see that. So it's not a handy way to deliver that information, but it's one way.

And the other thought I have is, you know, we always have the goal of developing more information on our website, so we might be able to do more of that kind of communication about that issue via materials on our website.

CHAIRPERSON BRADMAN: We had a comment from Dr. Schwarzman, and then I wanted to ask if there's -- I guess additional public comments or anything that's come in by email that we should consider?

MS. DUNN: No.

CHAIRPERSON BRADMAN: No. Okay.

PANEL MEMBER SCHWARZMAN: I just wanted to continue on this topic for a minute, because it's such a rich one with the need for study. And it makes me think about whether over the next year or two, as a Panel and as a program, we could think a little bit about prioritizing or structuring studies looking at chemicals with shared health effects that are thought to work either synergistically or additively or, you know, contribute because of similar mechanisms of action that is coming -- biomonitoring has so frequently started just with the
chemicals. We need to see what chemicals are out there, but -- and as a program, we're starting to think about how to group them more efficiently and in ways that make sense, like we think including classes of chemicals the way we've been doing over the last while.

And I think it would be interesting to explore -- you may already be thinking a little bit about this -- whether there are some other kinds of groupings like outcome based groupings that would be interesting to prioritize as a program.

I'm seeing furrowed brows, at least from some. I don't know if that's clear.

MS. HOOVER: I think I understand what you mean. So let me repeat back to you. So I think what you were referencing is the fact that we do chemical-based groupings, functional-based groupings. And so you're proposing the possibility of looking at health-based groupings?

PANEL MEMBER SCHWARZMAN: (Nods head.)

MS. HOOVER: Yeah, interesting. Yeah. And you're talking about for chemical selection, actually identifying --

PANEL MEMBER SCHWARZMAN: (Nods head.)

MS. HOOVER: Yeah. Yeah. We have not explored that. It's an interesting idea.
PANEL MEMBER SCHWARZMAN: Look at some things that are acknowledged to have multiple modes of action. Like I think about some reproductive outcomes that -- where there are many paths to a final common pathway. And we know that chemicals acting on multiple parts of that pathway can have more than additive effects.

DR. MORELLO-FROSCH: Yeah, I mean, for example in the firefighters studies, we're focusing on compounds that have been shown to be mammary carcinogens in animals. That's our focus. So I think there's some interesting, you know, reviews. And there's potentially some good places to start in the literature to experiment with that kind of approach to see how much it makes sense, and -- yeah.

MS. HOOVER: This is Sara again. I have another thought about it, which is again going back to the website idea. So it would be maybe a way to add a layer of information like that, so we have our regular groupings, but then have layers of information. Like in our designated list, how many of these are carcinogens, how many of these are known to affect hormones? So that might be another way to show that. You know, add like layers of health information that we have confidence in.

PANEL MEMBER SCHWARZMAN: Yeah, I think that's an interesting idea. And I just want to acknowledge that
it's a little bit different than what we're talking about, because of just thinking of carcinogenicity as such a product category, and --

MS. HOOVER: Yeah, I wasn't being really specific, but I just mean -- yeah, mammary carcinogen. I mean you could make it more specific, but I'm just saying that would be a way to, you know, add richness to the list to provide that information, as opposed to necessarily considering it, you know, as a class, you could add that information on the chemicals that are there, and actually link to other chemicals maybe as well. So just a thought.

CHAIRPERSON BRADMAN: So I think we're going to take a 15-minute break right now. That is scheduled -- so it's about 3:12 now. Why don't we reconvene here at 3:30. But if you could get here two minutes earlier, so you'll have a 15-minute break and then we'll actually start on time.

Thanks.

(Off record: 3:12 PM)

(Thereupon a recess was taken.)

(On record: 3:30 PM)

CHAIRPERSON BRADMAN: Is the microphone on?

MS. CHRISTENSEN: Yes.

CHAIRPERSON BRADMAN: It looks like everyone is on their way to sit down or we're close. So I want to
welcome everyone back and call the meeting back to order. For the next agenda item, we're going to consider two chemical classes as potential priority chemicals. We've talked about this before, but I want to introduce Dr. Laurel Plummer, who's a staff toxicologist in the Safer Alternatives Assessment and Biomonitoring Section of OEHHA, who will present a brief summary of information on ortho-phthalates and PFOS-related compounds relevant to the criteria for priority chemicals.

If you recall, we have identified chemicals on our kind of base list, and then the question is whether we want to elevate these as priority chemicals?

(Thereupon an overhead presentation was presented as follows.)

DR. PLUMMER: All right. As the second to last talk of the day -- we'll hear one more after me, so -- all right. So today, I'm going to present on potential priority chemicals, two classes.

--o0o--

DR. PLUMMER: The purpose of this agenda item is so the Panel can consider ortho-phthalates as a class and perfluoroalkyl and polyfluoroalkyl substances, or PFASs, as potential or priority chemicals.

--o0o--

DR. PLUMMER: So I'll just review the criteria
for recommending priority chemicals. We've recently gone through the designation this year of two. So these priority criteria are slightly different. The degree of a potential exposure to the public or specific subgroups. The second one is the likelihood of a chemical being a carcinogen or toxicant. And then the third one is the limits of laboratory detection for the chemical. And then lastly, other criteria the Panel may agree to.

And I'll just remind you that these criteria are not joined by and.

--o0o--

DR. PLUMMER: Okay. So I'll start with some background on the class ortho-phthalates. Some of these -- some phthalates were added as designated chemicals via inclusion in CDC's National Biomonitoring Program, which lists several phthalate metabolites.

In March 2009, the SGP recommended that the already designated phthalates be added as priority chemicals. And then just at our last meeting in July 2015, the Panel recommended adding the class ortho-phthalates to the designated -- to the list of designated chemicals. So though this, in essence, expanded the list that was already there.

--o0o--

DR. PLUMMER: And switching to PFASs. 12 PFCs,
perfluorochemicals, were added as designated chemicals, also for the same reason as several phthalates, via inclusion in CDC's National Biomonitoring Program.

In July 2009, all 12 were added as priority chemicals, based on the SGP's recommendation. And then in March, 2015, Dr. Gail Krowech presented on this class for consideration as potential designated chemicals. And at that meeting, the Panel recommended to add this class PFASs, perfluoroalkyl and polyfluoroalkyl substances to the list of designated chemicals.

--o0o--

DR. PLUMMER: Okay. So switching back to ortho-phthalates. This table shows some example ortho-phthalates listed in the first column there. That would be included as priority chemicals if the class is listed -- recommended for listing by the Panel.

The second column identifies some selected metabolites that have been identified in human urine. And then the third column shows the detections of the parent compound -- the parent ortho-phthalate that had been detected in dust in the studies.

--o0o--

DR. PLUMMER: So I'll just give some highlights on ortho-phthalates just sort of an update on recent -- some recent developments. Ortho-phthalates continue to be
the most widely used plasticizers worldwide. And in 2014, they represented 70 percent of the global market. And publicly available market research indicates that China is actually projected to be the top consumer of plastic additives, which includes ortho-phthalates obviously, by the year 2019.

The dioctyl sub-type of phthalates, which includes DEHP as one example, is still -- still dominates the global phthalate plasticizer market. And as we talked about quite a bit at the July meeting, increasing regulation of DEHP and other phthalates have -- are contributing to market shifts in the U.S., Europe, and are also expected to occur in Asia.

And then we've also highlighted here a few phthalates that have been recent -- mentioned in recent patents that are not currently on our list of priority chemicals.

--o0o--

DR. PLUMMER: So switching back to PFASs, this table lists examples of PFASs that would be included as priority chemicals. And this would be in addition to the PFCs that are already listed. And you can see the table shows some example classes and some example compounds within those subclasses or subtypes, and then also shows detections of PFASs in human serum and urine and breast
milk where they've been identified.

--o0o--

DR. PLUMMER: Okay. And this slide shows some highlights from recent studies on the class PFASs. One recent study looked at perfluoroalkyl ether carboxylic and sulfonic acids, which are replacing PFOA as processing aids in fluoropolymer manufacturing. And this study identified 12 previously undiscovered PFECAs and ESAs in surface water from northern -- or from North Carolina.

And then another recent study looked at levels of PFASs in effluent from wastewater treatment plants in the San Francisco Bay that were collected in 2014. And this study found significant increases in levels of short-chain PFASs in the 2014 samples as compared to 2009 samples that were reported in a separate study of San Francisco Bay wastewater effluent. And this was concluded -- or this suggests a reflection of changes in the manufacturing process.

And then that study also found the highest levels of PFASs, including 6,2-fluorotelomer sulfate, or FTS, as well as PFOS, in two treatment plans receiving wastewater from areas where firefighting foam was used.

--o0o--

DR. PLUMMER: So I'll just talk a little bit about analytical methods. So PFASs are measured by
Department of Substances Control Environmental Chemistry Lab. And the existing method measures 12 PFASs and can be expanded to include additional ones, additional analytes. There is a second method that's being finalized for analysis of a wide range of PFASs, including polyfluorinated and short-chain compounds.

And then ortho-phthalates are measured by the other State lab for Biomonitoring California, the Environmental Health Lab at the California Department of Public Health. This phthalate method includes 10 phthalate metabolites, as being expanded to include two additional ones. And there's some more details about this in the potential priority document that you received, and it's on the web as well.

And then this method can be further expanded to target additional phthalates or phthalate metabolites, and -- you know, pending identification of appropriate biomarkers for these.

--o0o--

DR. PLUMMER: And so that brings us to setting forth the options for the Panel today with regard to these two classes of chemicals. The Panel can recommend the class ortho-phthalates be added to the list of priority chemicals, recommend the class perfluoroalkyl and polyfluoroalkyl substances, or PFASs, be added to the list
of priority chemicals.

The Panel can defer consideration of one or both classes, or decide against adding one or both classes as priority chemicals.

And so with that, I'll take any questions.

CHAIRPERSON BRADMAN: So we have 10 minutes now for Panel questions about the presentation. And then we'll have an opportunity for public comment.

Dr. McKone.

PANEL MEMBER McKONE: Yeah. Just a clarification, do -- I know it's in the write-up, but I can't -- what's the number -- roughly, the number of compounds in each class that we might be considering. I mean, there's the number that are commonly in use and then there's probably a greater number that could be in use. And most of these classes of chemicals, there are a smaller -- there -- a small set that are used in industry. I mean, I'm thinking like phthalates -- the regular phthalates. There's hundreds, but there's only a few that are really heavily used. Do we have a sense of that?

DR. PLUMMER: Yeah, I mean -- so I -- you know, in the slides today, you know, we've provided some examples. And, you know, for ortho-phthalates these were chosen, you know, for various reasons, you know, largely
for, you know, it's been found in the environment is one major reason.

The di-2-propyl heptyl phthalate has very high production volume. So these are definitely the ones that rose to the surface. And when I first started researching, you know, I had a very long list of phthalates that exist. And we don't really know -- there's really -- it's kind of a, I wouldn't say infinite, list, but it's a pretty long list that we don't -- because our last production volume information is from 2012, which represents even earlier than that, it's hard to even say if there are more that are emerging. So this is sort of an example of ones that really rose to the surface -- so one, two -- like eight or so.

PANEL MEMBER McKONE: But we're -- just to clarify, we're going to, if we vote to set these as priority, it will be the whole class --

DR. PLUMMER: Correct, Yeah, and that's the case for both.

PANEL MEMBER McKONE: So that as the industry evolves and changes, you know, I'm assuming there will be some non-targeted assessment across the class to kind of watch what's showing up, because you may see -- you may see some, you know, really commonly showing up. And then those might disappear, because the industry switches over
for technical reasons or some other reason to another
chemical in the exact same class, but with a little bit
different structure, so --

        DR. PLUMMER: Yeah, that's exactly correct.

        PANEL MEMBER McKONE: So we're covered if we
do -- that's why we do classes, right? Just confirm that
we're not picking out a handful but a full class so we can
see or have the opportunity to monitor that whole class.

        DR. PLUMMER: Yeah, exactly.

        PANEL MEMBER McKONE: Thank you.

        CHAIRPERSON BRADMAN: Anymore Panel questions or
discussion?

        Dr. Bartlett[sic].

        PANEL MEMBER BARTELL: I have a couple issues. I
don't know if now is the best time or the longer
discussion. It kind of gets into the details of, you
know, maybe some reasons to consider prioritization, but I
don't know if it's a question, per se.

        DR. PLUMMER: I'll take whatever you want.

        PANEL MEMBER BARTELL: Okay. Well, let me throw
this out here then. So it strikes me in thinking about
this decision, at least for PFASs that there are kind of
two pretty relevant issues for considering whether or not
to list these -- this broader group as priority chemicals.
And I'd just be curious about, you know, your thoughts on
One is metabolism. So a number of these chemicals that are not currently part of the priority list are actually potentially metabolized directly into chemicals that are on the priority list. So that's certainly true of the fluorotelomer alcohols, and Scott Mayberry has published some other work recently on how -- it's probably true for diPAPs as well and PAPs.

And so, you know, that strikes me as one potential argument. It turns out metabolism can be pretty complicated. It's not entirely clear to the extent to which occurs in humans. But certainly in rodent studies there's some evidence that the diPAPs, for example, can be actually metabolized into PFOA and PFOS and things that are already listed as priority chemicals.

And that strikes me as maybe an important argument, so I'd like to hear any thoughts you have on that, and then I'll ask the second question after that.

DR. KROWECH: Okay. I think it's true -- this is Gail Krowech, OEHHA. So diPAPs -- certain diPAPs can be metabolized to PFOA, but they also can be measured, and, you know, by themselves. And it depends on the diPAP whether or not we actually measure that particular degradation product. Some of the newer compounds -- the newer PFASs that are based on the shorter chain, we
wouldn't be able to capture those, because for instance, the perfluorohexanoic acid is not currently a priority chemical. So that was one question -- was that the basis of your question?

PANEL MEMBER BARTELL: Yeah, I guess you can sort of think of this in terms of pros and cons. Number one is that you do actually directly measure the metabolites to the extent that that occurs.

DR. KROWECH: True.

PANEL MEMBER BARTELL: On the other hand, if you're thinking about sort of how we're decreasing use of PFOA and PFOS, but not necessarily the diPAPs, then you know it might point to, okay, well, maybe these are very important to measure because they could remain higher for longer.

DR. KROWECH: And there are also very many, other than what we measure right now. There are just many, many PFASs that we don't really even know -- you know, we don't even know what those subclasses are or the individual compounds.

So, yeah, I think that we -- it's true, a certain segment will go -- will be degraded or metabolized to our known priority compounds, but we'd be missing a lot.

Second question I wanted to ask is I know --

MS. HOOVER: Talk into the mic.

PANEL MEMBER BARTELL: Oh, sorry.

Yeah, the second questions I'd like to ask is I know in the last year or so, I think EPA came out with a report with some evidence -- new evidence that -- suggesting or implicating PPAR-alpha is a sort of common mechanism for a variety of PFASs. I don't -- I'm not a toxicologist. I don't follow that literature too closely, but I was wondering if that also potentially plays a role or has implications in thinking about sort of listing PFASs as a class for priority.

DR. KROWECH: Yeah, I think we were looking in -- you know, at the whole class. There are many, many mechanisms that could be involved, but we were really looking at exposure to the entire class, most of which hasn't been studied.

DR. SANDY: Sure. And this is Martha Sandy, OEHHA. I think several of the other health effects observed with members of this class. Right now, we don't have any indication that PPAR-alpha is involved in that, but -- yeah.

PANEL MEMBER BARTELL: Just to clarify, you know, one of the reasons I'm asking this, and I'm sure there may be a lot of just independent considerations about exposure
that should come into play when proposing this, but, you know, as I see on the, I think, third slide here, the second bullet point, you know, on criteria for recommending priority chemicals. One of them is the likelihood of a chemical being carcinogenic -- a toxicant based on peer-reviewed health data, of which there's not very much for most of these PFASs.

But then it goes on to say also, or potentially based on chemical structure or the toxicology of chemically related compounds. And that's what sort of gets me thinking along this track, and, you know, wondering what the evidence is that might lead us on the second two points?

DR. KROWECH: We discussed -- most -- you know, the research that we were able to locate on the newer -- new to us PFASs in the potential designated document, and so we're referring to that. And there -- you know, there was indication in that document of, for instance, covalent binding and, you know, various indications of potential toxicity.

CHAIRPERSON BRADMAN: I'll speak up. I just have a question too. It seems from the presentations that from a laboratory point of view expanding the methods to include both the phthalates or the PFOS, but, you know, depending on the respective laboratory that that is
feasible, and not, I guess, unduly burdensome or expensive or -- is that a yes?

MS. HOOVER: This is Sara. I'm just -- you know, to speak for the lab, and the lab can certainly pipe up. I mean, the idea -- and I want to make really clear that the examples we're listing -- we're not necessarily saying we're going to run out and try to measure those. So the idea is by listing as a class the benefit, as everyone knows and Tom eloquently put, is it allows us, if a new member -- if a new PFAS is cropping up, it's like, oh, this is really important, or there's new toxicity information we want to target a particular one, this allows us to do that, you know, going forward. Like, that's -- and that's already -- we're actually already captured in the designated list that's true. By elevating it to priority, you're saying, yes, we want you to -- you know, we want you to focus on that going forward. We could already chose to do it as a program, but this is the Panel's opportunity to elevate it and say we think these classes are important for you to track going forward and keep an eye on emerging chemicals.

DR. K RoweCH: I could say a little bit more about the toxicology -- sort of interesting that there was one study on diPAPs that we were able to locate. And that study showed that several of them affected
steroidogenesis. So I think there is information -- the problem is we have this whole group that has been so poorly studied.

MS. HOOVER: Did you have a follow up or did we answer your question well enough?

Talk into the mic, please.

PANEL MEMBER BARTELL: No, on both counts.

(Laughter.)

PANEL MEMBER BARTELL: I think the discussion was somewhat helpful, but I guess I still have lingering questions about what the toxicity data are really, as a -- you know, which is a hard question to even formulate when you have such a broad mix of chemicals, I guess. But maybe we should move on.

CHAIRPERSON BRADMAN: No more questions then from the Panel right now, so why don't we have an opportunity for public comment. And we have two comments from people in the audience. And then after that, if there's anyone who sent in email, we can hear from that.

So first, Veena Singla from Natural Resources Defense Council.

DR. SINGLA: Hi. Veena Singla with NRDC. And I wanted to speak in support of recommending both these classes as priority chemicals. On the -- I wanted to talk a little bit more about the first criteria, which was the
degree of potential exposure. And what we've seen with both phthalates and PFASs, because they have such widespread use in applications and numerous consumer products, are kind of every day products, as well as food packaging, that there really is a high likelihood of widespread exposure to these classes of chemicals, as certain phthalates, or PFASs, are phased out and new ones come in. So I think it really does make sense to think about the class and the likelihood of widespread exposure as different chemicals in these classes are used in various applications and consumer products.

CHAIRPERSON BRADMAN: Then we had another comment from Erika Houtz from DTSC.

MS. HOUTZ: Yes. Hi. So I'm one of the people involved in doing some of the PFC, PFAS analysis. And I just wanted to make a few comments on the list of chemicals.

I definitely think it's -- yeah, it's an ever-evolving problem with kind of a moving target. But one of the things we were thinking about emphasizing within that list was the processing aids, which are used in a lot of different kinds of products and are something that you can potentially see at the same kinds of levels as PFOS and PFOA.

I also think firefighting foam can result in some
types of acute exposures, like the one -- well, I know the biomonitoring data was not particularly elevated in New Hampshire and the people who were drinking the foam-contaminated well. But I could see some compounds that are not in our current list that are really important as reflective of that type of acute exposure.

Another thing I wanted to point out is that some of these chemicals are relatively easy to add from sort of sample preparation, analytical point of view. There are -- I mean, they may be more challenging to QA/QC and they're just adding another chemical to go through and to report. But in a way, it's like you can kind of collect the data easily enough to decide if you want to use it or not. I know sometimes there's an obligation to report everything that you potentially measure.

And one other comment I wanted to make is that there are alternative methods that could get around the analyte by analyte analysis. That doesn't seem to be something that we're pursuing in this arena, but there are sort of like total fluorine methods or total polyfluorinated chemical methods that we could potentially apply to get around sort of the numerous number of analytes issue.

So that's just the comments I wanted to make.

CHAIRPERSON BRADMAN: No, not here. Were there
any emails that were sent in?

    MS. DUNN: No.

CHAIRPERSON BRADMAN: Okay.

    DR. KROWECH: I just -- I wanted to follow up a little bit more on the tox, in that some of the fluorotelomer alcohols showed estrogenic activity. So some of them would have -- would be degraded to PFOA, but others -- they also showed it with 6,2-fluorotelomer alcohol, which would be degraded to the hexanoic -- perfluorohexanoic acid, which is not on our priority list. And, again --

    Okay. They also looked at bioactivation of some fluorotelomer alcohols as well as 6,2-diPAP, which was shown to covalently bind to glutathione, as well as -- not as -- as well as proteins in plasma, liver, and kidney. So from what we -- we have been able to find several studies that suggest there's reason for concern there.

    PANEL MEMBER BARTELL: So if I can ask a question. I guess --

    MS. HOOVER: Use the mic, please, Scott.

    PANEL MEMBER BARTELL: Oh, yeah. So if I'm hearing them, it sounds like they're -- you all may not be convinced there's a shared mechanism across -- of toxicity across this family of compounds that, you know, may
actually differ depending on, you know, which chemical you're looking at and --

DR. KROWECH: We don't know. There's a body of literature that showed bioaccumulation and toxicity were related to chain length, so we know that. But that the lower chain length PFASs haven't been well studied. And I just gave you a couple of examples from that where there were different toxicities that we're seeing.

PANEL MEMBER BARTELL: Okay. Thank you.

MS. HOOVER: This is Sara.

I just want to add one thing. And so I think it's important to remember again what Laurel said, which they're not joined by "and", so you don't have to meet each of those criteria. And that's important, and that's actually one of the reasons why we focus on exposure, and where we think there's a likelihood of exposure, partly because of a dictate that the Panel has given to us, which is we want to catch things on the upswing, and we want to look at emerging chemicals and potentially less well studied chemicals.

So that's -- you could tell the angle of our presentation was more on exposure, so -- and, you know, the criterion is the likelihood of and, you know, based on structurally similar chemicals. But again, you don't have to think that you have to meet -- there's not like a
burden to meet each criterion.

    PANEL MEMBER BARTELL: That is very helpful. I mean, I'm very convinced on the first and third bullet points. I mean, there's no doubt that these compounds are still around, and, you know, the industry is just shifting to different versions than the ones that were phased out. And, you know, I think you all but said that you have the ability to measure them, so I'm not worried about the third point.

    I'm just scratching my head over the second bullet point, and how to interpret that, you know, partly as being a new Panel member and trying to figure out the difference between the designated and priority chemicals.

    CHAIRPERSON BRADMAN: Is there anymore discussion, Panel members?

    I know -- I'll chime in if there's not. I mean, one point I would make is that in -- I think these particular groups of compounds are analogous to previous cases where we've elevated a class of compounds to a priority chemical group. And one example might be brominated flame retardants, where we, you know, knew from historical reasons that there's a lot of exposure to compounds that had similar chemical structures, and new forms were coming onto the market, but they're all within a general class of concern in terms of exposure, and
potentially health.

And I know, at least on my individual basis that it seems to me we have an analogous situation, where we have a group of phthalates and PFAS compounds that are similar to prior analytes that we've identified as designated -- priority chemicals, in that it -- you know, I think it makes sense from a Program point of view to group these as a class, so that way we have the freedom to investigate any individual compounds that, you know, raise kind of longer term exposure and health concerns.

PANEL MEMBER SCHWARZMAN: Can I just echo --

CHAIRPERSON BRADMAN: Sure.

PANEL MEMBER SCHWARZMAN: I just wanted to echo a piece of that, which is I think something that comes out very clearly in the material that you've provided to us is the dynamic nature of the industries that are producing both of these classes of compounds. And I think it requires a parallel dynamic capacity in the program, and that we have the chance to give that -- or to help you have that dynamism by prioritizing this -- both of these classes.

MS. HOOVER: And, Asa, can I just add? I just wanted to clarify, because -- to make it really clear. These -- both of these classes are on our list of designated chemicals, which means we could choose to
measure them. So today, it's true. Actually, Meg said it well. We also have to prioritize -- you know we have to prioritize what we're doing. So by the Panel saying, yes, these classes are priorities, then that says yes you should go, you know, work on the method for these. You should track these. So it gives the Panel's guidance to the Program that you think these classes are worth, you know, prioritizing in our many duties.

CHAIRPERSON BRADMAN: Right, as -- they warrant that level of attention.

MS. HOOVER: Exactly.

PANEL MEMBER SCHWARZMAN: And if I could add one other thing actually. To me, partly, it's the absence of some toxicological information that is particularly of interest here. And because we have the opportunity to prioritize chemicals because of their likelihood of exposure, it gives us the opportunity to gather a lot of information that might help us later on elucidate some of the toxicological properties also that are missing.

And so I'm glad that we have that flexibility, and that you have that flexibility and I guess I would support taking advantage of it.

CHAIRPERSON BRADMAN: Anymore discussion by the Panel or would somebody like to make a motion to raise -- well, why don't we deal with first the ortho-phthalates to
identify them as a priority chemical. You want to make that motion?

PANEL MEMBER McKONE: Can we do both at once or --

CHAIRPERSON BRADMAN: What was that?

MS. HOOVER: One at a time.

PANEL MEMBER McKONE: One at a time.

CHAIRPERSON BRADMAN: Do you want to make motion?

PANEL MEMBER McKONE: So I would make a motion that we recommend the class ortho-phthalates --

MS. HOOVER: Can you speak into the microphone?

PANEL MEMBER McKONE: Hmm?

CHAIRPERSON BRADMAN: I have some language here. If you want, I can --

PANEL MEMBER McKONE: Well, I have to read it, that's why -- I put my face down to read it. I don't want to make a mistake.

(Laughter.)

PANEL MEMBER McKONE: All right. There we go. Okay. So again, I move that we recommend the class of ortho-phthalates be added to the list of priority chemicals.

PANEL MEMBER SCHWARZMAN: Second.

CHAIRPERSON BRADMAN: Okay. We have a vote. Why don't we start with Dr. Bartell.
PANEL MEMBER BARTELL: Yes.
PANEL MEMBER QUINTANA: Yes.
CHAIRPERSON BRADMAN: Yes.
PANEL MEMBER SCHWARZMAN: Yes.
PANEL MEMBER KAVANAUGH-LYNCH: Yes.
PANEL MEMBER McKONE: Yes.
CHAIRPERSON BRADMAN: Okay. So I think we've completed that motion. And clearly, there's a unanimous recommendation here.

Does anyone -- would anyone like to make a motion that we include the perfluoroalkyl and polyfluoroalkyl substances, abbreviated PFAS, to be included as priority chemicals in the California Environmental Contaminant Biomonitoring Program?

Would someone else like to make that motion?

PANEL MEMBER SCHWARZMAN: I would make that motion, sure.

CHAIRPERSON BRADMAN: Okay. Well, here, I'll read this language here.

Dr. Schwarzman motions that the chemical class perfluoroalkyl and polyfluoroalkyl substances be included as priority chemicals in the California Environmental Contaminant Biomonitoring Program.

So why don't we start from the left, if we --

MS. HOOVER: Second.
PANEL MEMBER McKONE: Do we have to second the motion.

CHAIRPERSON BRADMAN: Oh, that's true. Does anyone second the motion.

PANEL MEMBER McKONE: Second.

CHAIRPERSON BRADMAN: Okay.

PANEL MEMBER McKONE: Aye, yes.

PANEL MEMBER KAVANAUGH-LYNCH: Yes.

PANEL MEMBER SCHWARZMAN: Yes.

CHAIRPERSON BRADMAN: Yes.

PANEL MEMBER QUINTANA: Yes.

PANEL MEMBER BARTELL: Yes.

CHAIRPERSON BRADMAN: Okay. So we have two unanimous recommendations to elevate these designated chemicals as a class to be priority chemicals for the Biomonitoring Program.

And this point then, I think we want to introduce Sara again who will be making a brief announcement about possible agenda items for 2016 for the Panel.

(Thereupon an overhead presentation was presented as follows.)

MS. HOOVER: Okay. Thank you so much. And thanks for a great meeting today.

So what we wanted to do with this item is basically just announce some ideas and themes we've come
up for 2016. We actually originally scheduled it just for
questions only, because we didn't have time, but now we do
have a little time. So if the Panel wants to talk about
it or discuss it a little, we actually would have time for
that.

So some possible themes. And I want to say at
the outset that a number of the slides are interlinked, so
you'll see common themes. So -- and this relates back to
some of the priorities that Michael DiBartolomeis was
alluding to in his update talk and that we've talked to
you about.

So one theme is just consumer product chemicals,
in general, and we've had that recurring theme really
since the beginning of the Program; discussing an
intervention study, for example, our FREES study or
studies like that; chemical selection activities related
to consumer product chemicals. We've also had discussions
about collaboration with the Safer Consumer Products
program and Safe Cosmetics Program and we want to continue
that going forward.

We're also very interested in continuing to talk
about environmental justice as a focus for the Program.
It's in our enabling legislation, and we're just sort of
highlighting that as a key component of our future
studies. An example would be further discussion of diesel
exhaust and further discussion of our collaboration with
the CalEnviroScreen program in OEHHA.

And then a really important point that's been
brought up actually a number of times by the Panel over
the years and within OEHHA is the topic of biomonitoring
children. For example, we might consider biomonitoring
children in the context of pesticides. And I'll say more
about that in a bit. Or maybe I would say more right now.
Let me say a little bit more right now what I mean.

The reason why we're highlighting pesticides for
children is, for example, with pet pesticides and the
possibility of high levels of exposure for children, so
that's the link there. And then collaborations with the
Environmental Health Tracking Program in that regard.

--o0o--

MS. HOOVER: Back to chemical selection
activities here. So pesticides. You may recall that the
Panel already previously screened some pesticides. So we
would go back and follow up on some of those. We also
have the desire to research other high use, high exposure
pesticides.

With regard to some components of consumer
products, we've had on our list to go back and do a
preliminary screen of UV stabilizers. And this is, for
example, chemicals related to BP-3. So we found in
California, you know, in firefighters we found high levels of BP-3.

And I'm pleased to announce that actually today this morning we found out that our paper has been finally accepted into Environment International. It's going to go into the proof stage. So we wanted to follow up on related compounds and conduct a preliminary screen with the Panel.

And then we want to continue scoping research on other consumer product chemicals, for example, fragrance chemicals. And then we have this -- we do have this effort that we're very interested in as a Program of non-targeted or semi-targeted screening where you do a more broad analysis of samples for similar types chemicals. And we'd be interested in looking at those in terms of chemical selection activities.

---o0o---

MS. HOOVER: So again interlocking themes here, the environmental justice theme. With regard to diesel exhaust, we talked about this with the Panel. And 1-nitropyrene was highlighted as important, and the only really known biomarker at this point. It's non-specific, but it's been shown to be useful.

And Dr. Bradman has conducted a pilot study with Dr. Chris Simpson of University of Washington and found
some very interesting results in children.

   And then possibly discussing a follow-up
collaboration, a larger collaboration, on measuring
1-nitropyrene in Biomonitoring California.

As another environmental justice theme, again,
we're continuing to work with CalEnviroScreen. For
example, we've been using data in a pilot study to look at
arsenic levels in drinking water from CalEnviroScreen to
try to help us evaluate elevated levels of arsenic in the
BEST study. So this is something we could bring to the
Panel and discuss. Just as a reminder, I'm referencing
all of these topics as just discussion topics with the
SGP.

And, you know, we hope to, going forward -- and
this has been brought up before, but we hope to go forward
with CalEnviroScreen and explore possible options to
identify impacted communities for future biomonitoring
studies using the information from CalEnviroScreen.

--o0o--

MS. HOOVER: And now here we're back to
biomonitoring children. Okay. So this is -- like I said,
we've got these echoed themes. So again, pesticides,
we're highlighting school site pesticides of potential
interest with regard to biomonitoring children and pet
pesticides. And we've talked about pet pesticides for a
number of years with the Panel.

   And this is one we've done -- as I mentioned earlier, we've done chemical structure-based categories and we've done like a mix with functional-based, like brominated flame retardants. This would be a function-based category purely, pet pesticides. So that could be a potentially interesting thing to follow up on.

   There's so many chemical exposures to consider in children. Again, the diesel exhaust pilot I alluded to. Other -- and just looking at other exposures of potential importance specific to children.

   And then discussion of challenges and opportunities in biomonitoring children. We were talking about some of the challenges in results return with children, including children in studies. And we had a discussion of that with CDC in one of our meetings previously, at an SGP meeting.

   --o0o--

   MS. HOOVER: So we also always want to bring to the Panel an in-depth discussion of our ongoing work. And here's some examples that we're considering for an in-depth discussion in 2016.

   One is the FREES study that Michael talked about, which is looking at flame retardants, which is of particular interest to the Panel, as well as an EJ
component. There's the Asian-Pacific Islander Community Exposure Project. And this is of great interest also for EJ component reasons.

Measuring Analytes in Maternal Archived samples, will continue to revisit that as hopefully an approximation of a statewide sample.

And then we have been expanding our work on measuring organophosphate flame retardants and new bisphenols, and we'd want to come and talk to you about what we found there.

--o0o--

MS. HOOVER: And then what we'd like to try to do, and the reason why I was trying to group those as themes, is we like to make meetings that have a certain theme, or the morning session, the afternoon session has particular themes.

So with those topics in mind, we would identify possible guest speakers. In this case, we also have the opportunity -- so we've been very fortunate that CDC has come out for visits at the same time as the SGP meetings and brought CDC scientists to speak to us.

So some ideas, and this is more of an opportunity of which scientists might be able to come. For example, an inorganic expert to talk more about metal speciation, and then CDC's expert that is an expert both in tobacco
biomarkers and perchlorate. So these are very tentative, and it's just I want to gauge interest in these topics as guest speakers.

And then we would also hope to invite, for example, if we have an in-depth discussion of FREES, we'd want to bring a FREES collaborator as a guest speaker to talk more about that.

And then just in general, other experts on any topics of interest to the Panel.

--o0o--

MS. HOOVER: And I think that's it.

And as I mentioned, we do have a little time to talk about this publicly. We haven't firmed up our topics. And so I invite the Panel and the public to send any input that you have to the biomonitoring email.

So now I'll take questions and we have a bit of time to brainstorm ideas.

I think Jenny has a question.

CHAIRPERSON BRADMAN: Dr. Quintana.

PANEL MEMBER QUINTANA: I just had in terms of brainstorming, all those are great ideas. And I'd be happy with any of those, just to be clear. But I just had a couple things that came up after today's very interesting presentation from the states, and that I'm a relatively new member of the Panel and I know this was
discussed in the past, but not since I've been here, which
is what makes California special? We just haven't had an
explicit discussion about California. And we've had some
discussion about what exposures might be unique here, like
the flame retardants, but not so much about what
populations are quite unique.

And so I was just thinking it might be
interesting to revisit what is particularly of interest to
us as Californians from the Guidance Panel perspective.

And the other thing is, following up on an email
that I've been bothering Sara with off and on, which is an
article came out in 2014, "New Exposure Biomarkers as
Tools for Breast Cancer, Epidemiology, Biomonitoring, and
Prevention:", by Rudel, 2014. And they have a specific
list of biomarkers from animal studies which they felt
were chemical biomarkers of chemical exposure, which they
thought would be of interest in pursuing breast cancer.

And my understanding with -- from the history of
this Program that breast cancer risk was one of the
founding reasons for this Program. And so I thought maybe
we could revisit that focus again too.

MS. HOOVER: Yeah, I think that's a great
proposal. And I have looked at that paper, and it's
definitely on our radar in our tracking. But I think, you
know, kind of the idea, and also it was raised -- you
know, Meg raised that idea, the idea of looking at chemicals shown to cause breast cancer. That could be a potential interesting discussion topic.

CHAIRPERSON BRADMAN: Dr. Schwarzman.

MS. HOOVER: Go ahead, Lauren.

ACTING DIRECTOR ZEISE: I just wanted to let the Panel know that we are doing -- OEHHA is doing a health, and mostly, an exposure study of synthetic turf fields. And as part of that study, we are doing an Institutional Review Board report on potential biomonitoring and personal monitoring.

And we'd actually like to get some very early input on what a study might look like. We aren't funded to do the biomonitoring study yet, but we are funded to put together a protocol. So we're also hoping that we could get your wisdom on that. It does involve -- we think it probably should involve monitoring children. So just to put that out there for a comment as well.

CHAIRPERSON BRADMAN: When you say as a comment, for a comment now or for an agenda item for next March?

ACTING DIRECTOR ZEISE: Well, for an agenda item -- for an agenda item for a future meeting.

PANEL MEMBER SCHWARZMAN: I appreciate this presentation of possible topics. And I agree it all sounds rich and interesting. And I just wanted to pick up
on the idea that we had started exploring a little bit earlier about potentially grouping chemicals of interest by health outcome or by mechanism of action. And you mentioned a potential to collaborate with the folks in CalEnviroScreen and target potentially highly affected communities.

And I just started sort of thinking about how you might take that along kind of prevalent disease theme. So, for example, you could think of, you know, neurodevelopmental compounds that are suspected to affect neurodevelopment. And that's something that's seen a lot in the overburdened communities or zip codes is multiple chemical exposures that are out of proportion, or you could think of asthmagens similarly.

And I guess I would just propose that as a potential theme at some point is to explore what some of those disease outcome or pathway-oriented groupings might be, and particularly thinking of it in collaboration with CalEnviroScreen and targeting particular communities.

MS. HOOVER: Other questions or comments about this?

CHAIRPERSON BRADMAN: I just wanted to respond to Dr. Zeise's comments about the turf. You know, I think that's something that I would definitely be interested in talking about any topics within the Panel that are
relevant to biomonitoring.

I know it's a huge issue. I've gotten probably 10 or 15 calls or contacts from people concerned about this at -- in Las Vegas at the International Society for Exposure Science. You know, there was probably a discussion with 15 people. I've had neighbors call me because of a new playground in our neighborhood. So I think there's a lot of interest in that. There's even an association of soccer moms that has --

(Laughter.)

CHAIRPERSON BRADMAN: -- Healthy Soccer, that's raising these issues. So to the extent that it's related to biomonitoring, I think that would be an interesting discussion.

MS. HOOVER: I mean, I'm just thinking of linking it to one of the themes we talked about, because we've also had a lot of inquiry -- we actually have had a fair number of inquiries about pesticides and school site pesticides. So, you know, school site exposures might be an interesting broader theme that would also capture turf and other exposures to children at school sites.

CHAIRPERSON BRADMAN: In terms of looking at school site pesticides, the DPR PUR database right now for school- and child-care related pesticide use is becoming much fuller and more complete. I interact with them on a
regular basis. And because of revisions to the Healthy Schools Act, there's much better reporting really starting this year, and fully implemented next year, on pesticide use in schools and child care settings.

And they're actually planning to publish some reports based on the PUR data. Again, this is not ag use. This is actually school site or child care site use. And that could be interesting to inform decisions here about what compounds to look for.

MS. HOOVER: I was kind of curious -- and, you know, like I said in the past, we talked a lot about pet pesticides. Is there interest in us looking more into that as a category?

CHAIRPERSON BRADMAN: I don't want to sound like a broken record here, but yes, capital letters. You know, I mean, I think that's a big issue. And some of the, you know, more concerning, you know, neonicotinoids, imidacloprids, and, you know, many of these things are used, right, in the environment, and on animals where little kids spend time, so I think that's kind of a natural.

MS. HOOVER: Okay. Well, like I said, you know, so it sounds like our concepts of themes are people generally like them and I like the additions that people have proposed. If people -- panel members and the public
have other concepts, I'd love to hear them.

And any public comment, at this point, any emails or any audience comments on any of these themes?

Okay.

CHAIRPERSON BRADMAN: One more comment from the Panel.

PANEL MEMBER SCHWARZMAN: I just wanted to pick up on Dr. Quintana's point about what is specific to California, but look at it through an occupational lens. And I don't, off the top of my head, apart from agriculture and pesticide exposures, know what is particular about California occupationally, but I think it would be -- it would be great to address that topic.

MS. HOOVER: Actually, I was thinking -- I was thinking the same thing at certain moments like workers. I was having an interesting conversation about turf with Dr. Melanie Marty, who's the Deputy under Lauren, and, you know, for synthetic turf workers as a potential concern. So -- and I -- you know, like farmworkers was raised too.

So I think that's a great idea. I think looking at worker -- other worker populations, you know, looking back at that in California is a really good idea. I mean, there's lots and lots of good ideas. So at some point, we'll have to narrow it down into three meetings.

So, yeah, if you also have your favorite ideas or
your, you know, particularly high priority ideas,
definitely let us know about that.

Okay.

CHAIRPERSON BRADMAN: I'm sorry?

MS. HOOVER: Open public comment.

CHAIRPERSON BRADMAN: Right. So at this point then, we have an open public comment period for -- on -- this can be on any topic related to the Program or biomonitoring, if there's any additional comments from anyone listening on-line or in the audience here.

DR. SINGLA: Just one comment on the last topic that was discussed in terms of kind of unique worker populations in California. And one thought I had was the Asian population and workers in nail salons and beauty salons might be another interesting worker population to look at.

CHAIRPERSON BRADMAN: It looks like we don't have any more comments.

So at this point, I guess we can formally adjourn the meeting. But before we do that, I just want to actually note that perhaps unconsciously we came back to the issue of worker exposures and health. And maybe that's an example of Julia Quint's presence that is still here.

So with that --
MS. HOOVER: There's a few announcements. Check your agenda.

CHAIRPERSON BRADMAN: Oh, there's another page. (Laughter.)

CHAIRPERSON BRADMAN: So I want to announce a couple things, that the transcript of this meeting will be posted on the Biomonitoring California website when it's available. And all the presentations that were presented today will be available in a few days. They're not there yet, but they will be very shortly. And then the next Scientific Guidance Panel meeting will be March 3rd, 2016, and that will be in Sacramento.

So with that, I think we can adjourn this meeting. Thanks.

(Applause.)

(Thereupon the California Environmental Contaminant Biomonitoring Program, Scientific Guidance Panel meeting adjourned at 4:25 p.m.)
CERTIFICATE OF REPORTER

I, JAMES F. PETERS, a Certified Shorthand Reporter of the State of California, do hereby certify:

That I am a disinterested person herein; that the foregoing California Environmental Contamination Biomonitoring Program Scientific Guidance Panel meeting was reported in shorthand by me, James F. Peters, a Certified Shorthand Reporter of the State of California, and thereafter transcribed under my direction, by computer-assisted transcription.

I further certify that I am not of counsel or attorney for any of the parties to said meeting nor in any way interested in the outcome of said meeting.

IN WITNESS WHEREOF, I have hereunto set my hand this 3rd day of December, 2015.

James F. Peters, CSR
Certified Shorthand Reporter
License No. 10063